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ABSTRACT 
 
Influenza A virus causes significant and well publicised morbidity and mortality as a 
single infection. However, in combination with a secondary bacterial super infection the 
resulting prognosis is worse and can result in hospitalisation or death. Despite 
extensive clinical and epidemiological evidence, the precise immunological 
mechanism(s) responsible for increasing susceptibility to secondary bacterial infections 
remain unknown. Possible mechanisms include disruption to the epithelial barrier, up-
regulation of bacterial adhesion receptors, virus-induced immune suppression or a 
combination of all three.  
 
In this thesis we examine a novel hypothesis that suggests influenza virus infection 
alters the lung homeostatic microenvironment resulting in a state of immune 
unresponsiveness that increases susceptibility to subsequent respiratory bacterial 
infections. This thesis demonstrates that respiratory bacterial complications only arise 
once influenza has caused significant respiratory damage and can occur many days 
after viral elimination. We also demonstrate that influenza infection results in a long 
term desensitisation of alveolar macrophage responses to subsequent bacteria and 
their products. Furthermore, in an attempt to resolve viral associated inflammation, the 
airway inadvertently over regulates by enhancing an innate immune negative regulator, 
CD200R, resulting in a transient state of immune hypo-responsiveness. Removal of 
this single receptor limits bacterial burden and completely prevents lethal bacteraemia. 
Finally, we provide preliminary data that suggests airway antimicrobial peptide 
expression is altered during an influenza infection and that innate immune status of the 
host can influence commensal bacteria communities of the upper respiratory tract.  
 
This thesis highlights that infection history can significantly influence host immunity to 
subsequent infections and how an increased awareness of this could lead to more 
targeted use of existing antimicrobial therapies and the development of much needed 
novel therapeutics. Adjustment of the level of innate responsiveness may therefore 
provide a novel opportunity to prevent life-threatening consequences of lung influenza 
virus infection. 
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RPMI   Roswell park memorial institute 
RSV   Respiratory syncitial virus 
SAP   Serum amyloid protein 
SEM   Standard error of the mean 
SH   Src homology 
SHIP   SH2-containing inositol phosphatase 
SIgA   Secretory immunoglobulin A 
SIGIRR  Single immunoglobulin IL-1 related receptor 
SIRP   Signal regulatory protein 
SOCS   Suppressor of cytokine signalling 
SR   Scavenger receptor 
STAT   Signal transducers and activators of transcription 
TCR   T cell receptor 
TGF-   Transforming growth factor- 
Thx   T helper subset 
TIR   Toll interleukin receptor 
TLR   Toll like receptor 
TOLLIP  Toll interacting protein 
TNF   Tumour necrosis factor 
Treg   Regulatory T cell 
TRAF   TNF Receptor Associated Factor 
TREM   Triggering receptor expressed on myeloid cells 
WHO   World health organisation  
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Chapter 1 
 
 
Foreword 
This thesis examines how influenza virus infection enhances susceptibility to 
secondary respiratory bacterial pneumonias. To this end this introduction looks to 
describe basic immune functions of the respiratory tract and regulatory mechanisms 
involved in controlling innate immune responses.  
 
1.0 Mucosal immunity 
Throughout evolution, vertebrates have developed an elaborate collection of defense 
mechanisms that provide protection against the perpetual threat of invading micro-
organisms. In mammals, the mucosal surfaces of the body, including the respiratory 
tract, form the largest surface that is exposed to opportunistic pathogens and 
exogenous antigen and as a result, contains the largest collection of lymphoid tissue 
in the body. Consequently, the respiratory tract has developed an array of intricate 
physiological systems to ensure both optimum conditions for gaseous exchange and 
protection against pathogen invasion. However, despite numerous mucosal defense 
systems, pathogens inevitably acquire virulence factors to target and subvert immune 
effectors and facilitate infection. This may result in inflammation within the delicate 
microenvironment of the lung which ultimately has serious consequences for the 
host. Respiratory infections can afflict anyone, but display an increased incidence 
when the immune status of the host is compromised or if the invading pathogen is 
highly virulent. In part, for these reasons respiratory infections are common and new 
respiratory infections are likely to emerge frequently. 
 
1.1 Epidemiology of respiratory infections 
The Burden of Disease data produced by the World Health Organisation (WHO) 
highlights that respiratory lung infections (excluding tuberculosis and pneumonias in 
patients with HIV/AIDS) cause more than 6 % of the global burden of disease 1;2;12. 
This equates to an estimated 3.9 million annual deaths worldwide with at least 18, 
000 in the USA alone 13. The same WHO data also illustrates that respiratory 
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infections account for the highest burden of disease of all infectious diseases, 
responsible for an estimated 100 million disability adjusted life years (DALYs), 
exceeding that of HIV/AIDS, tuberculosis and other highly publicised infections 
(Figure 1.1). In addition to the significant mortality associated with such infections, is 
the substantial morbidity and subsequent economic disruption. Lung infections 
disproportionately burden low income countries where effective methods of 
prevention and primary care are underdeveloped or not available. Normalising 
DALYs against population size highlights a more than 20 fold increase in relative 
burden of disease in low income countries compared to the rest of the world 12;14. 
Infectious diseases cause less of a burden in high income societies than do chronic 
lifestyle diseases such as cardiovascular disease, type II diabetes and gerontological 
diseases. However, in both the wealthiest and the poorest societies, lung infections 
are the most common, and perhaps severe, illness experienced by the general 
public, regardless of age or gender (Figure 1.2).  
 
 
 
Furthermore, it is likely that the prevalence of lung infections will increase in high 
income countries, where an aging population is more susceptible to respiratory 
Figure 1.1 The WHO Global Burden of Selected Diseases, as measured by Disability-
Adjusted Life Years (DALYs) lost worldwide. DALYs take into account the amount of 
otherwise healthy life lost to morbidity and/or mortality. Data acquired from 
1
. 
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infections 15. The emergence of novel respiratory infections, such as the novel H1N1 
swine influenza strain, SARS coronavirus and the continuing H5N1 influenza A virus 
epidemic in South East Asia, will contribute to the increasing burden of respiratory 
disease. A third and often neglected concern is the increasing number of common 
agents of community and nosocomial acquired pneumonias acquiring antibiotic 
resistance. All taken into account, global lung infections seem poised to become 
even more of a concern in the near future.  
 
 
 
 
 
 
 
 
 
 
 
1.2 Innate immunity of the respiratory tract – The front line  
Both the upper and lower respiratory tracts are protected against infection by many 
non specific innate and specific adaptive defences. A complex interplay between 
both innate and adaptive components results in the maintenance of a pathogen free 
environment throughout the lower respiratory tract that ensures optimal physiological 
function. Innate immunity fulfils a highly significant role early in infection against a 
diverse array of pathogens and is critical in the development of the more pathogen 
specific adaptive immunity. 
1.2.1 Physical barriers 
The initial obstacle to micro-organisms entering the respiratory tract is an array of 
mechanical barriers that act to limit pathogen invasion beyond the respiratory 
epithelium. Upper respiratory tract epithelial cells are covered with cilia that beat in a 
synchronised upward fashion to propel particles and bacteria toward the oropharynx. 
The ciliated epithelium is also coated with a layer of mucus that traps inhaled 
particles, prevents access to epithelial cells and aids their propulsion toward the 
Figure 1.2 The WHO Global Burden of Selected Diseases. The number of deaths 
attributed to infections in low (a) and high (b) socioeconomic regions of the world 
2
. 
a b 
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mouth. Further barrier defence is conferred by tight junctions between epithelial cells 
of respiratory mucosal surfaces, airflow pressure, differential temperature gradients 
and nasal passage and laryngeal particle size exclusion.  
 
1.2.2 Chemical barriers – The role of antimicrobial peptides 
Antimicrobial and immunomodulatory peptides produced by resident lung cells also 
play a major role in the rapid first line defence against respiratory infections 5. 
Production of these soluble mediators may be constitutive or induced via recognition 
and detection of micro-organisms and can impart both direct and indirect immunity 
towards the invading micro-organism. A number of the most significant antimicrobial 
mediators and their proposed mechanisms of action are shown in Table 1.1 below.  
 
Table 1.1 Pulmonary antimicrobial peptides  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protein Structure Pulmonary 
Source 
Antimicrobial 
activity 
Immunomodulatory activity 
Lactoferrin 
Iron binding 
glycoprotein 
80kDa 
Neutrophil 
secondary 
granules & 
submucosal gland 
epithelial cells 
Bactericidal/static, 
inhibits biofilm 
formation, anti-
viral & anti-fungal 
Binds LPS & CpG motifs preventing 
septic shock. Anti-oxidant 
Secretory leukocyte 
proteinase inhibitor 
(SLPI) 
11.7 kDa non 
glycosylated 
protein 
Macrophages, 
neutrophils & 
epithelial cells 
Bactericidal/static 
& anti-viral  
Potent anti protease. Inhibits LPS 
induced  NF-κB activation. Attenuates 
neutrophil recruitment in sepsis 
models. Impairs monocyte activation.  
Lysozyme 14 kDa enzyme 
Neutrophil 
secondary 
granules & 
submucosal gland 
epithelial cells 
Bactericidal/static Unknown 
Human defensins 3-5 kDa peptides 
Neutrophil 
azurophil granules 
& pulmonary 
epithelial cells  
Bactericidal/static, 
anti-viral, anti-
fungal and anti-
parasitic 
Mitogenic and chemotactic activity. 
Adds to epithelium repair by enhancing 
epithelial proliferation. 
LL-37 
Requires 
proteolytic 
processing to 
liberate functional 
antimicrobial 
peptide 
Neutrophil 
secondary specific 
granules & 
submucosal gland 
epithelial cells 
Bactericidal/static, 
anti-viral & anti-
fungal 
Reduces macrophage produced TNF 
after LPS stimulation. Also thought to 
have chemotactic activity. 
Bactericidal 
permeability 
increasing protein 
(BPI) 
55 kDa protein 
Neutrophil primary 
granules 
Bactericidal/static 
& opsonises for 
neutrophil 
phagocytosis 
Dampens LPS and endotoxin 
responses in vivo. 
Surfactant proteins 
A & D 
Lipoprotein 
complex 
Type II 
pneumocytes & 
airway Clara cells 
Bactericidal/static, 
anti-viral, anti-
fungal & opsonin 
for phagocytosis 
of bacteria and 
viruses.  
Modulate multiple leukocyte functions 
Lactoperoxidase Enzyme Airway epithelium 
Bactericidal/static, 
anti-viral & anti-
fungal 
 
CCL20 Chemokine Airway epithelium 
Bactericidal 
against Gram 
negative bacteria 
B cell, immature DC and T reg 
chemoattractant. 
 Information contained within Table 1.1 was adapted from 5. 
CHAPTER 1: INTRODUCTION 
6 
1.2.3 Cells of the innate immune response 
There are many effector cells that comprise the innate immune system, which exert 
potent antimicrobial activity and are fundamental in the establishment of a rapid 
response to invading micro-organisms. Some innate immune cells reside in the 
healthy lungs of uninfected individuals, but there is further recruitment in response to 
inflammatory signals generated during infection. Effector cells of the innate immune 
system are largely phagocytic. They recognise invading micro-organisms through 
detection of conserved proteins or polysaccharides uniquely expressed on their 
surface or contained within micro-organisms. This detection augments their activation 
resulting in increased antimicrobial capacity and release of chemokines and 
cytokines that promote inflammation 16. Many of the proteins that are detected by the 
innate immune system are highly conserved and perform essential functions within 
micro-organisms, therefore allowing a limited number of host receptors to detect the 
vast array of micro-organisms that reside in the same environment as the host. 
Examples of such conserved microbial products include lipopolysaccharide (LPS), 
the cytosine guanine (CpG) dinucleotide DNA motif, peptidoglycan, flagellin and 
lipoteichoic acid (LTA). Toll-like receptors (TLRs) constitute an important family of 
host receptors that represent a significant mechanism for inducing production of 
antimicrobial products and in the establishment of a rapid and potent immune 
response to infection 16;17. These are discussed in greater detail in the next section.  
 
Macrophages are central cells of the innate immune system and fulfil a pivotal role in 
immunosurveillance and are consequently fundamental to the establishment of a 
protective inflammatory response to infection 18. Alveolar macrophages are resident in 
the respiratory tract, comprising 90-95 % of all cells in the airways of uninfected 
individuals. Alveolar macrophages express a large number of receptors that facilitate 
recognition and phagocytosis of microbial pathogens, including TLRs, Fc, 
complement, mannose binding lectins and numerous scavenger receptors 19;20. 
Phagocytosed micro-organisms are subsequently exposed to toxic mediators, such 
as reactive oxygen species (ROS) and proteases that can kill the engulfed micro 
organism 21. The plethora of cytokines produced by activated macrophages is critical 
for the ensuing immune response and pulmonary defence. These include TNF-α, IL-
12, IFN-γ, IL-10, IL-1 and a selection of chemokines that direct recruitment of cells 
22;23. These cytokines increase the production of additional chemokines and promote 
the up-regulation of adhesion molecules on lung endothelium and epithelium, 
facilitating the recruitment and diapedesis of neutrophils and lymphocytes into the 
lung.  
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Dendritic cells (DCs) are another important facet of the innate immune system that 
form a network within the submucosa of the nasopharynx, trachea and bronchial tree 
24;25. They constitutively express high levels of co-stimulatory molecules such as 
CD80, CD86 and MHC II. DCs engulf and process micro-organisms and other 
stimulatory antigens for presentation and are capable of migrating to draining lymph 
nodes to present antigen to effector lymphocytes which is critical for the development 
of an adaptive immune response and immunological memory 25;26.  
 
Neutrophils, another cellular component of the innate immune response, which like 
macrophages display direct antimicrobial activity and release multiple cytokines. 
Neutrophils are the principal effector cells against many bacterial pathogens but also 
fulfil a significant role in protection against other microbial infections of the lung 27. 
Neutrophils are recruited rapidly from the periphery to the site of infection in response 
to various stimuli such as chemotactic proteins KC (the murine homologue of IL-8) 
and MIP-2α produced by alveolar macrophages and airway epithelial cells 28. Once at 
the site of infection, neutrophils are activated by local pro-inflammatory cytokines. 
Similar to macrophages, neutrophils are strongly phagocytic and exhibit a propensity 
for ingesting and killing invading pathogens 27. They also produce a number of 
cytokines such as TNF-α, IL-1β, IL-6 and MIP-2α, which act to enhance and refine 
the pro-inflammatory response 29;30.  
 
Finally, Natural Killer (NK) cells also respond rapidly to respiratory infections. They 
express a variety of both activator and inhibitory surface receptors that discriminate 
expression levels of MHC class I on infected and non infected host cells 31. If the NK 
cell detects reduced expression levels of MHC I, as may be caused by viral infection, 
then it will proceed to kill the infected cell 32-34. NK cell cytotoxicity is mediated by 
perforin/granzyme induced lysis and Fas-dependent apoptosis 35. NK cells are 
activated by IL-12 derived from pulmonary macrophages and in turn generate IFN-γ, 
which further activates the macrophage and resident DC populations 35;36.  
 
The immune system can be viewed as a co-ordinated interplay between innate/non-
specific immunity and acquired/specific immunity. Through the production of cytokines 
and professional antigen presentation, the innate cellular response fulfils a 
fundamental role in orchestrating the development of an acquired immune response, 
crucial for specific cell mediated and humoral responses. However, there is growing 
appreciation for the intricate reciprocation that exists between the development and 
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maturation of the adaptive immunity and the termination and resolution of innate 
immune responses. This concept is revisited later in the introduction and throughout 
the thesis.  
 
1.3 Detection, response and clearance of micro organisms 
1.3.1 Pathogen recognition 
To initiate the many effector functions of the innate immune system, described 
above, the recognition and detection of pathogen presence is essential. Despite the 
lack of precise specificity that is provided by the adaptive immune system there is a 
fundamental need for the host‟s innate immune system to decipher self from non self. 
The innate immune system harbours a family of cell surface and intracellular 
receptors, collectively referred to as pathogen recognition receptors (PRRs), which 
recognise pathogens directly and initiates signalling cascades that culminate in an 
„appropriate‟ immune response. Each PRR has the ability to detect a broad specificity 
of ligands that have a common structural motif, such as regular patterns of lipids, 
matrix proteins, unmethylated dinucleotides, double stranded RNA or complex 
carbohydrates. These microbe associated molecular patterns (MAMPs) are present 
on or within all micro-organisms but absent from host cells. An important aspect of 
pattern recognition is that the PRRs cannot distinguish between pathogenic and non 
pathogenic micro-organisms as the conserved MAMPs are not uniquely expressed 
by pathogens. This fundamental predicament is essential for maintaining innate 
immune homeostasis, as demonstrated in the intestinal tract, and dysregulation of 
these interactions are thought to lead to inflammatory bowl diseases and other 
disorders 37. A number of the major PRR family members are introduced below. 
 
1.3.1.1 Collectin family members 
Not all PRRs are tethered to the host cell surface. Members of the collectin family, so 
called because they contain both collagen like and lectin biding domains, are 
humoral molecules of the innate immune system that interact with pathogens at 
mucosal surfaces such as the respiratory tract 38. Eight members of the collectin 
family have been identified thus far, of which mannose binding lectin (MBL) and the 
surfactant proteins A and D are the most characterised 38. They are present as free 
protein in blood plasma and respiratory epithelium exudate respectively. Collectins 
recognise a specific orientation of carbohydrates uniquely present on the surface of 
micro-organisms, resulting in the production of collectin - pathogen complexes that 
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highlight the presence of an invading pathogen and act to neutralise, agglutinate and 
opsonise pathogens for nearby professional phagocytes.  
 
1.3.1.2 Macrophage bound C-type lectin and scavenger receptors 
Professional phagocytes also contain C-type lectin receptors that are expressed on 
their cell surface that act in a similar manner to secreted collectin family members. 
The macrophage mannose receptor is a cell bound C-type (calcium dependant) lectin 
that binds carbohydrates present on the surface of invading microorganisms. In 
addition to its recognition properties the macrophage mannose receptor can act as a 
putative phagocytic receptor due to its transmembrane domain 39. Another well 
characterised surface bound C-type lectin is Dectin 1, a transmembrane receptor that 
binds β-glucan 40. Dectin 1 contains an atypical immunoreceptor tyrosine based 
activation motif (ITAM) and has an important role in antifungal defence 41. Another 
family of macrophage surface receptors that recognise various anionic polymers and 
acetylated low density lipoproteins are termed scavenger receptors (SRs) 42. SRs can 
be characterised by their broad ligand specificity and are thought to have evolved as 
PRRs through gene duplication. Macrophage receptor with collagenous structure 
(MARCO) is one of five members of the SR-A subclass, expressed highly on human 
and mouse alveolar macrophage and has been shown to play an instrumental role in 
the detection and phagocytosis of respiratory bacterial pathogens 20. Many of the 
members of the SR-A family are alternative splices of the same gene; MARCO is, 
however, a distinct gene product.  
 
1.3.1.3 Toll like receptors (TLRs) and NLRs family members 
TLRs belong to the evolutionary conserved toll/interleukin-1 receptor (TIR) super 
family, which can be divided into two main subgroups: the IL-1 receptor and the TLR 
receptor family. The IL-1 receptor subgroup consists of at least 10 receptors 
including the IL-18 receptor and the orphan receptors ST2 and single 
immunoglobulin IL-1 related receptor (SIGIRR). The TLR subgroup is made up of 10 
extracellular and intracellular receptors namely TLR 1 through 10 43. Figure 1.3 
illustrates the cellular location of all TLRs and cytosolic pathogen recognition 
receptors (introduced below). All members of this family are transmembrane 
receptors, expressed by cells from the myeloid lineage but also select epithelium, 
that recognise MAMPs and signal through a common signalling TIR domain motif 
culminating in the activation of the transcription factor nuclear factor κB (NF-κB) and 
stress activated protein kinases 44;45. Some TLRs utilise co-receptor complexes, for 
example TLR4 uses MD2 and CD14, which control receptor expression and increase 
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ligand binding avidity 46. TLR intracellular signalling cascades are introduced in 
section 1.3.2.  
 
The complete picture of TLR function in antimicrobial defence remains unresolved, 
however TLR ligation is essential in provoking inflammatory and innate effector 
responses and enhancing adaptive immunity against pathogens 47;48. Furthermore, 
members of the TLR family have also been implicated in the pathogenesis of 
autoimmune, atherosclerosis, chronic inflammatory, asthma, rheumatoid arthritis and 
infectious diseases 49-57. In reality, the host is constantly exposed to TLR ligands and 
stress induced proteins that if left unchecked would result in overwhelming 
inflammatory cytokine production and chronic myeloid cell activation. TLR function 
and signalling cascades are therefore tightly regulated during homeostasis and 
throughout ongoing innate inflammatory responses to limit gratuitous host 
immunopathology. The complexity of this regulation is introduced in section 1.3.2.  
 
In addition to TLR family members expressed on the cell surface and in endosomal 
compartments, there is an additional family of cytosolic PRRs that detect the 
presence of pathogens that reside and replicate intracellularly. These include the nod 
like receptors (NLRs) and the intracellular sensors of viral nucleotides, retinoic acid 
inducible gene I (RIG-I), melanoma differentiation associated gene 5 (MDA5) and 
DNA dependant activator of interferon regulatory factors (DAI). The NLR family is 
composed of circa 20 intracellular proteins that share a common protein domain. All 
NLRs contain a nucleotide binding oligomerization domain (NOD) followed by a 
leucine rich repeat domain. NLRs can be further categorised in to three subfamilies, 
NOD, NALP and NAIP, by virtue of their amino terminus domains 58;59. It is this amino 
terminus domain that determines ligand specificity and downstream functional 
properties. The proteins of the NOD family, NOD 1 and NOD 2, have been shown to 
sense bacterial peptidoglyans 60. The NALP family members, of which there are 14, 
in combination with NAIP family members combine to form varying types of 
inflammasome that are responsible for cleaving the precursors of several  
inflammatory cytokines, such as IL-1β, IL-18 and IL-33, through the activation of a 
cascade of caspases 61. Inflammasome generation can be induced by several 
bacterial infections but the precise mechanisms that control this remain unclear 62. 
The involvement of caspase activation has suggested that NALPs may also 
contribute to antimicrobial defence by inducing apoptosis of infected cells.  
 
 
CHAPTER 1: INTRODUCTION 
11 
 
 
 
 
 
 
 
 
In addition to TLR 3 and TLR7/8 recognition, cytosolic recognition of viral RNA is 
mediated by the RNA helicase family proteins RIG-I and MDA5, whereas viral DNA 
has been recently been shown to be detected by DA 63,64. These proteins recognise 
structural features of viral RNA that are absent from host RNA, therefore allowing 
discrimination and the rapid production of the type I interferons, IFN-α and IFN-β and 
thereby the induction of antiviral immunity 65-67. The details of how DAI recognises 
viral DNA and its subsequent anti-viral effector function remains to be elucidated.  
 
Figure 1.3 TLR and NLR expression patterns. The cellular location of TLR/NLR ligand 
determines the cellular location of the corresponding TLR/NLR. This acts as an additional 
regulatory mechanism that prevents unwarranted inflammation. Adapted from 
9-11
. 
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1.3.2 TLR signalling cascades 
Upon ligand recognition TLR signalling is initiated by receptor dimerisation or hetero-
dimerisation 68. With the exception of TLR 3, which utilises the alternative signalling 
adapter TRIF, activation of the receptor recruits MyD88, an intracellular adapter 
protein, through its TIR domain which interacts with the TIR domain in the 
cytoplasmic tail of the TLR. This receptor-adapter complex promotes the recruitment 
and activation of several downstream kinases such as IL-1 receptor associated 
kinases (IRAK) 1, 2 and 4 68. The order in which these adapters are recruited is 
important with IRAK 4 recruited first that subsequently becomes activated and 
phosphorylates IRAK 1. The importance of IRAK 4 recruitment and involvement in 
TLR signalling has recently been exemplified in a clinical study that highlights IRAK 
4‟s importance in childhood immunity to S. pneumoniae infection 69. This receptor-
adaptor complex then activates tumour necrosis factor associated factor 6 (TRAF 6) 
through death domain interactions common to MyD88 and IRAK adaptor proteins. 
Subsequently, the activation of additional kinases, including inhibitor of NF-κB (IκB) 
kinases (IKKs), results in the release of NF-κB from its inhibitory complex, allowing 
NF-κB to translocate to the nucleus and mediate inflammatory cytokine gene 
expression. A complex programme of cytokine production ensues resulting in a 
customised immune response relating to the initial TLR signal. Common TLR 
signalling cascades are depicted in Figure 1. 4.  
 
In order to generate pathogen specific immune responses and diversity in TLR 
responses a selection of intracellular adaptor molecules are utilised 70;71. For example 
TLR 3 uniquely uses TRIF to induce IFN-β synthesis through IRF-3 expression, a 
signalling pathway crucial for anti viral immunity 72;73. TLR 4 can also activate IRF 3 
through the use of TRIF, MAL and TRAM adaptor proteins 74;75. Additional pathways 
also contribute to TLR function, such as Jun N terminal kinase (JNK) and the mitogen 
activated protein kinases (MAPKs) 76;77. However, there remains a large void in our 
understanding in how a limited number of TLR can utilise a limited combination of 
adaptor signalling cascades to produce a highly specific and complex immune 
response ideally suited to the micro organism that was initially detected.    
 
1.3.3. TLR negative regulators 
As alluded to earlier, specific sites of the body, such as mucosal surfaces, are 
continuously exposed to a complex array of TLR ligands. Therefore, there must exist 
exquisite regulatory mechanism that determine when TLR signalling and effector 
functions are needed and when they are not. There exist several intracellular 
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negative regulators of TLR signalling that not only prevent unwarranted TLR 
responses during homeostasis but are also control the amplitude of TLR effector 
responses as a result of pathogen recognition. All TLRs, with the exception of TLR 3 
and 6, utilise MyD88 in combination with other adaptor proteins to initiate their 
effector signalling cascades. Extensive investigation has demonstrated that inhibition 
of MyD88 abrogates NF-κB activation, and that other adapters such as MAL, TRIF 
and TRAM can only partially recover NF-κB activation. MyD88 is therefore an ideal 
target for negative regulation as it is critical for the initiation of TLR signalling 
cascades. In addition IRAK family members also play a fundamental role in initiating 
TLR signalling cascades and are also the target for several regulatory mechanisms. 
Alternatively spliced variants of both MyD88 and IRAK family members play a key 
role in negative feedback regulatory mechanisms to control excessive TLR mediated 
signalling and in the fine tuning of TLR responses 78-80. This was demonstrated 
through over expression studies of MyD88s, an alternative spliced variant of MyD88 
that lacks an interdomain critical for TLR and IRAK 4 binding. The study highlighted 
expression of MyD88s inhibited IL-1 and LPS but not TNF-α induced NF-κB 
activation 78. Although MyD88 is ubiquitously expressed, expression of MyD88s has 
only been detected in the spleen and brain. Its expression has been shown in a 
human monocytic cell line THP-1 following a 16 hour stimulation with LPS 78. Over 
expression of IRAK 2 splice variants have also been shown to inhibit LPS induced 
NF-κB activation in a dose dependant manner and have been shown to be up 
regulated in RAW 264.7 macrophage cells 3 hours after LPS treatment indicating a 
possible feedback effect on TLR signalling 81. Figure 1.4 also highlights a number of 
negative TLR signalling regulators.  
 
Additional TLR regulatory mechanisms are discovered at an ever increasing rate and 
for brevity a few of the most significant mechanisms will be introduced herein. IRAK 
M is a family member of the IRAK family and has been shown to have considerable 
regulatory properties on TLR signalling. Macrophages isolated from IRAK M deficient 
mice produce enhanced levels of inflammatory cytokines in response to TLR 4 and 
TLR 9 ligands 82. IRAK M deficient mice also show increased in vivo inflammatory 
responses to bacterial infection compared with wild type mice, despite demonstrating 
equivalent bacterial load. Several members of the SOCS family have also been 
implicated in suppressing cytokine signalling 83. Furthermore, SOCS-1 deficient mice 
are highly susceptible to sepsis compared with wild type mice, consistent with the 
belief that SOCS-1 is a non redundant negative regulator of TLR signalling 84;85. 
However, two reports have indicated that the inhibitory effect of SOCS-1 on TLR 
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Figure 1.4 TLR intracellular signalling cascades and negative regulation. There exists a 
complex array of adapter proteins that inhibit and fine tune TLR receptor signalling in order to 
limit inflammation. Sterile alpha and armadillo motif containing protein (SARM). Adapted from 
9-
11
. 
signalling is indirect and occurs by inhibiting type I IFN signalling pathways following 
IFN-β up regulation by TLRs and not the main NF-κB pathway 86;87. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Other important inhibitory regulators include toll interacting protein (TOLLIP) that has 
been shown to interact with several TLR members and can inhibit TLR 2 and TLR 4 
medicated NF-κB activation through interacting with IRAK 1 88;89. In addition TOLLIP 
expression is elevated in intestinal epithelial cells which are hypo responsive to TLR 
2 ligands 90. A20 is another negative regulatory candidate that is rapidly induced by 
both LPS and TNF-α and is expressed by many cell types. A20 has been implicated 
in preventing the host from endotoxic shock and has been shown to cleave ubiquitin 
from TRAF 6 which is essential for TLR downstream signalling and NF-κB 
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translocation 91;92. This suggests that A20 can control both MyD88 dependant and 
MyD88 independent TLR signalling pathways. Finally, TLR signalling can be 
controlled through reducing or compartmentalising the expression of TLRs 
themselves or even through the removal of TLR expressing cells through apoptosis. 
This can be achieved by the degradation of TLRs through ubiquitylation or inhibition 
of TLR expression by anti inflammatory cytokines such as IL-10 and TGF-β 93-95. 
These mechanisms might play a physiological role in the tolerance to commensal 
bacteria. This concept is supported by the observation that intestinal epithelial cells 
(IECs) are non responsive to LPS stimulation but can mount a normal response to IL-
1, this is thought to occur due to the low expression of TLR 4 levels and the lack of 
MD2, a co-receptor for LPS, which is indispensible for TLR 4 signalling 96. 
Furthermore, there is growing evidence that pathogenic bacteria can regulate TLR 
signalling through the secretion of TIR domain homologues that directly bind to 
MyD88 and interfere with subsequent signalling cascades 97.  
 
1.3.4 Phagocytosis – pathogen clearance and apoptotic cells 
The eventual end point for the elaborate detection and recognition systems 
discussed above is ultimately to either tolerate or clear the micro-organism and 
develop immunological memory. In addition to the humoral aspects of both innate 
and adaptive immunity and the pleitropic activities of inflammatory cytokines, 
phagocytosis is necessary to ensure antigen presentation, pathogen clearance, 
resolution of inflammation and the initiation of tissue regeneration through the 
clearance of dead or apoptotic host cells from the site of infection.  
 
Classic phagocytosis can be characterised by membrane extensions that require Syk 
tyrosine kinases resulting in the activation of NADPH oxidase and the production of 
pro-inflammatory cytokines 7. However, there exist several forms of phagocytosis that 
do not require membrane extensions, do not involve Syk and are accompanied by 
the production of anti-inflammatory cytokines 7. Despite over 100 years of research 
into this fundamental mechanism, phagocytosis remains an incredibly complex 
process that requires many parallel signalling pathways that collectively define the 
phagocyte‟s response and fate. As is seen with TLRs, phagocytes express a broad 
spectrum of receptors that participate in target recognition and internalisation. Some 
of these receptors transmit intracellular signals that trigger phagocytosis whilst others 
appear primarily to participate in binding or increasing the efficiency of internalisation. 
Furthermore, some receptors enable the recognition and internalisation of opsonised 
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pathogens whilst others detect and rapidly degrade apoptotic host cells. Several of 
the most characterised phagocytic receptors are illustrated in Table 1.2.  
 
Table 1.2 Phagocytosis receptors 
 
 
 
 
All these receptors induce rearrangements in the actin-cytoskeleton that leads to the 
internalization of the micro-organism/apoptotic cell. However, fundamental 
differences in the underlying molecular mechanisms and ensuing response exist 
between the various receptors. For example, micro-organism phagocytosis through 
Fc mediated recognition results in pro-inflammatory cytokines production and 
assembly of the NADPH oxidase complex and super-oxide production, however, 
micro-organisms opsonised with complement do not initiate this inflammatory 
response 98. It is unsurprising therefore that many pathogen associated virulence 
factors target phagocytosis and phagolysosome fusion mechanisms in order to 
Phagocytosis receptors  Ligands 
Micro-organism receptors  
FcγRI (CD64) IgG, CRP, SAP-opsonised particles 
FcγRII (CD32) IgG, CRP, SAP-opsonised particles 
FcγRIII (CD16) IgG, CRP, SAP-opsonised particles 
FcεRI IgE-opsonised particles 
FcεRII (CD23) IgE-opsonised particles 
FcαRI (CD89) IgA-opsonised particles 
CR1 (CD35) MBL, complement-opsonised particles 
CR3 (αMβ2,CD11b/CD18, Mac1) Complement-opsonised particles 
CR4 (αXβ2,CD11c/CD18, gp150/95) Complement-opsonised particles 
SR-A Bacteria, LPS, LTA 
MARCO Bacteria 
Mannose receptor (CD206) Mannan 
Dectin-1 Β 1,3-glucan 
CD14 LPS, PDG 
C1qR(P) MBL, SAP and complement 
Apoptotic cell receptors  
SR-A LDL, PS 
SR-B (CD36) Collagen type I, PS, thrombospondin 
Vitronectin (αVβ3) Thrombospondin 
CR, complement receptor; SR, scavenger receptor; CRP, C-reactive protein; SAP, 
Serum amyloid P; PS, phosphotidylserine; LDL, low density lipoprotein. Adapted 
from 
7;8
. 
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ensure pathogen survival 99;100. On the contrary, phagocytosis of apoptotic cells is a 
process crucial in the development and homeostasis of all multi cellular organisms 
101; consequently it would be detrimental to the host if such phagocytic events 
invoked an inflammatory response. Indeed, it has been demonstrated that 
macrophages ingesting apoptotic neutrophils do not produce IL-1β, TNF-α, IL-8 and 
MCP-1, normally secreted by activated macrophages, instead they secreted anti-
inflammatory compounds such as TGF-β, prostaglandin E2 (PGE2) and platelet 
activating factor (PAF) 102. Furthermore, a recent study demonstrated that the 
phagocytosis of apoptotic lymphocytes by alveolar macrophage resulted in the 
production of PGE2 that subsequently compromised anti bacterial capacity of the lung 
103. It is becoming increasingly apparent that the decision to mediate an inflammatory 
or anti-inflammatory response is regulated by the co-operation of other receptors that 
themselves are not involved in phagocytosis. For example, TLRs are recruited to the 
de-novo phagosomes providing a mechanism by which phagocytosis and 
inflammatory responses can be linked 104;105. This suggests that the activation state of 
the macrophage might dictate the combination of receptors used, and this, in turn, 
could influence whether phagocytosis is accompanied by anti-inflammatory or pro-
inflammatory mediators. This remains a very exciting and active area of research.  
 
1.4 Innate immune regulation 
1.4.1 Regulatory receptors and inflammatory activity of myeloid cells 
As discussed above, the immune system must detect and quickly respond to the 
presence of an invading micro organism to ensure both host survival and pathogen 
clearance, but at the same time demonstrate a degree of refinement to minimize 
inappropriate or over-exuberant inflammation and immunopathology 106;107. As 
previously mentioned, myeloid cells represent a population of immune cells with 
pleiotropic functions that utilise an array of potent effector functions that can result in 
unwarranted pathology to the host unless their activity is tightly controlled. Regulation 
can be achieved through cognate cell-cell interactions or via the secretion of soluble 
mediators 108;109. Although the secretion of soluble factors can modulate a large 
number of cells over a large area of tissue, direct cell-cell contact mediated 
regulation provides a more specific and selective method of regulation. Investigation 
into the receptor interactions that mediate myeloid cell regulation identified members 
of the immunoglobulin superfamily (IgSF) as being important. The IgSF domain is the 
most abundant domain type in leukocyte surface proteins and receptors and has 
been shown to play a major role in regulating immune system function. Receptors 
CHAPTER 1: INTRODUCTION 
18 
with IgSF domains that regulate myeloid cell activity include CD200R, CD172a 
(SIRP-), triggering receptors expressed on myeloid cells (TREM1 and TREM2) and 
macrophage Ig-like receptor (MIR) 110-113. 
1.4.2 CD200 – CD200R interaction and the regulation of myeloid cells 
After CD200 (OX-2) was discovered in rat brain and thymus over 25 years ago it has 
now been shown to impart an inhibitory signal delivered to the myeloid cell through 
ligation with its receptor CD200 receptor (CD200R) 114. CD200 was subsequently 
cloned and characterised in mice and humans 114-116. Ensuing cloning analysis 
identified CD200 as a 41-47kDa transmembrane surface glycoprotein and a member 
of the IgSF with 2 extracellular IgSF domains 114;117. In mice, it is a protein of 269 
amino acids constituting a hydrophobic signal peptide, a membrane distal Ig-V-like 
domain, a membrane proximal Ig-CH2-like domain, a transmembrane segment and a 
short cytoplasmic tail 115;116. It also possesses 6 N-linked glycosylation sites and 
shares structural homology to CD80/CD86. The cytoplasmic tail is only 19 amino 
acids long and shares no homology to known signalling kinases, which, combined 
with the lack of an ITIM/ITAM sequence or SH2/SH3 domain implies that it lacks any 
ability to induce an intracellular signal. 
 
The cellular distribution of CD200 is very similar in mice, rats and human suggesting 
that it plays a fundamental role in the immune system of higher vertebrate 110;114;118. 
To date CD200 expression has been reported on thymocytes, B cells, activated T 
cells, neurons, follicular dendritic cells, endothelium and cells in reproductive organs 
110;114;118-121.  
 
After the discovery of CD200, Barclay et al were also responsible for identifying and 
cloning its corresponding receptor, aptly named CD200R, and postulated its likely 
origin as a result of gene duplication of the CD200 gene 110. The receptor has 
subsequently been independently characterised in humans and mice 122;123. Similar to 
its ligand, CD200R is also an IgSF member, containing two extracellular IgSF 
domains, it also possesses an unusually high number of N-linked glycosylation sites, 
with 8 identified in rats and 10 in mice 110;123. In addition, the cytoplasmic tail of 
CD200R contains 67 amino acids, substantially longer than the cytoplasmic tail of 
CD200. Further analysis identified the presence of three tyrosines residues as 
potential phosphorylation sites, therefore implying that the action of CD200 is solely 
delivered through the receptor and is not bi-directional 110;123. One of these tyrosine 
residues is located within a NPXY motif, and a recent study in mast cells has 
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demonstrated this residue is phosphorylated upon ligation of the receptor 124. 
Furthermore, this phosphoryation leads to the recruitment of adaptor proteins Dok-1 
and Dok-2, which are in turn phosphorylated and associate with RasGAP and SH2-
containing inositol phosphatase (SHIP). Ultimately, this was demonstrated to inhibit 
the phosphorylation of ERKs, p38 and JNK 124. There have, however, been limited 
studies thus far citing the downstream signalling events from CD200R in other 
myeloid cells. 
 
CD200R expression is far more restricted than that of the ligand being largely 
confined to myeloid cells. The expression profile of the receptor again appears to be 
conserved between mice, rats and humans and has thus far been described upon 
macrophages, dendritic cells, neutrophils, basophils and mast cells 110;123-125. Though 
expression appears largely confined to myeloid cells, a number of studies describes 
expression of CD200R on peripheral blood CD4+ T cells and B lymphocytes in mice 
and humans, and further identified high levels of CD200R mRNA expression in Th2 
polarised T cells 123;126. Furthermore, several more members of the CD200R family 
have recently been identified, taking the existing number to four isoforms of CD200R 
in mice (R1-4) and two in humans (R1-2), yet the exact role of these other receptors 
as well as their natural ligands remains ambiguous 123;127. Table 1.3 highlights the 
expression profiles of CD200 and CD200R.    
 
Table 1.3 Cellular expression of CD200 and CD200R 
 
Cell Type CD200 CD200R 
T cells -/+ -/+ 
Thymocytes + - 
B cells + - 
Monocytes/Macrophage - + 
Dendritic cells -/+ + 
Neutrophils - + 
Mast cells - + 
Basophils - + 
Endothelium -/+ - 
Epithelium -/+ - 
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1.4.3 In vivo role for CD200 and CD200R – the knock out power of mice 
The development of CD200 and CD200R knock out (KO) mice provided the first and 
best clues as to the physiological role for CD200 and CD200R 128. Studies 
highlighted that the intrinsic defects demonstrated in naïve CD200 KO mice occurred 
in cells that expressed CD200R rather than the cell types expressing CD200. Naïve 
CD200 KO mice develop splenomegaly and display heightened numbers of splenic 
CD11b+ myeloid cells, elevated numbers of splenic red pulp macrophages and a 
thicker marginal zone macrophage layer 128. Furthermore, elevated levels of the 
immunotyrosine activating motif (ITAM) containing intracellular DAP-12 were 
detected within the marginal zone and on dendritic cells located within the red pulp. 
This implies an elevated level of myeloid cell activation. Lymph nodes are also 
slightly enlarged and exhibit an unusual tubular structure with no demarcation 
between nodes. Macrophage populations are again expanded and exhibit heightened 
activation. Microglia (macrophage-like cells of the CNS) also exhibit heightened 
activity, forming clumps reminiscent of that seen with inflammation or neural 
degeneration and express heightened levels of activation markers CD11b and CD45.  
 
This apparent abnormality in myeloid homeostasis correlated with an increased 
propensity for the development of autoimmune conditions, showing increased 
susceptibility to collagen induced arthritis (CIA) 128; experimental autoimmune 
uveoretinitis (EAU) 129;130, a model for retinal inflammation; and experimental 
autoimmune encephalitis (EAE), a model of multiple sclerosis 128 and a model for 
alopecia 131. Symptoms of these diseases develop more rapidly in CD200 KO mice 
and lesions contain greater macrophage numbers in a heightened activation state. 
Collectively, these studies suggest that CD200 fulfils a significant role in regulating 
macrophage activation and ensuing inflammation, and that the CD200-CD200R 
interaction is important in down-regulating the activity of myeloid cells expressing 
CD200R 128;132. CD200 has also been shown to be up-regulated on the surface of 
several tumours including chronic lymphocytic leukaemias 133-135. Additional support 
to the concept of CD200 attenuating inflammatory and immune responses is 
provided by the recent identification of viral homologues of CD200, such as human 
herpesvirus 8, cytomegalovirus and myxoma virus, that transmit an inhibitory signal 
to tissue macrophages and dendritic cells, thereby reducing their ability to prime T 
cells and preventing viral clearance 136-139.   
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1.4.4 The CD200 – CD200R axis: A potential immunotherapeutic target 
There is overwhelming evidence to suggest that CD200 has the capacity to modulate 
myeloid cell activity in an inhibitory manner. Manipulation of the CD200-CD200R 
interaction has clearly defined an important role for these molecules in dictating the 
phenotype of the myeloid response in conditions characterised by excessive 
immunity. Furthermore, it has become apparent that delivery of this inhibitory signal 
can be utilised immunotherapeutically to alleviate symptoms attributable to such 
excessive immunity or block inhibition in situations of tumour immune suppression.  
For example, the use of a blocking CD200 antibody, thereby inhibiting CD200-
CD200R interaction, has been shown to exacerbate EAE and CIA, whilst the 
administration of an agonistic antibody to CD200R or a CD200:Fc fusion protein halts 
CIA disease progression and can reduce established arthritic disease 110;128;140;141. 
Several of the studies described above also cited the potential for manipulating the 
CD200-CD200R axis during autoimmune conditions.  
 
Finally, there is also a clear role for CD200 in governing alloimmunity. It has been 
demonstrated that blockade of CD200 signalling reduces graft survival 142 and that 
the administration of CD200:Fc results in prolonged graft survival in both 
allotransplants and xenotransplants 143. Furthermore, the expression of CD200R on 
mast cells begs the question of the involvement of CD200 in regulating allergy and 
other atopic diseases 110;123. Indeed, in a murine model of passive cutaneous 
anaphylaxis (PCA), the systemic administration of an agonistic antibody to CD200R 
inhibits FcR1-dependent responses 144. 
1.4.5 The mechanism underlying CD200 mediated inhibition 
The potential therapeutic applications for CD200-CD200R manipulation are clear, 
however, the molecular mechanisms that determine the inhibitory effect of CD200 
when bound to CD200R remain ambiguous. A recent study demonstrates that 
CD200 signalling inhibits degranulation in mast cells and basophils and production of 
IL-13 and TNF-α by mast cells 125;144. Furthermore, an agonistic antibody to CD200R 
was demonstrated to reduce IFN-γ and IL-17 induced production of IL-6 in murine 
resident peritoneal macrophages, and reduced cytokine and chemokine production of 
CD200R transfected U937 cells 145. Therefore, it would appear that signalling through 
CD200R reduces the ability to produce pro-inflammatory cytokines. Finally, ligation of 
CD200R on plasmacytoid dendritic cells causes an up-regulation of indolamine-2,3- 
dioxygenase (IDO) expression and activity 146. IDO mediates the catabolism of 
tryptophan leading to its immunosuppressive products being generated, and high 
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levels of IDO expression are affiliated with inhibition of alloreactivity and enhanced 
regulatory T cell function 147-149. 
1.5 Adaptive Immune response to respiratory Infection 
Fundamental to the resolution of infection and the development of immunological 
memory is the establishment of an acquired specific immune response, comprising 
both T cell mediated and humoral B cell responses.  
1.5.1 T Cell mediated immunity 
T cells are a subset of lymphocytes that originate from the bone marrow and mature 
in the thymus. They are identified by the expression of CD3 and can be further 
categorised into two main subsets: CD4+ T helper (Th) lymphocytes and CD8+ 
cytotoxic (CTL) lymphocytes. CD4+ helper T cells exert their effector function 
primarily through the release of cytokines that activate and stimulate other cells. They 
also fulfil a significant role in antibody production by providing a critical signal for B 
cell activation through the CD40-CD40L interaction. CD8+ cytotoxic T cells are 
proficient killers of infected and tumour cells, lysing infected cells via a 
perforin/granzyme or a Fas/FasL-dependent mechanism. They are also critical 
mediators in the resolution of viral infections 150.  
 
Activation of both CD4+ and CD8+ T cell subsets requires interaction of the α and β 
chains, that make up the T Cell Receptor (TCR), in combination with CD3 and 
antigen peptide displayed on the major histocompatability complex (MHC) of the 
antigen presenting cell (APC). Antigenic products can be processed by distinct 
pathways and presented in conjunction with MHC class I or class II molecules. MHC I 
expression is universally observed on all nucleated cells and such presentation is 
important in the activation of CD8+ T cells. Conversely, MHC II expression is 
restricted to APCs and such presentation of antigenic peptide is responsible for the 
activation of CD4+ T cells. In addition to classic αβ TCR expressing T cells there 
exists a small number of T cells that utilise a γδ TCR. These γδ T cells are often 
associated with mucosal sites and anticipated to infer protection of epithelial 
surfaces. Furthermore, there is a population of unique intraepithelial T cells (CD103+) 
in the respiratory tract, which recognize generic immunological distress signals rather 
than pathogen specific motifs, and fulfill a significant role in the recognition and 
eradication of infected epithelial cells 151. 
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In addition to TCR/MHC interaction a second co-stimulatory signal, provided by the 
APC, is needed to ensure activation of naïve T cells. The successful integration of 
two such signals results in the proliferation and differentiation of antigen specific T 
cells. The most well known co-stimulatory signal is the CD28/B7 pathway, which 
governs activation of naïve T cells 152. This co-stimulatory signal up-regulates IL-4, 
IL-5, IL-8, IL-13, IFN-γ and TNF-α 153;154, and prevents T cell anergy 155;156 or cell 
death by inducing the expression of the anti-apoptotic molecule Bcl-XL both in vitro 
and in vivo 157;158. Other co-stimulatory signals include OX40, 4-1BB, ICOS and CD27 
152;159;160.  
1.5.2 T helper cell subset classification 
The CD4+ T helper subset can be further subdivided into Th1, Th2, T regulatory (Treg) 
and Th17 cells defined by the distinct array of cytokines each subset produces; IFN-γ, 
TNF-α and IL-2 from Th1 cells; IL-4, IL-5 and IL-6 from Th2 cells; IL-17 and TNF - α 
from Th17 cells and IL-10 and TGF-β from Treg 
161-166. In recent years the addition of 
multiple Treg subsets has added complexity in understanding T cell immunology. Treg 
consist of four main subsets; natural Treg that express CD4, CD25 and CD152 as well 
as the transcription factor foxp3; Tr1 cells, that are induced Treg cells which do not 
express foxp3, these express high levels of CD152 and require IL-10 for their 
differentiation and suppression; and anergic CD4+ and CD8+ cells that are capable of 
suppression by competing for antigen and IL-2; they have a very high stimulation 
threshold and therefore do not become activated except in situations of very high 
antigen exposure 167. Some studies also imply that CD8+ T cells can also be 
subdivided on cytokine secretion profiles 168. In spite of these concerted attempts to 
define each T helper subset by their individual cytokine and transcription factor 
expression profile, the distinction between the various subsets in vivo remains 
ambiguous. For example, some view the Th1/Th2 dichotomy not as discrete subsets, 
but rather as a continuum of different combinations of cytokines 169. Figure 1.5 
highlights the cytokine production profile from each subset and the transcription 
factor that is used as a marker for each subset differentiation. 
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1.5.3 Subset differentiation and function 
 
Peripheral T cells exists as a common naïve precursor that upon antigen stimulation 
secrete IL-2 before differentiating, via an intermediate (Th0), into one or more distinct 
polarized subset 170-172. The generation of a specific subset directed response is 
dictated by the cytokine milieu at the time of T cell activation 173;174, although the 
antigen dose, environmental conditions and transcription factor expression has also 
been shown to be important 175. Longer contact of MHC with the TCR is required to 
Figure 1.5 CD4
+
 T Cell subsets. CD4
+
 T helper subsets are derived from CD4
+
 peripheral 
precursors under specific cytokine environments. The transcription factors that determine 
each subset and the cytokines that each subset produces are also shown. Reviewed in 
3
. 
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produce a stable Th2 response than Th1; it is also suggested that a higher degree of 
stimulation is required for Th1 polarisation 
176;177. 
 
Another feature of T cell subset differentiation is the strong antagonism observed 
between different T cell subsets 178-181. An example of these self-reinforcing gene 
expression patterns is highlighted by IFN-γ gene expression and concomitant 
silencing of IL-4 gene expression, while the opposite is seen on Th2 differentiation 
182. 
Type I and II interferon signalling causes the STAT1-dependent expression of IL-12 
receptor; ligation of this IL-12R leads to activation of T-bet, a transcription factor 
critical for the development of Th1 responses, and STAT4-dependent potentiation of 
IFN-γ production. In a Th2  polarised response, IL-4 signalling activates STAT6 and 
the transcription factor GATA-3 182. GATA-3 suppresses STAT4 while inducing 
positive epigenetic changes in the Th2 cytokine cluster of IL-4, IL-5 and IL-13 genes 
183;184. Less is understood about how Th17 and Treg subsets are polarised although IL-6 
and TGF-β have been implemented in Th17 polarisation (reviewed in 
185). Such 
antagonism reinforces development of distinct polarised T helper subsets and 
explains the strong bias observed in many infection models. Th17 cells are entirely 
separate from the Th1 and Th2 lineages; cytokines from both Th1 and Th2 cells 
antagonise Th17 generation, and it is likely that they have evolved to deal with 
different pathogens to those efficiently cleared by Th1 and Th2 responses 
162. IL-23 
can polarise naïve cells into Th17 cells in an ICOS and CD28-dependent manner (Th1 
cells are dependent on CD28 but not ICOS) 162. Generation of Th17 cells is 
independent of STAT1, STAT4 and STAT6 but requires TGF-β 162;186;187. In APC-free 
culture conditions, Th17 cells can be generated with the addition of only TGF- β and 
IL-6 186. 
 
During the generation of functional T cells, inappropriate self-directed effector 
responses are avoided primarily by deletion of self-reactive clones in the thymus. 
However, many antigens are not present in the thymus, and T cells are capable of T 
cell receptor (TCR) rearrangement in the periphery. To regulate effector responses, 
subsets of Treg have evolved, which are suppressive of activation of other cells in a 
contact-dependent mechanism. Treg are able to interact with and suppress both Th1 
and Th2 effector T cells both through MHC-dependent mechanisms via DC, and 
directly through T cell-T cell interactions 161. Treg can be either CD4
+ or CD8+. There 
are four main Treg subsets; natural Treg are produced in the thymus and constitutively 
express CD4 and CD25 as well as the transcription factor foxp3 and surface CD152. 
Their generation is dependent on TGF- β. Tr1 cells, by contrast, are induced Treg, 
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which do not express foxp3 but express high levels of CD152 and require IL-10 for 
their differentiation and suppression. In addition to these Treg subsets, anergic CD4+ 
and CD8+ cells are capable of suppression by competing for antigen and IL-2; they 
have a very high stimulation threshold and do not therefore become activated except 
in situations of very high antigen exposure 167. 
 
Cytokine expression profiles of each subset determine the discrete functions 
implemented by each population in an immune response. Th1 cytokines enable a 
cell-mediated immune response to target intracellular pathogens by activating CD8+ 
cytotoxic T cells (CTLs), macrophages and NK cells, whereas a Th2 cytokine 
response induces a humoral response targeting extracellular pathogens – Th2 cell 
cytokines activate mast cells and basophils through IL-4 and eosinophils through IL-5 
188;189. This polarisation extends to the effect on B cell antibody production; Th1 and 
Th2 cells induce switching from IgM to IgG2a, but only Th2 can induce production of 
IgG1, IgA and IgE 190.  
 
1.6 Influenza A virus 
1.6.1 Epidemiology of influenza infection 
Influenza infection is an acute respiratory disease that is one of the most persistent 
and important infectious diseases that continues to afflict humans. Influenza is a 
global dilemma inducing seasonal epidemics that can affect 10 to 20 % of the 
population191. It is estimated that influenza A viral infections are responsible for 
between 10,000 to 20,000 deaths in the United Kingdom each year 192. Furthermore, 
increasing numbers of human deaths attributed to the South Asian avian H5N1 strain 
and the novel H1N1 pandemic influenza strain are likely to increase influenza 
associated morbidity and mortality.   
 
Influenza infection is typically self-limiting, culminating in a local and systemic 
reaction, whereby the afflicted individual may experience fever, chills, headaches, 
coughing and myalgia. However, there remain a significant proportion of patients who 
are considered to be at high risk of developing severe illness and complications, such 
as the elderly, the very young, pregnant women and the immunocompromised.  
1.6.2 Classification and structure 
Influenza viruses are enveloped, single stranded negative sense RNA viruses that 
belong to the family Orthomyxoviridae. Of the three types of influenza virus, types A 
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and B cause seasonal epidemics whilst C causes sporadic disease. Type A viruses 
can be further subtyped based on the haemagglutinin (HA) and neuraminidase (NA) 
surface-expressed glycoproteins. These outer membrane proteins are functionally 
significant and are essential to the viability and replicative potential of the virus. The 
HA protein is fundamental for binding and subsequent fusion to the host cell, 
whereas the NA protein fulfils a critical role in preventing viral aggregation and aiding 
release of viral particles from the host cell post-replication. Currently, 16 HA (H1-
H16) and 9 NA (N1-9) subtypes have been identified in type A viruses. The RNA 
genome of influenza consists of 8-segmented genes, containing the genetic 
information for expression of 10 viral proteins, each encased by nucleoprotein (NP) 
193.  
 
1.6.3 Antigenic shift and drift 
The ability of influenza virus to cause seasonal infection across the human 
population is attributed, in part, to its antigenic variability that enables it to 
successfully evade pre existing neutralizing antibodies of the host. As introduced 
above, influenza A viruses express HA and NA on its surface to enable the virus to 
gain access to and exit cells. Antigenic variation in these glycoproteins allows viral 
immune evasion and is largely responsible for the generation of novel viral strains 
responsible for epidemics and pandemics. There are to date at least 16 
haemagglutinin subtypes and 9 neuraminidase subtypes. Human infection is 
commonly restricted to 3 HA subtypes (H1-3) and 2 NA (N1-2), with the remaining 
subtypes being seen in viruses that persist within avian reservoirs.   
 
The antigenic variability that occurs within the influenza genome takes two forms: 
antigenic drift and antigenic shift. Antigenic drift occurs when genes encoding the 
surface glycoproteins undergo stepwise mutation, owing to the low fidelity of the 
influenza RNA-specific RNA polymerase (replicase) which lacks proof reading 5‟-3‟ 
exonuclease activity. These mutations can lead to attenuated or non viable influenza, 
but can also result in immune evasion allowing the virus to continue to replicate. If 
the surface glycoproteins are sufficiently different that the host‟s antibodies are 
incapable of neutralizing it then the new strain is capable of causing disease.  
 
Antigenic shift is a far less frequent form of antigenic change but can lead to the 
generation of a novel influenza viral strain capable of causing a large epidemic or 
pandemic. Antigenic shift occurs when two different viruses from distinct host‟s 
(possibly different species) co-infect a single host and exchange gene segments. The 
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ensuing re-assortment results in a new virus that possesses gene segments from 
each of the two original strains. This re-assortment can result in viral attenuation, but 
it can also result in a highly virulent viral strain due to expression of novel surface 
proteins derived from the animal host virus. In this scenario, the human host may 
possess little or no immunity to the novel surface proteins and the new variant can 
cause widespread disease through evasion of the host‟s immune response.  
 
1.6.4 Influenza A viral replication cycle 
Influenza virus is transmitted between individuals through droplet dispersion of viral 
particles from infected hosts 194;195. The primary site of infection are epithelial cells of 
the upper respiratory tract, however alveolar macrophages and airway resident 
leukocytes have also been shown to be infected 194-196. Influenza virus has the ability 
to infect any cell that possesses a suitable receptor, notably those expressing a 
specific form of sialic acid containing cell surface glycoprotein 195;196. For example, 
HA molecules on avian viral strains preferentially bind to α 2,3 linked sialic acids, 
whereas the HA from human influenza viruses prefer α 2,6 linked sialic acids 197. This 
difference, together with the occurrence of α 2,6 linked sialic acids on non ciliated 
human tracheal cells likely explains the difference in tropism between avian and 
human influenza viruses 198;199. As introduced above, attachment and fusion to the 
host cell is mediated through HA. HA exists as a native precursor termed HA0, which 
attaches the virion to putative cell surface receptors containing sialic acid, and is 
subsequently cleaved through the action of extracellular host proteases to yield HA1 
and HA2 194;200. The virion is subsequently endocytosed to form an endosome with 
HA2 mediating the fusion between virus membrane and host cell 194;195. The low pH 
of the endosome induces a conformational change in the HA2 protein, culminating in 
enhanced proximity of viral and host cell membranes, and ultimately the fusion event 
194;195;201. Fusion subsequently leads to the liberation and nuclear import of viral 
nucleocapsids, which contains the crucial genetic code that dictates the amplification 
and generation of substantial viral progeny.  
 
The viral RNA genome, once inside the host nucleus, is transcribed by viral RNA 
polymerases resulting in the synthesis of viral mRNAs. The mRNAs are subsequently 
transported to the cytoplasm of the host cell where they are translated to form viral 
nucleoproteins and polymerases 195;201. The newly generated viral proteins are then 
re-directed towards the host nucleus where they assist in viral replication and further 
mRNA synthesis 195;201. This positive feedback loop greatly amplifies the quantity of 
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viral RNA and proteins, which are subsequently packaged to form viral nucleocapsids 
that are exported from the nucleus before budding from the host plasma membrane 
to form active virions 195. Hence the virus envelope is derived from host cell plasma 
membrane and the budding event is mediated via influenza neuraminidase protein. 
Figure 1.6 depicts the replication cycle of influenza A virus.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.6.5 Immunity to influenza 
Succeeding influenza infection, the immune system of the host mounts an immediate 
response to restrict viral replication and limit the associated cytopathology. Infected 
cells activate a host of transcription factors, including NF-kB (nuclear factor-kB), IRFs 
(IFN regulatory proteins) and NF-IL6 (nuclear factor of interleukin-6), that co-ordinate 
the release of chemokines and cytokines that subsequently initiate antiviral defences 
195. Infected epithelial cells primarily release RANTES, MCP-1 and IL-8, whereas 
monocytes/macrophages secrete MIP-1α, MIP-1β, RANTES, MCP-1&3, IFNα/β, 
TNFα, IL-6 and IP-10 202. The plethora of chemokines released ultimately favours the 
recruitment of blood mononuclear cells to the site of infection. NK cells, in addition to 
their cytotoxic function, also contribute to the cytokine milieu releasing IFNγ, TNFα 
Figure 1.6 Influenza A virus cycle. Influenza virus binds to sialic acid containing receptors 
and enters the cell via an endocytic pathway (1). After fusion of viral and endosome 
membranes viral ribonucleoprotein complexes are transported into the nucleus (2-3). A series 
of primary and secondary transcriptions occur which produces viral transcription machinery 
and structural proteins (4-5). Viral nucleocaspsids are assembled in the nucleus, transported 
into the cytoplasm, where budding and release of new virions takes place (6). 
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and GM-CSF, all of which activate APCs 195. Neutrophils are also prominent, and 
again, their numbers reflect the virulence and dose of virus. In the early phase of the 
response IFNα/β is critical in the containment and resolution of an influenza infection 
due to direct anti-viral effects and potential to mediate the further recruitment of 
inflammatory cells 203;204.  
 
Ultimately, to resolve viral infection effectively, the induction of an adaptive immune 
response is a requirement and a combination of both cell-mediated and humoral 
components fulfil essential roles. Antibodies specific to HA and NA are fundamental 
in resistance to infection and subsequent recovery, as they act to neutralize viral 
infectivity and hinder viral release from infected cells. Cytotoxic CD8+ T cells also 
confer a central role in resolution of viral infection via their cytopathic elimination of 
infected cells, whilst CD4+ T helper cells also confer a significant role in resolution of 
influenza infection via the delivery of signals to the main effectors 194. 
 
1.7 Group B Streptococcus 
1.7.1 Epidemiology of Group B Streptococcus 
Group B Streptococcus (GBS), also known as Streptococcus agalactiae, is the 
leading cause of invasive bacterial infections in human neonates and is increasingly 
recognised as a pathogen in adult populations including the elderly, pregnant 
women, diabetics and the immunocompromised 205;206. GBS is an opportunistic 
pathogen that colonises the gastrointestinal and genitourinary tract of up to 50 % of 
healthy individuals 207. Approximately 20-30 % of healthy women are colonised 
rectovaginally with GBS and a high percentage of neonates born to infected women 
will themselves become colonised with the bacterium 208. The overall incidence of 
invasive neonatal GBS disease has been estimated to be 0.6 to 1.8 cases per 1000 
live births in the USA with mortality rates between 4-6% 209.  
 
Neonatal GBS infections can be characterised into two distinct forms, early-stage 
onset and late-stage onset. Early-stage onset infections are classified as occurring 
within one week of partum and present symptoms of respiratory pneumonia 
complicated by bloodstream septicaemia. This type of infection typically results from 
an ascending infection of the bacterium through the placental membrane in utero, or 
alternatively by aspiration of infected vaginal fluids during the birth process into the 
neonate lung 210. In contrast, late-stage onset infection occurs in infants between 1 
week and 4 months of age with gradual symptoms related to bacteraemia and a high 
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incidence of meningitis 210;211. Late-onset is much less common than early-onset 
disease but is becoming increasingly important as its incidence is not declining as a 
result of prophylactic measures 211;212. Little is known about the pathogenesis of late-
onset infections, but vertical transmission from mother to baby probably explains 
most infections during this period. The major risk factors for GBS invasive infection 
include rupture of membranes before labour onset and increased interval between 
membrane rupture and delivery 210. Importantly, a substantial proportion of neonates 
who survive GBS infection suffer from sequelae, cortical blindness, deafness, 
uncontrolled seizures and speech and language delay 210. Nevertheless, despite the 
clinical importance of GBS our knowledge about the molecular events that lead to the 
development of invasive disease is very limited.  
 
1.7.2 Classification and structure 
GBS belongs to the family Streptococcaceae and is characterized by the Lancefield 
group B antigen. GBS is a Gram positive encapsulated bacterium possessing an 
array of immune resistance phenotypes and secreted toxins. Based on variations of 
the capsular polysaccharide (CPS), nine different serotypes have been described; 
serotypes Ia, Ib and II-VIII. Numerous experimental investigations have illustrated 
that only four serotypes, Ia, II, III and V, account for 80-90% of all clinical isolates 213. 
GBS are commonly identified by colony phenotype and the presence of β-haemolysis 
when plated on sheep blood agar. In addition, a number of biochemical tests exist 
that can distinguish between the individual GBS serotypes 214.  
 
1.7.3 GBS Virulence factors 
The spectrum of GBS disease reflects a complex interplay of the host innate and 
adaptive immune systems with many surface associated and secreted bacterial 
components. Disease progression indicates that GBS has to adhere, invade and 
transcytose several epithelial and endothelial cell barriers to gain access to the 
bloodstream and cause invasive disease. GBS contains several virulence factors that 
contribute to disease at critical junctures of the infection process. The CPS is 
regarded as the most important virulence factor, as noncapsulated isogenic mutants 
are avirulent and a correlation was found between the lack of maternal anticapsular 
antibodies and invasive neonatal disease 215;216. One mechanism by which CPS acts 
is by inhibiting the binding of the activated complement component C3b to its 
surface, preventing the activation of the alternative complement pathway 217.  
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In early-onset GBS disease, severe pneumonia and pulmonary damage is the major 
clinical presentation 218. Investigations into the cause of this pathology identified the 
β-haemolysin/cytolysin (βH/C) surface associated toxin as having cytopathic effects 
on pulmonary epithelial cells 219. The βH/C toxin is a surface associated molecule 
expressed by the majority of GBS strains and is encoded with in the GBS cyl operon 
220. The βH/C toxin is cytolytic for a broad range of cells including fibroblasts, lung 
epithelial cells, macrophage and neutrophils 219;221;222. In addition, an interesting 
feature of the βH/C toxin is its close association to an orange-red carotenoid pigment 
co-expressed on the surface of GBS. The pigment has recently been found to play a 
role in pathogenesis by virtue of antioxidant properties. The pigment confers 
protection against antimicrobial effects of hydrogen peroxide, singlet oxygen and 
superoxide, all of which play a role in the oxidative burst killing mechanisms of host 
phagocytic cells 221.  
  
GBS encodes several other virulence factors, including a C5a peptidase that cleaves 
the chemotactic complement component C5a causing impaired leukocyte recruitment 
to sites of infection 223.  A secreted hyaluronate lyase allows GBS to break down 
hyaluronic acid, a major component of the connective tissue, and has been 
postulated to facilitate spread through infected tissue 224. Due to space limitation 
Table 1.4 summarises the key virulence factors of GBS.   
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Table 1.4 Key virulence factors of Group B Streptococcus 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.7.4 Immunity and host interactions 
As previously mentioned, during the course of infection GBS encounters a number of 
different barriers. GBS attaches and gains access to target cells using a combination 
of membrane bound and secreted factors, illustrated in Table 1.2 above. 
Nonetheless, entry into the bloodstream, as occurs in invasive neonatal infections, 
requires the bacteria to not only traverse the pulmonary epithelial cell layer, the 
basement membrane and the vascular endothelial layer but simultaneously subvert 
ensuing innate defence mechanisms.  
 
Adapted from 
6
. 
 
Virulence factor Gene name 
Chemical 
nature 
Molecular/ cellular 
action(s)  
Contribution(s) to 
disease pathology 
Exopolysaccharide 
capsule 
cpsA-L,  
neuA-D 
High molecular 
weight polymer 
with terminal 
sialic acid 
residues 
Impairs complement C3 
deposition. Decreases 
immune recognition through 
molecular mimicry of host 
sialic acid epitopes. 
Blocks opsonophagocytic 
clearance. 
Delays neutrophil 
recruitment. 
β – haemolysin/cytolysin cylE 
CylE protein 
(79 kDa) 
Forms pores in cell 
membranes. Induces 
apoptosis. Promotes cellular 
invasion. Triggers NOs and 
cytokine release. 
Direct tissue injury. 
Penetration of epithelium. 
Induction of sepsis 
syndrome. Phagocytic 
resistance.  
+ linked pigment cyl locus Carotenoid 
Antioxidant blocks H2O2 and 
singlet oxygen. 
Impairment of oxidative 
burst killing.  
Hyaluronate lysase hylB 
HylB enzyme 
(110 kDa) 
Cleaves hyaluronan and 
chondroitin sulphate. 
Host dissemination. 
Impairs leukocyte 
trafficking. 
C5a peptidase sapB 
ScpB protein 
(120 kDa) 
Cleaves human C5a. Binds 
fibronectin. 
Inhibits neutrophil 
recruitment. Epithelial 
adhesion and invasion.  
CAMP factor cfb 
CAMP protein 
(24 kDa) 
CAMP reaction (co-
haemolysin). Binds to Fc 
portion of IgG & IgM. 
Direct tissue injury. 
Impairment of Ab 
function. 
Lipotechoic acid Complex 
Amphiphilic 
glycerol 
phosphate 
polymer of 
complex lipids 
and short chain 
fatty acid 
Binds host cell surfaces and 
TLRs. Alanylation inhibits 
host anti-microbial peptide 
function. 
Epithelial cell attachment. 
Activation of sepsis 
syndrome. Resistance of 
neutrophil killing.  
C protein (α and β 
components) 
bca (alpha) 
cba (beta) 
Alpha: protein 
with multiple 
identical 
tandem repeats 
(14-145 kDa). 
Beta 84-94 
kDa.  
Blocks intracellular killing by 
neutrophils. 
Epithelial cell attachment 
and invasion. Resistance 
to phagocytic clearance. 
Serine protease cspA 
CspA protein 
(142 kDa) 
Cleaves fibronectin to fibrin 
like fragments. 
Resistance to phagocytic 
clearance? Promotes 
tissue spread.  
Fibrinogen receptor fbsA 
FbsA protein 
(44.2 kDa) 
Binds fibronectin through 
repetitive structure motifs. 
Epithelium adherence. 
Resistance to 
opsonophagocytic 
clearance.  
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Effective phagocytosis of extracellular bacteria relies on efficient opsonisation by 
compliment and serotype specific antibodies. The importance of these mechanisms 
are illustrated by increased GBS susceptibility in neonates deficient of maternal 
antibody and a reduction of LD50 in C3 or C4 knockout mice 
215;225. GBS employs 
several mechanisms that act to impair opsonophagocytosis and as a result remain 
undetected by resident phagocytes. The ability to resist immune detection is also 
demonstrated by GBS ability to cleave C5a, a chemotactic component of the 
compliment system that plays a key role in neutrophil recruitment 223.  Even 
phagocytosis of GBS does not guarantee bacterial death as the presence of the CPS 
and the orange-red carotenoid permits GBS to survive within macrophage for more 
than 24 hours 226. Conversely experimental animal models have illustrated pulmonary 
surfactant, in particular surfactant protein A, can reduce haemolysin associated 
epithelial cell damage and inhibit bacterial proliferation 227;228.  
 
GBS remains a major cause of invasive bacterial infection in neonates, although 
extensive research is continuing to elucidate its virulence factors and mechanisms of 
immune suppression, the complex interaction between host and bacterium remain to 
be fully understood.  
 
1.8 Streptococcus pneumoniae 
1.8.1 Epidemiology of Streptococcus pneumoniae 
Streptococcus pneumoniae, commonly referred to as the pneumococcus, is the 
leading cause of morbidity and mortality among children worldwide, particularly in 
developing countries where it is responsible for approximately 25 % of all preventable 
deaths in children under the age of 5 and more than 1.2 million infant deaths per year 
229;230. It is estimated that 10.6 million children less than 5 years of age present with 
S. pneumoniae infections per year 229. However, the true burden of S. pneumoniae 
infection is likely to be much higher as disease surveillance systems and diagnostic 
facilities are limited in developing countries. In the developed, world S. pneumoniae 
is responsible for approximately 30 % of all hospitalised cases of community 
acquired pneumonia (CAP) which can have mortality rates of more than 20 % and an 
incidence of 18.3 cases per 100, 000 elderly persons 231-233. In countries with high 
HIV prevalence, there has been a significant increase in the incidence and 
prevalence of S. pneumoniae pneumonia and associated bacteraemia 234;235.  
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S. pneumoniae colonises the mucosal surfaces of the upper respiratory tract and can 
readily be cultured from the naso-oropharynx of healthy individuals. Once acquired, 
S. pneumoniae can be carried for weeks or months before its eventual clearance. 
The rates of carriage and distribution of disease causing serotypes vary considerably 
across geographical regions and age cohorts. The most prevalent serotypes 
worldwide are 6, 14, 19 and 23 but serotypes 1, 5 and 8, contribute significantly to 
invasive pneumococcal disease in young children in developing countries 236. The 
majority of those healthy individuals colonised with S. pneumoniae appear to be 
asymptomatic, however if bacteria gain access to sterile parts of the respiratory tract 
a rapid inflammatory response ensues that results in disease. The most common 
clinical manifestations of S. pneumoniae infection include acute otitis media (middle 
ear infection) or bacterial pulmonary pneumonia. In a small proportion of those that 
develop pneumonia, invasive bacteraemic pneumococcal pneumonia can precede 
which is associated with increased morbidity and mortality. The mortality rates of 
patients that develop invasive bacteraemic pneumococcal pneumonia range from 10-
30 % in adults and around 3 % in children 237. Furthermore, of those that survive 
invasive pneumococcal disease around 25-50 % suffer from long term sequelae 238. 
 
1.8.2 Classification and structure  
S. pneumoniae is an encapsulated facultative Gram positive diplococcus which 
grows in pairs or chains and belongs to the group of α-streptococci. Based on 
variation within the capsule polysaccharide (CPS) 92 separate serotypes of S. 
pneumoniae have been identified. S. pneumoniae produces several virulence factors 
that have a role in colonisation and invasive pneumococcal disease. These include 
the CPS, the cell wall and several protein factors such as pneumolysin, 
neuraminidase and autolysin. Figure 1.7 shows the basic structure and virulence 
factors that are expressed by S. pneumoniae. These and there impact on host 
physiology is introduced below.  
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1.8.3 S. pneumoniae virulence factors and colonisation  
A prerequisite for the development of carriage, invasive bacteraemic pneumococcal 
pneumonia and meningitis is adherence and colonisation of the nasopharyngeal 
mucosal epithelium. The implementation of an array of virulence factors (highlighted 
in Figure 1.7 and Table 1.5) allows S. pneumoniae to resist initial innate immune 
defences and gain a foothold within the host. The expression of a CPS is essential 
for S. pneumoniae virulence as strains that are CPS deficient are avirulent in mice 
and humans. CPS expression is thought to reduce entrapment within sialic acid rich 
mucopolysaccharides, therefore allowing access to the underlying epithelium, and 
also prevent opsonisation by complement, IgM and collectin binding proteins 
resulting in the avoidance of phagocytosis from sentinel phagocytes 239;240. CPS 
expression variants are also more resistant to opsonophagocytic killing and are 
selected for during transition from the mucosal surface to the bloodstream 241;242. All 
S. pneumoniae strains express a range of surface proteins that facilitate pathogen 
host cell interaction. The expression of phosphorylcholine (ChoP), a homologue of 
platelet activating factor (PAF), is common to several other microorganisms that 
reside in the upper respiratory tract. In S. pneumoniae, ChoP allows bacterial 
adherence to the receptor for platelet activating factor (rPAF) culminating in host cell 
signalling and subsequent inflammation 243. rPAF is widely distributed on the mucosal 
surfaces of both the upper and lower respiratory tract epithelium. Other studies have 
identified additional adhesin interactions with host cell glycoconjugates, such as the 
choline binding protein A (CbpA) and the expression of surface associated 
Figure 1.7 S. pneumoniae structure and virulence factors. Adapted from 
4
. 
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exoglycosidases; a neuraminidase (NanA), a β-galactosidase (BgaA) and a β-N 
acetylglucosaminidase (StrH) that act to remove terminal sugars from host 
glycoconjugates thereby unmasking putative receptors for adherence or providing a 
nutrient source 244;245. The surface expression of pneumococcal adhesion and 
virulence A (PavA) and enolase (Eno) have also been shown to enhance S. 
pneumoniae adhesion through binding to the extracellular matrix components 
fibronectin and plasminogen respectively 246;247. 
 
S. pneumoniae also produces the thiol-activated cytotoxin pneumolysin. Pneumolysin 
is a member of a family of cholesterol dependant cytolysins, such as streptolysin and 
listeriolysin produced by Streptococcus pyogens and Listeria monocytogens 
respectively, that are synthesised by Gram positive bacteria. Pneumolysin is 
produced as a 52 kDa soluble protein that oligomerizes in the membrane of target 
cells to form a large ring shaped transmembrane pore. Multiple studies have 
demonstrated that pneumolysin is a potent, wide ranging virulence factor and can be 
isolated in virtually all pneumococcal isolates 248-251.  Pneumolysin has been shown to 
contain multiple activities including; inhibition of ciliary beating, inhibition of 
phagocyte respiratory burst, induction of cytokine synthesis through ligation of TLR 4 
and in CD4+ T cell activation and chemotaxis 252;253. Pneumolysin has also been 
shown to be essential for the survival of S. pneumoniae in both the upper and lower 
respiratory tract and has been implicated as a requirement for bacterial invasion from 
the lungs to the bloodstream 254;255. The expression of hyaluronidase is also thought 
to facilitate bacterial spread through the extracellular matrix and connective tissue 
that is rich in hyaluronan containing polysaccharide components 256.  
 
There are  a number of additional secreted and expressed factors that are thought to 
add to the virulence of S. pneumoniae but have yet to be defined as true virulence 
factors, these include; sIgA protease, cleaves host mucosal IgA reducing their 
opsonising capabilities; autolysin (LytA), an additional cytotoxic protein that increases 
the secretion of pneumolysin through self lysis 257; PspA, inhibits complement C3 
component from attaching to the pneumococcal cell surface 258; divalent metal ion 
binding lipoproteins, PpmA and SlrA and several LPXTG anchored proteins for 
example StrA 259-261. This list is by no means exhaustive and many S. pneumoniae 
virulence factors remain undefined. However, despite a growing appreciation and 
understanding of how the various virulence factors of S. pneumoniae function in 
concert to allow colonisation and subvert host innate immunity, there is little 
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understanding of how host epithelial and tissue barriers are breached during 
progression from colonisation to invasion.  
 
Table 1.5 S. pneumoniae virulence factors and their role in disease 
 
 
 
 
1.8.4 Innate immunity and host inflammatory response  
Research into the host immune response to S. pneumoniae respiratory infection has 
mainly focussed on the role humoral components of the innate and adaptive immune 
systems play in first line defence against S. pneumoniae. It is clear that complement 
pathways are fundamental to S. pneumoniae resistance as mice deficient in C1q or 
secretory IgM demonstrate rapid progression to invasive bacteraemia and a 
reduction in macrophage activation and phagocytic function 262. A recent case 
controlled clinical study has added credence to the significance of the classical 
complement pathway in S. pneumoniae host defence by demonstrating a significant 
S. pneumoniae virulence factors and disease Role in colonisation 
Upper airway colonisation  
Capsule 
Prevents entrapment in mucus, thereby allowing access to 
epithelial surfaces. Also inhibits opsonophagocytosis. 
ChoP Binds to rPAF on the epithelial surface of the nasopharynx. 
Cbp A 
Binds to human secretory component on polymeric Ig 
receptors during first stage of translocation across the 
epithelium. 
NanA, BgaA and StrH 
Act sequentially to cleave terminal sugars from human 
glycoconjugates which might reveal putative binding sites. 
Hyl Breaks down hyaluronan-containing extracellular matrix. 
PavA Binds to fibronectin. 
Eno Binds to plasminogen. 
Competition in upper airway   
Bacteriocin (pneumocin) Small antimicrobial peptide that targets other bacteria.  
Respiratory tract infection and pneumonias  
Ply 
Cytolytic toxin that also activates complement. Critical 
virulence factor in vivo. 
PspA 
Prevents binding of C3 onto pneumococcal surface. Also 
binds lactoferrin. 
LytA Digests the cell wall which results in the release of Ply.  
PsaA 
Component of the ABC transport system  which is involved 
in resistance to oxidative stress.  
PiaA andPiuA Component of the ABC transport system. 
NanA and NanB 
Aid colonization by revealing binding sites, modifying the 
surfaces of competing bacteria in the same niche and/or 
modifying the function of the host clearance glycoproteins.  
IgA Cleave human IgA 
 
A non exhaustive list of S. pneumoniae virulence factors adapted from 
4
. 
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association between MBL mutant genotypes and increased susceptibility to S. 
pneumoniae infection in adults 263. AMPs have also been implicated in host immunity 
toward S. pneumoniae infection. SP-D is present at high levels in the fluid lining the 
epithelium of the alveoli and is produced by alveolar type II cells and non ciliated 
Clara cells. Several studies have implicated SP-D in aggregating and opsonising S. 
pneumoniae resulting in the enhancement of neutrophil phagocytosis 264;265. 
 
Despite extensive research into multivalent conjugate vaccine development and the 
role complement plays in immunity to S. pneumoniae infection, there is little 
examination of the cellular immune response elicited in response to S. pneumoniae 
infection 266-268. As introduced above, TLRs are central in the recognition of micro-
organism presence and in the initiation of subsequent cellular immune responses. A 
number of recent publications have demonstrated both TLR 2 and TLR 4 to be 
important in protection against invasive S. pneumoniae infection 269-271. Epithelial and 
alveolar macrophage expressed TLRs respond to pneumolysin and bacterial cell wall 
components to produce inflammatory cytokines and chemokines, such as IL-β, TNF-
α, IL-6, KC and MIP-2, that activate nearby macrophages and recruit neutrophils to 
the site of infection 272;273. Nonetheless, despite mounting evidence supporting the 
importance of neutrophils in S. pneumoniae immunity, there exists a number of other 
studies that suggest an over exuberant neutrophil responses can increase pathology, 
resulting in increased mortality without affecting bacterial clearance 274. The 
dependence on neutrophils for clearance may depend on the serotype and the 
infection/colonisation site of the host. Protection has also been associated with a 
specific induction of IL-17 and MCP-1 in BALB/c mice, which in a recent study have 
been shown to enhance the recruitment and killing capacity of neutrophils in a 
nasopharyngeal S. pneumoniae colonization model 275.  
 
The role the adaptive immune system plays in a primary S. pneumoniae remains to 
be fully elucidated. A significant role for T cells has been suggested in MHC II KO 
mice that effectively lack CD4+ T cells and are significantly more susceptible to S. 
pneumoniae pneumonia and bacteraemia than isogenic wild type controls 276. CD4+ T 
cell help has also been shown to be required for stimulating IgG responses to 
pneumococcal phosphorylcholine, surface protein A (PspA) and polysaccharide 
antigens. There is also accumulating evidence that Th1 cytokines are crucial for 
bacterial clearance as IL-12 deficient patients develop severe S. pneumoniae 
infections. Inflammatory cytokine production in response to an in vivo S. pneumoniae 
infection is not only important in initiating protective innate immune function but also 
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in regulating the development of adaptive immunity and immunological memory 
277;278. A recent study has illustrated that IL-1β, IL-6, TNF-α, IL-12 and IFN-γ 
individually regulate the induction of both protein and polysaccharide specific Ig 
isotypes and that IL-10 down regulated Ig responses in an isotype non specific 
manner whereas IL-4 appeared to regulate Ig class switching 273. However, due to 
the extensive numbers of pneumococcal serotypes and the pathophysiological 
differences between colonisation and invasive disease there remains a large gap in 
our understanding of S. pneumoniae infection.  
 
1.9 Immunological interactions between respiratory viral 
infections and secondary bacterial super infections 
 
It is commonly accepted that outside highly controlled laboratory settings, the clinical 
and pathophysiological characteristics of most infectious diseases are much more 
complex than implied by a simple one pathogen one disease model. Unlike most 
animal models used to study infectious diseases, humans are never free of previous 
or concurrent infections. This is particularly prominent with upper respiratory tract 
viral infections and their associated bacterial complications. The earliest suggestion 
that respiratory viral infections can predispose to bacterial disease has been 
accredited to R.T Laennec in 1803. He observed the prevalence of pneumonia 
increases following an epidemic of influenza virus („la grippe‟) 279. Although influenza 
virus is most commonly thought of in this context, many others respiratory viruses 
including respiratory syncytial virus (RSV), measles virus and rhinovirus may also 
predispose to secondary bacterial infections 280. It was not until 1945 that the first well 
controlled study of secondary bacterial infections was conducted by M. V. de 
Torregosa et al 281. They reported that Haemophilus influenza, Streptococcus 
pneumoniae and Staphylococcus aureus all have the ability to cause fatal pneumonia 
in an intranasal co-infection model with the mouse adapted influenza virus A/Puerto 
Rico/8/34 (PR8).  
 
Clinically, with the exception of highly pathogenic strains such as H5N1 and H1N1 
(1918 pandemic strain), influenza viral infection is not usually sufficient to cause 
death from pulmonary causes alone. Although the primary viral infection that killed 
many healthy adults during the 1918 pandemic was the most prominent clinical 
feature of the pandemic, it appears secondary bacterial pneumonia was the more 
common cause of death 282. In addition, the majority of hospitalisations and deaths 
caused by more recent influenza outbreaks of 1957, 1968 and 1995 were more 
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frequently due to secondary bacterial pneumonia or exacerbations of underlying 
conditions 283-286. Numerous in vivo animal models have provided further evidence 
supporting these clinical observations, highlighting the synergistic interactions 
between influenza virus and respiratory bacterial pathogens 287-289. 
 
Despite the considerable clinical and experimental evidence, there remains relatively 
little knowledge regarding the immunological and molecular basis surrounding the 
interactions between influenza virus and respiratory bacterial pathogens. Initial 
studies during the 1918 influenza pandemic produced the concept of „viral‟ induced 
epithelial damage that permitted bacterial access to otherwise inaccessible lung 
compartments. This mechanism of viral-bacterial synergism was strengthened by 
histopathological studies during the 1957/59 Asian influenza pandemic which 
highlighted bacterial adhesion to areas of viral cytotoxicity in the trachea and bronchi 
290. Further investigations proposed influenza virus mediated dysfunction of immune 
effectors as a mechanism for secondary bacterial infections. Numerous animal 
models have provided evidence of virus induced leukopenia and granulocytopenia in 
bacterial co-infection experiments 291-293. Conversely, other experimental models 
demonstrate leukocytosis as the prominent clinical presentation of secondary 
bacterial infection. They argue that large numbers of activated neutrophils, 
macrophage and inflammatory mediators in the lung exacerbate tissue damage, 
particularly in combination with bacterial toxins and although the cellular infiltrate is 
increased the functional capabilities necessary for the clearance of bacteria may be 
altered 294;295. A third principal concept for viral induced bacterial secondary infection 
concentrates on the alteration of cell surface receptor profile and adhesion molecules 
in response to viral infection. Influenza viruses possess NA which acts to cleave 
terminal sialic acid residues on host cell glycoproteins allowing the release of viral 
particles. Exogenously administered bacterial NA has been shown to increase 
adherence of pneumococcus in vitro to tracheal epithelial in an organ perfusion 
model 296. It has therefore been postulated that NA contributes to bacterial adherence 
to epithelial tissue by exposing receptors for bacterial adherence and invasion. 
Administration of an influenza virus NA inhibitor prevented secondary bacterial 
pneumonia, thus suggesting that the combination of bacterial and viral NA at the site 
of infection is an important mechanism in synergism between the organisms 297.  
 
The increasing incursions of highly pathogenic H5N1 influenza virus into humans in 
Southeast Asia are an eminent warning that we are overdue the next influenza 
pandemic. It is therefore critical that identification and exploration of the underlying 
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mechanisms of viral bacterial synergism are revealed in order to provide targets for 
prevention and treatment using immune therapies, drugs and vaccines.  
 
1.10 Thesis objectives 
 
Despite extensive epidemiological and clinical evidence, there remains relatively little 
knowledge regarding the immunological and molecular basis surrounding the 
interactions between influenza virus and secondary bacterial super infections. 
Previous work within the laboratory has demonstrated that a preceding respiratory 
inflammatory insult can alter subsequent immune responses to a secondary 
heterologous infection that cannot be explained through cross reactive T cells 298-301. 
In reality, each individual has unknowingly acquired his/her unique history of 
respiratory infections and how this subsequently impacts on their immune 
responsiveness remains to be determined. We hypothesise that a preceding 
influenza viral infection induces a transient state of hypo-responsiveness that hinders 
the lungs capacity to respond and protect against respiratory bacterial pathogens.  
 
In the following thesis I will seek to address the following aims: 
 
1. Develop and characterise an in vivo secondary bacterial super infection 
model. 
2. Investigate the temporal relationship between influenza viral infection and the 
susceptibility to secondary bacterial super infection.  
3. Investigate the effects of influenza viral infection on the functionality of 
alveolar macrophages. 
4. Analyse nasopharyngeal commensal flora communities before and after 
influenza viral infection.  
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Chapter 2 
 
 
 
2.1 Laboratory Animals 
 
2.1.1 Mice strains 
 
Eight to twelve week old female BALB/c and C57BL/6 mice were purchased from 
Harlan Olac Ltd, Bicester UK. CD200R -/- were a kind gift from R. Williams (Kennedy 
Institute of Rheumatology, Imperial College, London). All mice were maintained in 
specific pathogen free conditions at Bio Safety Level 2 and kept in accordance with 
institutional and UK Home Office guidelines. 
 
2.2 Pathogen Stocks 
 
2.2.1 Influenza A virus 
 
Recombinant influenza A strain A/HK/X31 (haemagglutinin [HA] titre 8192) was a 
kind gift from Dr Alan Douglas (National Institute for Medical Research, London, UK). 
The virus was titrated by haemagglutination assay. Human group „O‟ red blood cells 
(RBC) were collected in Alsever‟s solution to prevent clotting (ratio 1:1). Cells were 
washed three times in Alsever‟s solution, each time centrifuging for 5 min at 240 g 
and re-suspended as a 10 % stock solution in PBS. Influenza stock solution was 
doubly diluted in PBS in a round-bottom plate. An equal volume (50 µl) of 0.5 % 
RBC/PBS was added and incubated at room temperature for 1 hour, or until RBCs 
had settled at the bottom of the plate. The HA titre was defined as the highest dilution 
of virus capable of causing agglutination, i.e. inhibit RBC precipitation into a defined 
button at the bottom of the well. The titre was expressed as the reciprocal of the 
highest dilution of virus showing agglutination, and represents 1 HAU/50 µl of virus.  
 
2.2.2 Streptococcus agalactiae (Group B Streptococcus - GBS) 
 
Human clinical isolate NCTC10/84 serotype V was a kind gift from Dr Toby Lawrence 
(Cancer Research, UK). GBS were grown at 37 0C to mid logarithmic phase in Todd 
Hewit Broth (THB) (Sigma, UK) then mixed (1:1) with 80 % glycerol and frozen at -80 
0C until required. For murine inoculation, fresh THB was mixed (1:10) with an 
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overnight GBS culture and allowed to grow until mid logarithmic phase was reached. 
The culture was centrifuged for 10 min at 5000 g and washed twice with 1 ml sterile 
LPS -/- phosphate buffered saline (PBS). Inoculum dose was calculated by diluting 
the GBS culture in LPS-/- PBS to an OD600 0.4 which correlates to 1 x 108 colony 
forming units (cfu) per ml. Recovered bacterial cfu was determined by manually 
counting colonies of serial tenfold dilutions plated on THB agar plates. GBS colonies 
were identified by their β–haemolysis when plated on sheep blood agar, their distinct 
bright orange pigment and colony morphology.  
 
2.2.3 Streptococcus pneumoniae (D39) 
 
Wild type S. pneumoniae (serotype 2) strain D39 (NCTC 7466, National Collection of 
Type Cultures, London, UK), a kind gift from Dr Jeremy Brown (Centre for 
Respiratory Research, UCL, London) and a transformant expressing GFP (D39 
pGFP 302 ), a kind gift from Professor P. Andrews (Nottingham, UK) were used. 
Bacteria were cultured at 37 °C o in 5 % CO2 on blood agar plates or in Todd-Hewitt 
broth (Sigma) supplemented with 0.5% yeast extract (OXOID) (THY broth) to an 
OD600 of 0.4 (approximately 1 x 108 cfu/ml) and stored at -80°C in 10% glycerol as 
single-use aliquots. Exact inoculum cfu used in each experiment and the recovered 
tissue cfu were determined by manually counting colonies of serial tenfold dilutions 
plated on Columbia agar supplemented with 5 % defibrinated horse blood. Bacteria 
were further identified by Gram stain, colony morphology, α–haemolysis on blood 
agar plates and by optochin sensitivity. GFP pneumococcal transformants (pGFP) 
were checked by UV microscopy for fluorescent activity following culture on blood 
agar plates and in THY broth.  
 
2.2.4 Pseudomonas aeruginosa (PAK) 
 
Wild type Pseudomonas aeruginosa PAK strain, an exceptionally kind gift from Dr 
Stephen Lory (Boston, USA), was grown at 37 0C to mid logarithmic phase in LB and 
stored at -80°C in 10 % glycerol as single-use aliquots. For infection, mice were 
challenged with mid log phase 5 x 106 cfu intranasally. Exact inoculum cfu used in 
each experiment and the recovered tissue cfu were determined by manually counting 
colonies of serial tenfold dilutions plated on LB agar. 
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2.3 Reagents used for in vivo studies 
 
2.3.1 In vivo use of TLR ligands 
 
Mice were intranasally (i.n.) challenged with 1 g flagellin FliC (Apotech, 
Switzerland), 1 g LPS (Sigma), 25 g LTA or 1 g recombinant chemokines KC or 
MIP-2α (R & D systems). All reagents, except LPS, were free of physiologically 
significant levels of endotoxin as measured by the LAL system, 6.4 endotoxin U/mg. 
 
2.4 Mouse infection models 
 
2.4.1 Single infection model 
 
On day 0, BALB/c or C57BL/6 mice were anaesthetised with isoflourane and 
intranasally inoculated with either 50 HAU influenza A virus, which equates to 1.25 x 
105 pfu, or a specified dose of bacterial pathogen, unless otherwise stated. 
Infectious agents were diluted in endotoxin free sterile PBS and administered i.n. in a 
volume of 50 µl to mice held in an upright position. In some experiments, infected 
mice were re-infected with an identical titre of homologous virus or bacteria 2-6 
weeks after the primary infection. Groups of 4-5 mice were weighed and followed 
daily for illness and mortality. Mice found to be moribund were culled and considered 
to have died on that day. Mice were harvested at predetermined time points post 
infection by injection of 3 mg pentobarbitone and exsanguinated via the femoral 
vessels. 
 
2.4.2 Co-infection model 
 
On day 0, BALB/c or C57BL/6 mice were inoculated with 50 HAU influenza A virus as 
previously described in 2.4.1. At the same time as, or at varying time points post 
influenza infection mice were inoculated with a pre specified dose of a bacterial 
pathogen, unless otherwise stated. Groups of 4-5 mice were weighed and followed 
daily for illness and mortality. Mice were culled at predetermined time points post 
GBS infection by injection of 3 mg pentobarbitone and exsanguinated via the femoral 
vessels.  
 
2.4.3 Resolved heterologous infection model 
 
On day 0, BALB/c or C57BL/6 mice were inoculated with either 50 HAU influenza A 
virus or a specified dose of bacterial pathogen, unless otherwise stated, as 
previously described in 2.4.1. Mice were allowed to resolve the primary infection as 
CHAPTER 2: MATERIALS AND METHODS 
47 
shown by viral plaque assay or bacterial culture and were subsequently infected with 
either influenza virus or a specified bacterial pathogen. Groups of 4-5 mice were 
weighed and followed daily for illness and mortality. Mice were culled at 
predetermined time points post secondary infection by injection of 3 mg 
pentobarbitone and exsanguinated via the femoral vessels.  
 
2.5 Sample recovery and cell preparation 
 
2.5.1 Tissue, serum and nasal wash recovery  
 
Bronchoalveolar lavage (BAL), lung tissue, spleen, serum and nasal wash were 
harvested by methods described previously 303. Blood was first harvested by 
exsanguination via the femoral vessel and, after clotting at 4 0C, centrifuged for 8 
minutes at 5000 x g. The serum was isolated and frozen at -20 0C for analysis of 
antibody and cytokines. BAL was obtained by inflating the lungs of each mouse 6 
times with 1.5 ml 1 mM EDTA in minimal essential media (MEM) and placed in sterile 
tubes at 4 0C. BAL was centrifuged for 5 minutes at 240 x g and the supernatant 
removed and stored at - 20 0C for analysis of cytokines by ELISA.  The pellet was re-
suspended in RPMI-1640 supplemented with 10 % fetal calf serum (R10F) at a final 
concentration of 1 x 106 cells per ml for further analysis. Lung tissue and spleen were 
disrupted to a single cell suspension by passage through a 100 µM sieve (BD 
labware, New Jersey, USA). The cell suspension was subsequently spun for 5 minutes 
at 240 x g rpm and red blood cells lysed by resuspending pellets in ACK buffer (0.15 M 
ammonium chloride, 1 M potassium hydrogen carbonate and 0.01 mM EDTA, pH 7.2) 
for 3 minutes at room temperature before centrifugation for 5 minutes at 240 x g and 
washing in R10F. Cell viability in all tissues was assessed using Trypan Blue exclusion 
and subsequently re-suspended in R10F to a final concentration of 1 x 106 cells/ml. 
Nasal wash was obtained by washing the nasopharyngeal cavity with 200 µl sterile 
PBS, collected and frozen at -20 0C for antibody ELISA analysis. 
 
2.5.2 Isolation of lung of Type II epithelial cells 
 
Lung type II epithelial cells were isolated as described previously 304. Briefly, lungs were 
perfused by the infusion of 10 ml PBS into the right ventricle of the heart. Lungs were 
subsequently inflated with 2.5 ml of 5 mg/ml dispase II solution (Roche, Basel, 
Switzerland) and then allowed to collapse naturally. 0.5 ml of 1 % low melting point 
agarose was then slowly injected into the lungs and immediately allowed to solidify by 
CHAPTER 2: MATERIALS AND METHODS 
48 
packing the lungs in ice. Lungs were then removed and incubated for 40 minutes in 
dispase solution before being transferred to DMEM containing 50 µg/ml of DNAse I 
solution (Roche, Basel, Switzerland) and the digested tissue teased away from the upper 
airways. Digested lung tissue was disrupted to a single cell suspension by passage 
through a 100 µM sieve (BD Labware, New Jersey, USA). Epithelial cells were enriched by 
negative selection, with removal of hematopoietic and endothelial cells by MACS 
separation. Briefly, lung homogenate was incubated with rat anti-mouse CD45 or CD90 
antibodies (BD Pharmingen, Heidelberg, Germany), followed by anti-rat Dynabeads 
(Invitrogen) and applied to an MS column (Miltenyi Biotec, Gladbach, Germany) in the 
presence of a magnetic field. Unlabelled epithelial cells were washed through with buffer 
(PBS containing 0.5 % BSA and 2 mM EDTA).  
2.5.3 Generation of bone marrow (BM) derived macrophages and DCs 
 
Femurs were removed from BALB/c or C57BL/6 mice and bone marrow extracted by 
flushing extensively with RPMI-1640 media. RBC depleted bone marrow cells were 
washed and counted by Trypan blue exclusion. To generate BM macrophages, 2 x 
105 cells/ml were plated out with 20 ng/ml M-CSF in 10 mls RPMI with 20 % FCS, 0.1 
U/ml penicillin / 0.1 μg/ml streptomycin and 10 % HEPES, and incubated at 37 C for 
72 hours. At this time, a further 5 mls of medium containing M-CSF (20 ng/ml; 
PeproTech Inc., Rocky Hill, NJ) was added on top of the existing 10 mls and 
incubated at 37 C for another 72 hours. Media was subsequently removed and cells 
incubated in versene for 20 minutes at room temperature. Cells were then scraped 
from the plates, washed and re-suspended in R10F and counted. To generate BM 
dendritic cells, 2 x 105 cells/ml were plated out in 10 mls RPMI with 10 % FCS, 0.1 
U/ml penicillin / 0.1 μg/ml streptomycin and 10 % J558 supernatant (containing GM – 
CSF), and incubated at 37 C for 72 hours. At this time, 5 mls of media was carefully 
removed and replaced with 5 mls of fresh media with 10 % J558 supernatant and 
incubated at 37 C for another 72 hours. Floating and weakly adherent cells were 
collected by gentle pipetting, washed and re-suspended in R10F and counted.  
2.5.4 Stimulation of BM macrophages/DCs 
 
BM derived macrophages and DCs were cultured at 2 x 106 cells/ml in 200 μl R10F in 
96 well flat bottomed plates. Cells were stimulated with IFN-γ (10 ng/ml or 100 
ng/ml), LPS (10 ng/ml or 100 ng/ml) or influenza virus (8 HA or 16 HA), S. 
pneumoniae (MOI 10, 5, 2) and GBS (MOI 10, 5, 2). Some cells were also cultured 
with OX110 (CD200R agonistic antibody) to a final concentration of 10μg/ml. Cells 
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were incubated at 37 C and at varying times after stimulation (as indicated in the 
text), supernatants were removed for cytokine/chemokine analysis and cells stained 
for surface markers by flow cytometry as described below.  
 
2.6 Flow Cytometric Analysis 
 
2.6.1 Cell surface antigens 
 
Cells were stained for surface markers and analysed by flow cytometry as described 
previously 303. All antibodies were purchased from BD Pharmingen (Heidelberg, 
Germany) unless otherwise stated (See Table 2.1). Briefly, a minimum of 2 x 105 or 
maximum 1 x 106 BAL, lung or spleen derived cells were stained using various 
combinations of FITC, PE, PerCP (Pe-Cy5.5), Pe-Cy7 APC or biotin conjugated anti-
mouse antibodies. All antibodies were diluted in PBS containing 1 % BSA/0.05 % 
sodium azide (PBA). Cells were stained for 30 minutes on ice, washed with PBA and 
spun for 5 minutes at 240 x g. For biotin conjugated antibodies streptavidin 
constructs conjugated to appropriate fluorophores were used. After washing, cells 
were then fixed for 20 minutes at room temperature with 2 % formaldehyde/PBS. 
Cells were then washed in PBA, data acquired on a BD FACS Canto II or LSR II and 
30,000 lymphocyte or myeloid events analysed with CellQuest Pro software (BD 
Biosciences, Belgium) or FloJo analysis programme. Forward scatter and side 
scatter gates were used to exclude debris in organ homogenates.  
 
2.6.2 Intracellular cytokine expression 
 
To detect intracellular cytokines, 1 x 106 cells/ml were incubated with 50 ng/ml PMA, 
500 ng/ml ionomycin (Calbiochem, Nottingham, UK), and 10 μg/ml brefeldin A for 3 
hours at 37 oC. Cells were then stained for external markers such as anti-CD4-APC 
or anti-CD8-PerCP and fixed as described above. After permeabilisation with PBS 
containing 1 % saponin / 1 % BSA / 0.05 % azide (saponin buffer) for 10 minutes, 
cells were stained with anti-TNF-α FITC, anti-IFN-γ-Biotin. 30 minutes later cells were 
washed once in saponin buffer and once in PBA. Data was then acquired as 
described above.  
2.6.3 Apoptosis Analysis 
 
2.6.3.1 Annexin V staining 
 
For apoptosis analysis, binding of FITC or PE-labelled Annexin V was detected 
according to manufacturers‟ instructions (BD Pharmingen, Heidelberg, Germany). 
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Briefly, cells were washed in PBS and re-suspended in Annexin-binding buffer 
containing Annexin V-PE or FITC and other extracellular markers of interest. After 
washing in binding buffer, 7-AAD was added to determine dead cells. Apoptotic cells 
were identified as 7-AAD-/Annexin V+. Data was then immediately acquired, 
collecting 30,000 lymphocyte events.   
 
2.6.3.2 TUNEL assay 
Apoptotic cells were detected using the in situ cell death detection kit (Roche). 
Briefly, cells were stained for differential surface markers and subsequently fixed in 2 
% PFA, as described in section 2.6.1. Cells were then made permeable with 0.1 % 
Triton X-100 and 0.1 % sodium citrate. Cells were incubated for 60 minutes at 37 0C 
in the TUNEL reaction mixture. Cells were subsequently washed twice in PBS and 
re-suspended in PBA for cytometric analysis  
 
Table 2.1 – Antibody reagents 
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2.7 Tissue Imaging 
2.7.1 Haematoxylin and Eosin staining of lung tissue 
 
The azygous lobe was inflated and fixed with 2 % formalin in PBS. The tissue sample 
was subsequently embedded in paraffin wax and 4 µM sections were stained with 
haematoxylin and eosin (David Essex, Imperial College, UK).  
2.7.2 Immunofluorescent staining for CD200 
Lungs from C57BL/6 mice, at days 0, 3 and 7 after influenza infection, were inflated 
with 1.5 ml OCT (Tissue-Tek) and snap frozen in OCT freezing medium by liquid 
nitrogen flotation. All frozen tissues were stored at -80 °C. Cryostat sections (5-8 µm) 
were fixed in cold 80 % acetone and 20 % methanol, air dried, then blocked with 15 
% normal goat serum for 30 minutes at room temperature. Sections were then 
incubated in primary mAbs to murine CD200 (OX90) (3 µg/ml) for 2 hours at room 
temperature, extensively washed in PBS, and then incubated for 1 hour in Alexa-488 
conjugated goat anti-rat IgG (Molecular Probes). Sections were then washed three 
times in PBS and wet mounted for fluorescent microscopy. Sections were examined 
under a Nikon ECLIPSE TE2000-U fluorescence microscope.  
2.7.3 Immunofluorescent staining for p65 translocation 
For p65 translocation analysis, AM were fixed in 4 % PFA, permeabilized in 0.2 % 
Triton-X and stained with an rabbit-anti-p65 antibody (Santa Cruz) and Alexa 488-
anti-rabbit antibody (Molecular Probes). Propidium iodide was used for nuclear 
staining. 
 
2.8 Determination of pathogen load in tissues 
 
2.8.1 Influenza-specific plaque assay 
 
Lung homogenates were freeze thawed three times, centrifuged at 5000 x g and 
supernatants titrated in doubling dilutions on Madine Darby canine kidney (MDCK) 
cell monolayers in flat bottomed 96 well plates. After incubation at room temperature 
for 3 hours, samples were over-layed with 1 % methycellulose and incubated for 72 
hours at 37 0C. Cell monolayers were washed and incubated with anti-influenza 
antibody (Serotec) followed by anti-mouse-HRP (Dako) and infected cells detected 
using 3-amino-9-ethylcarbazole substrate. Infectious units were then enumerated by 
light microscopy and total plaque forming units per lung quantified (number of 
plaques × dilution factor × total volume of lung homogenate).  
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2.8.2 Enumeration of recovered bacterial cfu from infected tissues 
 
Group B Streptococcus, S. pneumoniae and P. aeruginosa titre was determined by 
serial dilution of 20 µl aliquots from single cell suspensions of each tissue in sterile 
PBS. Serial dilutions were plated on THB agar (GBS), Columbia blood agar (S. 
pneumoniae) or LB agar (P. aeruginosa) and incubated overnight at 37 0C. The total 
cfu per tissue was then determined manually by counting evident bacterial colonies. 
(Number of colonies x dilution factor x original cell suspension volume).  
 
2.9 Soluble mediator detection 
 
2.9.1 Cytokine detection using ELISA 
 
IFN-γ, TNF-α, IL-6, IL-10, KC, and MIP-2α in BAL fluid and lung homogenate were 
quantified using OptEIA kits and following manufacturer‟s instructions (Pharmingen). 
Briefly, microtiter plates (Nunc, Roskilde, Denmark) were coated with 100 µl of 
capture antibody diluted in the recommended buffer and incubated according to the 
manufactures instructions. After 5 washes with PBS containing 0.5 % Tween-20, 
plates were blocked with 200 µl PBS containing 10 % FCS and left for 1 hour at room 
temperature. Samples and standards (diluted in PBS + 10 % FCS) were then 
incubated for a further 2 hours at room temperature.  After 5 washes, bound cytokine 
was detected using biotinylated antibodies pre-mixed with avidin-HRP followed by 
tetramethylbenzidine and hydrogen peroxidase. Optical densities were read at 450 
nm using 570 nm as a reference. The mean optical density of wells containing no 
cytokine was subtracted from the results obtained for samples and standards. The 
concentration of cytokine in each sample was calculated from a standard curve. 
 
2.9.2 Nitric oxide (NO) detection 
 
The concentration of nitrite in BAL and lung homogenate was used as a measure of 
NO production and was quantified using the Greiss reagent kit. Briefly, samples and 
standards (50 l) were added to a microtiter plate and treated with 1 % 
sulphanilamide for 10 minutes at room temperature. Subsequent addition of 0.1 % 
naphthylethylenediamine (NED) in 2.5 % H3PO4 yielded a magenta colour in the 
presence of NO. Optical densities were read at 550 nm.  The mean optical density of 
wells containing media alone was subtracted from the results obtained for samples 
and standards. The concentration of NO in each sample was calculated from a 
standard curve. 
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2.10 Quantitative RT-PCR 
 
2.10.1 Cytokine mRNA analysis 
 
RNA was extracted from frozen lung lobe using the nucleospin RNA kit (Macherey & 
Nagel, Switzerland) and cDNA generated for each sample using the superscript II 
reverse transcriptase using random hexamers (Invitrogen). Real time PCR was 
performed using platinum SybrGreen super mix (Invitrogen) and the Rotor-gene 6000 
(Corbett). The copy number of the gene of interest was calculated as arbitrary units 
using two standard curves method and normalized to 18S.  Similar results were 
obtained using the GAPDH or β-actin as housekeeping genes. Primers used: MIP-2α 
(CXCL2) forward 5‟-ATCCAGAGCTTGAGTGTGACGC-3‟ and reverse 5‟- 
AAGGCAAACTTT TTGACCGCC-3‟, KC (CXCL1) forward 5‟-
GCCAATGAGCTGCGCTGT-3‟ and reverse 5‟-CCTTCAAGCTCTGGATGTTCTTG-
3‟, TNF-α forward 5'- CCTCCACTTG GTGGTTTGCT-3' and reverse 5‟-
CATCTTCTCAAAATTCGAGTGACAA-3, β-actin forward 5‟-
GCTTCTTTGCAGCTCCTTCGT-3‟ and reverse 5‟-CGTCATCCATGGCG A ACTG-3‟ 
and 18S forward 5‟-ACATCCAAGGAAGGCAGCAG-3‟  and reverse 5‟-
TTTTCGTCACTACCTCCCCG-3‟ 
 
2.11 BAL proteomic analysis 
 
2.11.1 Protein concentration analysis 
 
BAL fluid protein concentration was determined using manufactures instructions 
provided with the Pierce BCA protein assay kit (Rockford, Illinois). In brief, individual 
BAL was pooled within each group to be analyzed. Pooled sample was centrifuged 
for 10 minutes at 15700 x g and subsequently filtered through a 0.2 µm sieve to 
ensure removal of any resident cell debris. Working reagent was added to samples 
and standards at a 4:1 ratio and incubated at 37 °C for 30 minutes. Absorbance was 
measured at 490 nm, and protein concentration calculated by comparison with an 
albumin standard. 
 
2.11.2 SDS Page protein separation 
 
1.5 mm 15 well NuPage 4-12 % Bis-Tris gels were prepared for use as described in 
the manufactures instructions (Invitrogen, UK). BAL samples were prepared as 
described in section 2.11.1 and diluted 1:1 in 2 x loading buffer (1 M Tris pH 6.8, 20 
% glycerol, 10 % SDS, 0.1 % Bromophenol and 20 % DTT). Loading samples were 
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heated to 80 0C for 5 minutes and centrifuged at 3000 x g for 1 minute before gel 
loading. SeeBlue pre-stained standard was used as a molecular weight marker in all 
experiments (Invitrogen, UK). After 2 hrs at 100 V gels were placed in Coomassie 
stain (40 % MeOH, 10 % Acetic Acid, 50 % dH20 mQ, 0.2 g Coomassie Brilliant Blue) 
and shaken overnight at room temperature. Gels were then de-stained in 10 % Acetic 
Acid, 30 % MeOH and 60 % dH20 until protein containing bands were clearly visible. 
After sufficient de-staining gels were rehydrated in dH20 and stored at 4 
0C until 
further use.  
 
2.11.3 Mass spectrometry and protein elucidation 
 
Proteins bands of interest were subjected to in gel digestion with trypsin as described 
previously 305. Samples were analysed by liquid chromatography coupled to tandem 
electrospray mass spectrometry (LC-ESI-MS/MS). Spectra were recorded using a Q-
Tof spectrometer (Micromass, Manchester, UK) interfaced to a Micromass CapLC 
capillary chromatograph. Samples were dissolved in 0.1 % formic acid and aliquots 
were injected onto a 300 m x 5 mm Pepmap C18 column (LC Packings, 
Amsterdam, NL) and eluted with an acetonitrile/0.1 % formic acid gradient. The 
capillary voltage was set to 3,500 V. A survey scan over the m/z range 400-1300 was 
used to identify protonated peptides with charge states of 2, 3 or 4, which were 
automatically selected for data-dependent MS/MS analysis, and fragmented by 
collision with argon. The resulting product ion spectra were transformed onto a singly 
charged m/z axis using a maximum entropy method (MaxEnt3, Waters) and proteins 
were identified by correlation of uninterpreted spectra to entries in 
SwissProt/TrEMBL, using ProteinLynx Global Server (Version 1.1, Waters) 306. The 
database was created by merging the FASTA format files of SwissProt, TrEMBL and 
their associated splice variants (1,768,175 entries at the time of writing). No 
taxonomic or protein mass and pI constraints were applied. One missed cleavage per 
peptide was allowed, and the initial mass tolerance window was set to 100 ppm. In 
parallel, the spectra were also searched against the NCBI nr database (3,879,234 
sequences at time of search) using Mascot (www.matrixscience.com). For an 
identification to be considered valid we required that two or more peptides 
independently matched the same protein sequence, that the peptide score was 
significant (typically greater than 55 (p<0.05), and that manual interpretation 
confirmed agreement between spectra and peptide sequence. In addition Mascot 
searches of all spectra were performed against a randomised version of the NCBI 
database using the same parameters as in the main search. In no case did this 
CHAPTER 2: MATERIALS AND METHODS 
55 
search retrieve more than a single peptide, and in all instances the peptide score was 
below the 0.05 significance level.  
 
2.12 16S rRNA analysis 
 
2.12.1 DGGE gel casting and electrophoresis 
 
Denaturing gradient gels (DGGE) were produced using a GM-100 Gradient Maker 
(CBS Scientific, Del Mar, USA) and run using a Protean II vertical electrophoresis 
system (Bio-Rad, Hercules, USA). In brief, an 8 % polyacrylamide gel (0.75 mm 
thick) with a gradient of 60- 30 % of denaturants (urea and formaldehyde) was cast 
and placed in 0.5 x Tris-acetate borate. All gels were run at 100 v for 16 hours at 60 
ºC. Gels were analysed by incubating in H2O/ethidium bromide for 60 minutes at 
room temperature and subsequently read using a UV illuminator. 
2.12.2 16S rRNA amplification and DGGE analysis 
For DGGE analysis, products were amplified using a two step, nested PCR 
approach. For the first round, 16S rRNA genes were amplified using the primers 
339F-5‟-ACTCCTACGGGAGGCAGCAGT-3' and 907R-5'-
CCGTCAATTCMTTTGAGTTT-3‟ 307;308. 25 µl PCR reactions were set up containing  
2 µl of template, 2.5 µl 10 x buffer (Roche Applied Biosystems), and final 
concentrations of 1.5 mM Mg, 6 % DMSO, 0.5 µM primers, 0.8 mM total dNTP (0.2 
mM each) and 1U HotStart Polymerase (Roche Applied Biosystems).  Cycling 
conditions were one cycle of 95 °C for 5 minutes, then 20 cycles of 95 ºC for 30 
seconds, 55 ºC for 30 seconds and 72 ºC for 60 seconds followed by a final 
extension of 72 ºC for 5 minutes.  PCR products were diluted (1:10) and 2 µl used as 
template for the second round of amplification. Primers 339F (with a GC-clamp) 
339F-GC-5'-CGC CCG GGG CGC GCC CCG GGC GGG GCG GGG GCA CGG 
GGG GAC TCC TAC GGG AGG CAG CAG T-3‟ and 539 R 5'-GTA TTA CCG CGG 
CTG CTG GCA C-3‟ 309 were used.  Reaction and cycling conditions were the same 
as used in the first round except for the number cycles which was incremented to 32. 
Two rounds of PCR were used to minimize the risk of unspecific and maximise the 
sensitivity of bacterial amplification. 10 μl of product and 2 μl of loading dye were 
loaded onto the gels and after electrophoresis for 17 hours at 100 V at 60ºC using 
0.5 TAE buffer, gels were stained with ethidium bromide solution (2 μl EtBr in 200 ml 
Water) and photographed using the Biotech-IT Imaging System. 
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2.12.3 DNA Cloning and sequence analysis 
16S rRNA gene sequences were initially amplified in duplicate 25 μl of PCR reaction 
which included (final concentration): 2 μl of sample, 2.5 μl 10 x HotStart buffer 
(Roche Applied Biosystems), 1.5 mM MgCl2, 6 % DMSO, 0.8 mM total dNTPs, 1U 
HotStart polymerase (Roche Applied Biosystems) and 0.5 μM of primers 339F – 5‟-
ACTCCTACGGGAGGCAGCAGT-3‟ and 907R-5‟CCGTCAATTCMTTTGAGTTT-3‟. 
Reaction mixtures were amplified with a 5 minute initial denaturation step at 95 oC 
followed by 32 cycles at 95 oC for 30 seconds, 55 oC annealing for 30 seconds and 
72 oC extension for 60 seconds. A final extension step of 5 minutes followed at 72 oC 
to ensure all products contained intact ends for cloning. After the initial PCR the 
duplicated samples were pooled and run on a 1.5 % agarose gel for 1 hour at 100 V. 
Subsequent DNA bands were excised and purified according to QIAquick Gel 
Extraction Kit. Subsequent DNA product was cloned into E. Coli using a pGEM-T 
easy vector (Promega) as described in the manufacturer‟s instructions. White 
colonies were picked, solubilised in 35 μl of liquid LB and arrayed on a 96 well plate 
and sent off for sequencing. Plasmid DNA was purified using the Qiagen Plasmid 
Miniprep Kit according to the manufacturer‟s instructions and sequenced using the 
primer SP6. 
2.12.4 Phylogenetic analysis and tree generation 
DNA sequence chromatograms were uploaded to the ribosomal database 
(http://rdp.cme.msu.edu/), vector sequences trimmed (using the LUCY program) and 
remaining sequences quality control checked (using PHRED). Sequences of high 
quality were downloaded, primer regions additionally trimmed and only full length 
sequences ranging from 359 until 906 (E. coli numbering of 16S rRNA gene) were 
included for further analysis. No chimeric sequences were detected using 
Bellerophon (http://greengenes.lbl.gov/cgi-bin/nph-bel3_interface.cgi).   
Briefly, 295 (including 52 from a human COPD patient) high quality sequences were 
aligned with NAST (http://greengenes.lbl.gov) and manually curated. A distance 
matrix calculating the pair wise distances of the high quality sequences was created 
on the green genes website (http://greengenes.lbl.gov/cgi-bin/nph-index.cgi), 
masking the hyper-variable regions with the lane mask utility. Operational taxonomic 
units (OTUs) were designated using DOTUR (Distance based OTU and richness 
determination) by the furthest-neighbour algorithm. For the creation of the 
phylogenetic tree, a cut off of 99 % was set and each OTU was then assigned an 
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organism name, based on the phylogenetic placement using sequence match of the 
ribosomal database (20 best match sequences define taxanomic rank), and 
compared to NCBI BLAST results for the percentage of sequence identity. The 
numbers of 16S rRNA gene phylotypes were calculated at 99 % sequence identity 
with the furthest neighbour clustering in the program DOTUR. Evolutionary distances 
were calculated with the Jukes-Cantor (tree-Markov) model and phlyogenetic trees 
determined by the Neighbour-Joining method, with 1000 trees generated using mega 
(http://www.megasoftware.net/). Bootstrap confidence levels are shown at the tree 
nodes for all values. OTU designations are located at the termination of each branch 
and represent potential organism names. Abundance data for each OTU were 
calculated and annotated using treedyn (http://www.treedyn.org/). 
2.13 Statistics  
All experiments analysed contained 4-5 individual mice per group unless stated in the 
text. GraphPad Prism software was used for all statistical calculations. Depending on 
the experiment and the datasets to be compared several statistical tests were used:  
Non parametric Mann Whitney t test, unpaired two-tailed t test assuming unequal 
variance and non Gaussian distribution, non parametric Kruskal Wallis with Dunns 
post test and Log rank Mantel-Cox test to determine significance in survival curve 
analysis. The Bonferroni correction was applied when needed. Data are presented as 
the mean ± standard error of the mean (SEM). p vales < 0.05 were considered 
significant (* p<0.05, ** p<0.01, *** p<0.001).  
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Chapter 3 
 
 
3.0 Bacterial infection model development 
 
3.1 Introduction 
 
3.1.1 The need for robust bacterial infection models 
 
Up until the advent of molecular biology and the genomics era, very little progress 
was made in understanding bacterial pathogenesis since the discovery of antibiotics 
by Sir Alexander/ra Fleming in the 1940‟s 310-312. The development of efficacious 
vaccines against many of the important childhood bacterial infections added to the 
common misconception that the unrelenting struggle against bacterial infections had 
been won. However, despite extensive vaccination programmes in both the 
developed and developing world and the ubiquitous use of antibiotics, bacterial 
infections alone still account for 7.6 % of global deaths annually 313. This figure 
excludes the number of deaths caused by respiratory bacterial pathogens that are 
categorised within the same Global Burden of Disease (GBD) code (W038) as 
respiratory infections 313. The addition of this data would significantly increase the 
proportion of global deaths attributed to bacterial pathogens. In the UK, the most 
commonly acquired bacterial infection is S. pneumoniae. It is responsible for the 
majority of community acquired pneumonia cases and can result in invasive 
pneumococcal septicemia in more than 20 % of patients 314;315. Worldwide, S. 
pneumoniae is responsible for more deaths from invasive infections than any other 
bacterium and is responsible for 25 % of all preventable deaths in children under the 
age of 5 and more than 1.2 million infant deaths per year 316-318. In addition, there is 
increasing concern over the emergence of multi drug resistant Staphylococcus 
aureus (MRSA), Mycobacterium tuberculosis (MDRTB), S. pneumoniae (DRSP) and 
Group A streptococcus amongst others and the increasing prevalence of serotypes 
of S. pneumoniae and H. influenzae that are not contained within the existing multi-
valent vaccines 319-322. This reality highlights the need for reliable and physiologically 
relevant models of infection to investigate the mechanisms and genetic basis of 
bacterial pathogenesis.  
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3.1.2 Existing respiratory bacterial infection models 
 
As a result of these growing concerns, there is a need for renewed interest into 
advancing our understanding of the mechanisms of bacterial pathogenesis in the 
quest to develop novel anti microbial therapeutics. The majority of bacterial 
pathogens colonise and infect the body‟s mucosal surfaces, such as the respiratory 
or gastrointestinal tract. However, respiratory infections, including viral/bacterial 
bronchiolitis and bacterial pneumonia, account for almost 20 % of annual deaths 
worldwide in children under the age of 5 years and are responsible for the highest 
burden of disease of all infectious diseases, exceeding that of HIV/AIDS, 
Tuberculosis, Malaria and other highly publicised infectious diseases 2;12;313. This has 
lead to the development of a plethora of both in vivo and in vitro models that 
investigate the pathogenesis of the major respiratory bacterial infections including, 
Mycobacterium tuberculosis, Streptococcal species (particularly S. pneumoniae, S. 
pyogens and S. agalactiae), Haemophilus influenzae, Staphylococcus aureus, 
Bordetella petussis and Pseudomonas aeruginosa 323-330. Despite this heightened 
interest and the large number of models used, several caveats and limitations remain 
when investigating bacterial pathogenesis in in vivo animal models. The major 
limitations reflect the physiological relevance to human clinical disease; this can be 
affected by the particular bacterial strain/serotype used, the route of infection and the 
strain of inbred mouse utilised. The huge numbers of possible combinations of these 
parameters result in confusing conclusions and difficulty in interpreting results across 
similar infection models. However, despite these problems, the use of forward 
genetic studies in inbred mice strains has led to the discovery of key innate response 
pathways that validate genetic determinants of susceptibility in vivo 331;332.  
 
S. pneumoniae has been studied extensively in both in vitro and in vivo models. 
Nonetheless, due to historical reasons the majority of in vivo models concentrate on 
investigating the microbiology of the pathogen and the roles its virulence factors play 
in pathogenesis. Despite a large proportion of research focussing on multivalent 
conjugate vaccine development and the role complement plays in immunity to S. 
pneumoniae infection, there is little examination of the cellular immune response 
elicited in response to S. pneumoniae infection 266-268;333. Furthermore, the existence 
of over 90 distinct serotypes of S. pneumoniae and the use of intra venous 
inoculation to study endothelial invasion, which occurs during pneumococcus 
meningitis, results in a lack of consistency and standardisation across the S. 
pneumoniae infection field. Research into Streptococcus agalactiae pathogenesis, 
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generally referred to as Group B streptococcus (GBS), follows a similar pattern. GBS 
is the leading cause of invasive bacterial infections in human neonates and is an 
emerging disease in immunocompromised adults 212. Little is known about the 
pathogenesis of GBS infection in adults and is thought to infect neonates in utero or 
by aspiration of infected vaginal fluids into the neonate lung during partum 205;207;210. 
As with S. pneumoniae, the majority of research into GBS investigates the 
importance of its virulence factors and the mechanisms by which GBS invades the 
meninges resulting in meningitis. There is a lack of investigation into the significance 
of cellular immunity to GBS and the mechanisms by which GBS can 
asymptomatically colonise mucosal surfaces, such as the upper respiratory tract, and 
occasionally result in invasive disease.   
 
3.1.3 Genetic basis to respiratory bacterial susceptibility 
 
Genetic epidemiology, including twin studies, provides robust evidence that genetic 
variation in human populations contributes to susceptibility to infectious disease. 
Even with today‟s medicine, infectious disease remain a major selective pressure 
and the genes involved in the immune response are the most numerous and diverse 
in the human genome, indicating the evolutionary advantages of a varied 
immunological response to a wide range of infectious pathogens 334. However, 
despite the discovery of innate immune genes, such as those encoding Toll-like 
receptors (TLRs) and nucleotide-binding oligomerisation domain-like receptors 
(NLRs), there remains a large gap in our understanding of the huge variation in 
individual outcomes following exposure to potentially life threatening pathogens 335. 
Susceptibility to infection and many other human diseases arises from the complex 
interaction of environmental and host genetic factors. This can involve the interaction 
of many genetic loci or can be the result of a single Mendelian gene disorder. An 
example of a single gene disorder that influences infection specific susceptibility is 
the protection afforded by sickle cell heterozygosity against falciparum malaria 336;337.  
 
Another example in which a single gene mutation can result in increased 
susceptibility to an infectious pathogen is the susceptibility to Mycobacterium bovis 
(BCG) replication in mice that carry a single G169D mutation in the Nramp1/Slc11a1 
gene 338-340. Nramp1 is responsible for the depletion of divalent cations in the 
phagolysosome that results in the inhibition of intracellular replication 341. 
Experiments in vitro have demonstrated its role in the intracellular replication of 
Salmonella typhimurium in macrophage and it has been shown that polymorphic 
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variants at or near the human NRAMP1 gene have been identified to associated with 
susceptibility to a number of infections and inflammatory conditions 342;343. 
 
By linking specific genotypes to disease susceptibility phenotypes we can better 
understand the genetic basis for inter-individual differences in disease susceptibility 
as well as gain insight into how gene-environment interactions influence infection 
outcomes. By using genetically distinct and specific knockout mouse strains one can 
dissect interactive pathways and molecular events modulating host resistance or 
susceptibility to specific pathogens.  
 
3.1.4 Aims and Hypothesis 
Human studies on the pathogenesis of respiratory bacterial infections are invaluable, 
but animal models provide an unbiased tool for discovering novel mechanisms and 
genes contributing to disease outcomes under controlled laboratory environments. 
Therefore we wished to develop a robust and reproducible model of respiratory 
bacterial infection that is physiologically significant but is non lethal. To fulfil this aim 
we will:   
 
1. Determine a non lethal infective dose of Group B streptococcus in commonly 
used mouse strains.  
2. Characterise the immunological response needed for clearance of Group B 
streptococcus infection and identify histopathological consequences of infection.  
3. Translate technical expertise developed using the Group B streptococcus 
infection model to characterise a more clinically relevant S. pneumoniae mouse 
infection model. 
 
3.2 Results 
 
Before investigating the influence respiratory viral infections have on immunity and 
pathology to a subsequent bacterial infection, a clear understanding of a common 
respiratory bacterial infection must first be examined. We selected Group B 
streptococcus (GBS) and S. pneumoniae as two relevant respiratory commensals 
that infect the host via the respiratory tract. The rational for using two separate 
bacterial species was to determine whether immunological and pathological 
parameters are shared between closely related respiratory pathogens or are species 
specific. A significantly different response would inform us which strain is more 
appropriate to use in our secondary bacterial infection model. The first part of this 
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results chapter will explain the development and characterisation of a GBS infection 
model before moving on to examine a S. pneumoniae infection model. 
 
3.2.1 Group B streptococcus infection model characterisation 
 
GBS is a leading cause of invasive bacterial infection in human newborns and is 
increasingly recognized as a pathogen in adult populations. To date, no suitable 
murine respiratory infection model for GBS exists. The majority of existing GBS 
infection models utilise high doses of bacteria that cause systemic toxic shock 
resulting in death within 24 to 48 hours. This is an unlikely situation in man; rather, 
bacteria asymptomatically colonise the upper respiratory tract and when presented 
with an opportunity, such as a virus infection or an altered state of homeostasis, 
invade surrounding tissues and result in infection. The response to GBS will clearly 
depend upon bacterial dose and mouse strain employed. Therefore, both BALB/c 
and C57BL/6 mouse strains were initially used in a comparative study to investigate 
immune responses to varying doses of GBS. 
 
3.2.2 GBS administered at 5 x 106 cfu induces a strong inflammatory response 
in the airway and lung of BALB/c mice that is non lethal 
 
Both strains of mice were intranasally inoculated with varying doses of GBS as 
described in Figure 3.1. Mice were weighed daily over the course of 7 days and at 
specified time points total lung and airway cellular infiltrates were enumerated and 
analysed by flow cytometry (FCM). In both strains of mice there was no statistically 
significant difference in weight loss across all inoculum doses (Figure 3.2 a & b). 
However as a general trend, increasing the inoculum dose increased weight loss in 
C57BL/6 mice and slowed weight gain in BALB/c mice during the first three days of 
GBS infection. In both strains of mice 5 x 107 colony forming units (cfu) (similar to the 
dose used by others) of GBS resulted in systemic sepsis, as defined by the presence 
of cfu in the peripheral blood (data not shown), and 100% mortality by day 1 
(C57BL/6) and day three (BALB/c) post infection. It has been demonstrated 
previously, in respiratory infection models, that pathogen induced weight loss and 
clinical illness often reflects the amplitude of cellular infiltrate into both the lung and 
airway compartments. All GBS inoculum doses induced a rapid cellular infiltrate into 
the lung tissue in both C57BL/6 and BALB/c mice by day one post infection (Figure 
3.2 c & d). In contrast, the airway cellular response observed in BALB/c mice was 
more than twice the amplitude of that seen in C57BL/6 mice across all doses 24 
hours post infection (Figure 3.2 e & f). Therefore, 5 x 106 cfu GBS was chosen to  
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Figure 3.1 An illustration of Group B streptococcus (GBS) dose determination 
protocol. BALB/c and C57BL/6 mice were intranasally inoculated with varying doses of 
mid log phase GBS. Mice were followed over a period of 7 days and harvested on the 
days specified in the results. Designated tissues were removed and analysed 
subsequently. 
Tissue harvest and analysis:
• Daily weight loss (Original body mass %)
• BAL
Cell phenotype – Flow cytometry
Bacterial cfu
Cytokines/chemokine analysis
• Lung
Cell phenotype – Flow cytometry
Bacterial cfu
Snap freeze lobe(s) – Cytokine analysis
• Nasal Wash – Bacterial cfu
Harvest at specific time points post GBS infection
5 x 105 cfu 5 x 106 cfu 5 x 107 cfu
Group B streptococcus dose determination in 
BALB/c and C57BL/6 mice 
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Figure 3.2 GBS intranasally administered at 5 x 106 cfu induced a strong non lethal 
phenotypic response in both airway and lung compartments. C57BL/6 and BALB/c 
mice (n=5) were infected i.n. with either 5 x 105, 5 x 106, 5 x 107 GBS colony forming units 
(cfu) or PBS control on day 0. Mice were subsequently harvested on days 1, 3 and 7 days 
post GBS infection. Individual mouse weight was monitored daily and expressed as a 
mean percentage of original weight (a & b). BAL was performed and lung tissue removed, 
homogenised and total viable cell counts were determined using Trypan Blue exclusion. 
Lung (c & d) and airway (e & f) total viable cell numbers 24 hours post infection are 
illustrated. Data are presented as the mean ± SEM of 5 mice per group. p<0.05 was taken 
to be significant. * = p<0.05  ** = p<0.01
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Figure 3.3 An illustration of the standard single GBS infection protocol. BALB/c mice were 
inoculated intranasally with 5 x 106 cfu mid log phase GBS. Mice were then followed over 
a period of 14 days and harvested on the days specified in the results. Designated tissues 
were removed and analysed subsequently. 
d0
5 x 106 cfu
i.n
d1 d2 d3 d4 d5 d6 d7 d14
Days post infection
Standard Group B streptococcus infection protocol 
Tissue harvest and analysis:
• Daily weight loss (% day 0 weight)
• BAL
Cell phenotype – Flow cytometry
Bacterial cfu
Cytokines/chemokine analysis
• Lung
Cell phenotype – Flow cytometry
Bacterial cfu
Snap frozen lobe(s) – Cytokine analysis
• Nasal Wash – Bacterial cfu
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continue the characterisation of GBS respiratory infection because of its good cellular 
recruitment and its non lethal outcome.   
 
3.2.3 BALB/c mice elicit a more vigorous immune response than C57BL/6 mice 
whilst ensuring bacterial elimination by day 14 
 
After identifying 5 x 106 cfu as a non lethal dose of GBS we next compared the 
cellular response profile and ability to resolve GBS in both BALB/c and C57BL/6 mice 
strains. Mice were infected with 5 x 106 cfu GBS and followed over a period of 14 
days. Figure 3.3 illustrates a standard GBS infection kinetic protocol. At chosen time 
points, lung and airway cellularity was enumerated, as previously described, and 
tissue specific clearance of GBS determined by plating 10 fold dilutions of single cell 
suspensions on Todd Hewitt Broth (THB) agar. As before, BALB/c mice elicited a 
greater cellular response in both the lung and airway compartments compared to that 
observed in C57BL/6 mice. In both strains this was rapid with the maximal response 
occurring three days post infection (Figure 3.4 a & b). In C57BL/6 mice, cellularity 
returned to naïve levels in both the lung and airways by day 14. However, cellularity 
in the lungs of BALB/c mice remained elevated over naïve levels up to and including 
day 14 post infection. On comparison of the GBS cfu titre between BALB/c and 
C57BL/6 mice, both strains demonstrated identical titres with no statistically 
significant difference between them in any tissue analysed (Figure 3.4 c-f). In both 
mouse strains GBS titre significantly increased from day one to day three, with the 
highest titres observed in the airways. Nevertheless, no detectable GBS cfu were 
recorded at any site 14 days post infection in either mouse strain (Figure 3.4 c-f). 
 
3.2.4 GBS induces a transient myeloid response containing an early neutrophil 
and a later macrophage response 
 
Due to the large, but transient, cellular response observed and the visible disease 
induced by influenza virus infection, we adopted BALB/c mice to dissect further the 
cellular response to a GBS infection. It is known that extracellular bacteria induce a 
strong and rapid innate immune response consisting of professional phagocytes, 
such as macrophage and neutrophils. Taking this into consideration, we used flow 
cytometric analysis to determine the proportion of specific innate cell subsets and 
determine their spatiotemporal relationship during a single GBS infection. Myeloid 
cell populations were primarily based upon differential expression of CD11b and 
CD11c as described by Gonzalez-Juarrero et al 344. CD11b and CD11c staining of a 
naïve mouse lung, excluding lymphocytes by their forward and side scatter 
properties, revealed four distinct populations: CD11blo CD11chi (R1), CD11bhi  
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Figure 3.4 BALB/c mice elicited a larger immune response than C57BL/6 mice whilst 
ensuring bacterial clearance by day 14 post infection. C57BL/6 and BALB/c mice 
(n=5) were infected intranasally with 5 x 106 cfu of GBS on day 0. Mice were subsequently 
harvested on days 1, 3 and 14 days post infection. Airway (a) and lung (b) total viable 
cells  were determined using Trypan Blue exclusion. CFU titres from the lung (c), airway 
(d), nasal wash  (e) and nasal associated lymphoid tissue (NALT) (f) were calculated 
using serial dilutions of single cell suspensions of each tissue and plated on Todd Hewitt 
Broth (THB) agar. Data are presented as the mean ± SEM of 5 mice per group. p<0.05 
was taken to be significant. * = p<0.05  ** = p<0.01
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CD11chi (R2), CD11blo CD11clo (R3) and CD11bhi CD11clo (R4) (Figure 3.5 a & b). 
Cells in the region R1 exhibited the same CD11b/CD11c profile as the majority of 
cells isolated from the airways of naïve mice (Figure 3.5 a) and appeared 
morphologically like alveolar macrophages (data not shown). Cells in R2 also 
expressed low levels of Gr1/Ly6g and high MHC II levels. They also appeared 
morphologically similar to activated macrophage or dendritic cells, with cytoplasmic 
processes (data not shown). Cells in R3 are difficult to distinguish due to their 
autofluorescence level. They express low levels of Gr1 and have small, horse-shoe 
shaped, nuclei resembling monocytes (data not shown). Fibroblasts and other 
connective cells are also likely to fall within this gate. Finally cells in R4 expressed 
high levels of Gr1, Ly6g and CD11b and were negative for MHC II. The majority 
appeared morphologically to be neutrophils as they possessed multilobed nuclei, 
however there was also the presence of small monocytes. This differential 
expression profile was subsequently utilised to distinguish distinct myeloid 
populations during single GBS infections and all subsequent infection models 
investigated throughout this thesis. However, during the course of many respiratory 
infections macrophage and monocytes up regulate CD11b and other cell markers 
upon activation, therefore the combination of alternative cell markers can be utilised 
to further scrutinize specific cell types.   
 
GBS infection transiently increased the total number of myeloid cells in the lung 
peaking on day three before decreasing by day 14 post infection (Figure 3.5 c). 
Further dissection of the lung innate response highlighted a significant population of 
neutrophils, peaking on day one before being replaced by macrophages on day three 
post infection (Figure 3.5 d & e). These observations were mirrored in the airway 
(Figure 3.6 a-c). NK cells also play an important role in innate defence against 
invading bacterial pathogens 30;345-347. NK and NK T (CD3+) cells followed similar 
kinetics to that of neutrophils with the percentage and cell number peaking on day 
one p.i (Fig. 3.7 a). NK cells also play a key role in early IFN-γ production in the lung 
(Fig. 3.7 b). This was also seen in the airway (data not shown). Myeloid cells are not 
only central to the establishment and maintenance of the inflammatory response to 
infection by secreting cytokines and chemokines but also play a key role in 
presenting antigen to recruited T cells, which consequently ensures their full 
activation. GBS infection elicits a CD4+ T cell dominated response in the lung by day 
three post infection (Figure 3.8 a & b). Further analysis of this lymphocyte response 
highlights a large percentage of activated CD4+ T cells (Figure 3.8 c). 
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Figure 3.5 5 x 106 GBS induced a transient myeloid response containing an early 
neutrophil and a later macrophage response. BALB/c mice (n=5) were infected 
intranasally with 5 x 106 GBS cfu. Mice were subsequently harvested on days 1, 3 and 14 
days post infection. BAL was performed and lung tissue removed, homogenised and total 
viable cell counts determined as previously described. Subsets of myeloid cells were 
determined from naïve airway (a) and lung (b) populations. Total myeloid cells were
determined by their relative forward and side scatter appearance (c). Lung neutrophils (d) 
were discriminated as Gr-1 hi MHC II lo CD11c lo CD11b hi and followed over the course of 
infection. Lung macrophage (e) populations were defined as R1, R2 & R4 (that are not 
neutrophils). Data are presented as the mean ± SEM of 5 mice per group. p<0.05 was 
taken to be significant. * = p<0.05  ** = p<0.01
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Figure 3.6 Airway recruitment of neutrophils and macrophage in response to GBS 
infection follows similar kinetics to that observed in the lung tissue. BALB/c mice 
(n=5) were infected intranasally with 5 x 106 GBS cfu. Mice were subsequently harvested 
on days 1, 3 and 14 days post infection. BAL was performed and total viable cell counts 
determined using Trypan Blue exclusion. Total airway myeloid cells (a) were determined 
by their relative forward and side scatter appearance. Recruited neutrophils (b) and 
macrophage (c) were also followed over the course of infection. Data are presented as the 
mean ± SEM of 5 mice per group. p<0.05 was taken to be significant. * = p<0.05  ** = 
p<0.01
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Figure 3.7 GBS infection activates a rapid NK and NK T cell response that 
contributes to IFN-γ cytokine levels. BALB/c mice (n=5) were infected intranasally with 
5 x 106 GBS cfu. Mice were harvested on specified days post infection at which BAL was 
performed and lung tissue removed, homogenised and total viable cell counts determined 
using Trypan Blue exclusion. Lung NK (closed)  and NK T (open) cell subsets were also 
quantified (a) and the total number expressing IFNγ (b) was determined by intracellular 
staining. Data are presented as the mean ± SEM of 5 mice per group. p<0.05 was taken 
to be significant. * = p<0.05  ** = p<0.01
a
b
Naive 1 3
0
0.5
1.0
1.5
2.0
2.5
C
e
lls
 (
x
 1
0
5
)
0
2
4
6
8
10
12
C
e
lls
 I
F
N
 γ
+
(x
 1
0
3
)
**
**
*
**
**
*
Time (d) post infection
NK T cellNK cell
Naive 1 3
Time (d) post infection
 CHAPTER 3: BACTERIAL INFECTION MODEL DEVELOPMENT 
73 
 
Figure 3.8 GBS infection elicited a CD4+ dominated T cell response. BALB/c mice 
(n=5) were infected intranasally with 5 x 106 GBS cfu. Mice were harvested on specified 
days post infection at which BAL was performed and lung tissue removed, homogenised 
and total viable cell counts determined using Trypan Blue exclusion. The percentage (a) 
and cell numbers (b) of lung CD4 + and CD8 + T cells were determined using flow 
cytometry. Activated T cells were determined as CD45rblo expressing cells (c). Data are 
presented as the mean ± SEM of 5 mice per group. p<0.05 was taken to be significant. * = 
p<0.05  ** = p<0.01
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A similar response was observed in the airway, but due to a lack of total lymphocyte 
numbers the results were insignificant (data not shown).  
 
3.2.5 GBS causes extensive lung inflammation and injury that is resolved by 
day 7 post infection 
 
To further investigate pathological changes to the lung in response to GBS infection, 
the right azygous lobe was processed for histology at days 1, 3 and 7 days post 
infection (Figure 3.9). Perivascular and peribronchiolar infiltrates were clearly visible 
on both 1 and 3 days post infection. The extent of this infiltrate was most evident on 
day 1 post infection. There was also evidence of bronchiolar wall hypertrophy, 
bronchiolar oedema, significant vascular leakage and the presence of cellular debris 
in the larger airways. By day 3 post infection, the cellular infiltrate showed a more 
diffuse and patchy distribution within the lung parenchyma tissue, with a reduction in 
both the perivascular infiltrate and vascular leakage. There was also a slight 
improvement in alveoli architecture by this time point. A significant improvement of 
lung histology was observed by day seven post infection. This was highlighted by the 
remnants of a small number of isolated foci of peribronchiolar infiltrate and a marked 
improvement in alveoli architecture.  
 
3.2.6 GBS re-challenge elicits a robust memory immune response resulting in 
reduced bacterial titre in all compartments analysed 
 
Having demonstrated that GBS infection elicits a robust innate immune response 
followed by the presence of activated CD4+ T cells we next investigated the ability of 
GBS to induce immunological memory by looking at the cellular infiltrate, bacterial 
clearance and T cell memory subsets in response to a GBS re-challenge. Upon re-
challenge with 5 x 106 cfu GBS, 14 days after a primary infection, a rapid cellular 
response was again observed in both lung and airway compartments. The re-
challenge response was significantly greater in amplitude in the lung compared to 
that seen in the initial primary response. This trend was also observed in the airway 
but failed to reach significance (Figure 3.10 a & b). The greater amplitude and quality 
of cellular recruitment observed in response to a GBS re-challenge resulted in 
reduced GBS cfu titres observed across all tissues analysed in comparison to the 
levels measured in a primary GBS infection (Fig. 3.10 c). Further investigation into a 
possible mechanism for the observed increase in immunity highlighted an increase in 
the proportion and total number of lung CD4+ effector (CD62Llo CD44hi) and CD4+ 
central (CD62Lhi CD44hi) memory T cells (Fig. 3.11 a & b). This significant difference 
was not observed in the airway (data not shown). 
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Figure 3.9 Progressive lung pathology and injury in the lungs of BALB/c mice 
during GBS infection. BALB/c mice (n=5) were infected intranasally with 5 x 106 cfu GBS 
on day 0. Mice were subsequently harvested on days 1, 3 and 7 days post infection. 
Processing of mouse lungs for histology and light microscopy of H & E stained sections 
were carried out as described in section 2.7.1. Magnification was x 10. Sections are 
representative of five mice studied at each time point. 
Time (d) post Group B streptococcus infection
Naive Day 1 
Day 7 Day 3 
BALB/c mice lung histology 
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Figure 3.10 GBS re-challenge elicited a robust memory immune response resulting 
in reduced bacterial titre in all compartments analysed. BALB/c mice (n=5) were 
infected intranasally with 5 x 106 GBS cfu on day 0. 14 days later mice were re-challenged 
with 5 x 106 cfu GBS. Mice were harvested 3 days post re-challenge on which BAL was 
performed and lung tissue removed. Total viable cell counts in lung (a) and airway (b) was 
enumerated using Trypan Blue exclusion. Bacterial cfu (c) from lung, airway (BAL), 
nasopharynx (NW) and nasal associated lymphoid tissue (NALT) were calculated using 
serial dilutions of single cell suspensions and plated on Todd Hewitt Broth (THB) agar. 
Data are presented as the mean ± SEM of 5 mice per group. p<0.05 was taken to be 
significant. * = p<0.05  ** = p<0.01
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Figure 3.11 The percentage and number of CD4+ effector and central memory T cell 
subsets are increased upon GBS re-challenge. BALB/c mice (n=5) were infected 
intranasally with 5 x 106 GBS colony forming units on day 0. 14 days later mice were re-
challenged (RC) with 5 x 106 CFU GBS and mice harvested 3 days later. Lung tissue was 
removed, homogenised and total viable cell counts were determined using Trypan Blue 
exclusion. Total number of CD4+ central (a) and effector (b) memory T cells were 
enumerated from naïve, day 14 primary (D14) and re-challenged (RC) mice. 
Representative dot plots of CD4+ lung CD62Lhi CD44hi (central memory) and CD62Llo
CD44hi (effector memory) are shown (c). Data are presented as the mean ± SEM of 5 mice 
per group. p<0.05 was taken to be significant. * = p<0.05  ** = p<0.01
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3.2.7 Streptococcus pneumoniae infection model characterisation 
 
Streptococcus pneumoniae is a commensal of the human nasopharynx and is a 
common cause of lobar pneumonia, otitis media, septicaemia and meningitis 324. It 
causes more deaths from invasive infections than any other bacterium and is the fifth 
leading cause of death worldwide 318. Attention has therefore been focused on the 
mechanisms of its pathogenesis and the role of its virulence determinants. 
Additionally, the recent emergence of antibiotic resistance and the growing 
recognition for its role in viral induced secondary bacterial pneumonia has increased 
the need for robust laboratory based animal models. Using the same approach used 
to investigate a GBS infection, we wished to determine a non lethal infectious dose 
and characterise the immunological response to S. pneumoniae in both BALB/c and 
C57BL/6 strains of mice.    
 
3.2.8 Streptococcus pneumoniae administered at doses higher than 1 x 105 cfu 
is lethal to C57BL/6 mice within 48 hours of infection  
 
Both strains of mice were intranasally inoculated with varying doses of D39, a 
historically important and commonly used serotype 2 strain of S. pneumoniae, as 
described in Figure 3.12. Mice were weighed daily over the course of 7 days and at 
specified time points total lung and airway cellular infiltrates were analysed along with 
the bacterial titres in specific tissue compartments. In C57BL/6 mice there was no 
statistically significant weight alteration compared to PBS infected controls (Figure 
3.13 a), however, as a general trend, increasing inoculum dose slowed weight gain 
over the course of infection. In contrast, infection of BALB/c mice with the two highest 
doses of S. pneumoniae resulted in a transient weight loss on days 3 and 4 post 
infection (Figure 3.13 b). Most strikingly, high doses of S. pneumoniae infection 
resulted in the death of C57BL/6 mice whilst BALB/c mice survived. No BALB/c mice 
died after infection with any dose over the course of the infection whereas C57BL/6 
mice demonstrated 50 % mortality by day 3 post infection with 1 x 106 cfu and 25 % 
mortality by day 7 with 1 x 105 cfu (Figure 3.13 c & d). The increase in lethality 
observed in C57BL/6 mice with increasing inoculum dose reached significance using 
the log rank Mantel-Cox test (p 0.03). 
 
We also determined the recoverable bacterial titres from specified tissue 
compartments in both strains of mice at 1, 3 and 7 days post S. pneumoniae 
infection. Bacterial titres recovered from the airways of C57BL/6 mice and BALB/c 
mice infected with 1 x 106 cfu were equivalent on day 1 post infection but are 
significantly reduced on days 3 and 7 in BALB/c mice compared to the levels  
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Figure 3.12 S. pneumoniae dose determination protocol. BALB/c and C57BL/6 mice 
were intranasally inoculated with varying doses of D39,  a commonly used clinical isolate 
of serotype 2 S. pneumoniae. Mice were followed over a period of 7 days and harvested 
on the days specified in the results. Designated tissues were removed and analysed 
subsequently. 
Tissue harvest and analysis:
• Daily weight loss (Original body mass %)
• BAL
Cell phenotype – Flow cytometry
Bacterial cfu
Cytokines/chemokine analysis
• Lung
Cell phenotype – Flow cytometry
Bacterial cfu
Snap freeze lobe(s) – Cytokine analysis
• Nasal Wash – Bacterial cfu
Harvest at specific time points post S. pneumoniae infection
5 x 104 cfu 5 x 105 cfu 5 x 106 cfu
Streptococcus pneumoniae dose determination in 
BALB/c and C57BL/6 mice
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Figure 3.13 S. pneumoniae administered at 1 x 105 cfu or higher is lethal to C57BL/6 
mice within 48 hrs of infection. BALB/c and C57BL/6 mice (n=4) were infected 
intranasally with 1 x 104, 1 x 105 or 1 x 106 S. pneumoniae cfu on day 0. Mice were 
subsequently harvested on days 1, 3 and 7 days post infection. Individual mouse weight 
was monitored daily and expressed as a mean percentage of original weight (a & b). 
Moribund mice, determined by home office guidelines, were culled and recorded as 
deceased using a Kaplan Meier survival curve (c & d). Data are presented as the mean ±
SEM of 4 mice per group. p<0.05 was taken to be significant. * = p<0.05  ** = p<0.01 Log 
rank Mantel - Cox test was used to determine significance in survival. 
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observed in C57BL/6 mice (Figure 3.14 a & b). Infection with 1 x 105 cfu produced a 
similar trend, again with a significant reduction in bacterial load measured in BALB/c 
mice on days 3 and 7 post infection. Both strains of mice clear 1 x 104 cfu bacteria 
from the airways by day 7 p.i (Figure 3.14 a & b). Intriguingly, no bacterial cfu were 
recovered from the lung tissue of BALB/c mice in response to all inoculum doses at 
any time point analysed (data not shown). In contrast, 1 x 105 and 1 x 106 cfu 
infectious doses resulted in a 3 log increase in bacterial cfu from day 1 to day 3 in the 
lung tissue of C57BL/6 mice (Figure 3.14 c). Bacteria were still present at day 7 at 
these two doses whilst there was no detectable presence with the 1 x 104 dose from 
day 3 onward (Figure 3.14 c). Nasopharyngeal carriage also differed significantly 
between C57BL/6 and BALB/c mice strains. As a general trend, there was a 2 log 
increase in bacterial titre at each infectious dose when comparing C57BL/6 to 
BALB/c mice (Figure 3.14 d & e). The presence of bacterial cfu in the nasopharynx 
occurred at all time points analysed and showed a dose response with regards to the 
initial infectious dose. As was seen with the difference in mortality between the two 
mice strains, the presence of bacterial cfu in the peripheral blood was also uniquely 
seen in C57BL/6 mice (Figure 3.14 f). Although one mouse infected with 1 x 104 cfu 
recorded the presence of bacteraemia by day 1 post infection, 50 % of both 1 x 105 
and 1 x 106 CFU infected mice recorded very high levels of blood bacteraemia. There 
were no peripheral bacterial cfu detected at any time point analysed across all 
inoculum doses used in BALB/c mice (data not shown).    
 
3.2.9 S. pneumoniae elicited a rapid cellular response in the airway and lungs 
of BALB/c mice that was absent in C57BL/6 mice   
 
As was seen with a GBS infection, there was little airway or lung cellular recruitment 
in C57BL/6 mice on days 1 and 3 post S. pneumoniae infection (Figure 3.15 a & c). 
However, by day 7 there was a small, yet significant, increase in the total airway cell 
numbers in response to both the 1 x 106 and 1 x 104 cfu in C57BL/6 mice (Figure 
3.15 a). Once more, mirroring that observed with a GBS infection, BALB/c mice 
elicited a robust cellular response in both the airway and lung in response to the 
highest dose of S. pneumoniae, the amplitude of which was approximately 3 times 
that observed in response to an identical inoculum dose in C57BL/6 mice (Figure 
3.15 b & d). In contrast to C57BL/6 mice, low doses of S. pneumonia elicited a 
cellular response in the lungs of BALB/c mice by days 3 post infection (Figure 3.15 
d). This was resolved by day 7 with the total cell number returning to that seen at day 
0. In contrast, infection with 1 x 106 cfu resulted in the total number of cells in both  
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Figure 3.14 Bacterial titres recovered from C57BL/6 mice were elevated in all tissues 
analysed compared to BALB/c mice. C57BL/6 (left) and BALB/c (right)  mice (n=4) were 
infected intranasally with 1 x 104, 1 x 105 or 1 x 106 S. pneumoniae cfu on day 0. On 
specified days post infection BAL and nasal wash was performed and lung tissue was 
removed. Airway (a & b), lung (c) and nasal wash (d & e) bacterial titres from C57BL/6 (left 
column) and BALB/c (right column) were determined by serial dilutions on Columbus 
blood agar. Peripheral blood bacterial titres from C57BL/6 mice were also analysed (f). 
Data are presented as the mean ± SEM of 4 mice per group. p<0.05 was taken to be 
significant. * = p<0.05  ** = p<0.01
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Figure 3.15 S. pneumoniae elicit a rapid cellular response in the airway and lungs of 
BALB/c mice that was absent in C57BL/6 mice. C57BL/6 (left) and BALB/c (right) mice 
(n=4) were infected intranasally with 1 x 104, 1 x 105 or 1 x 106 cfu S. pneumoniae on day 
0. Total airway cells (a & b) and lung cells (c & d) were harvested on specified days and 
total cells enumerated using Trypan blue exclusion. Data are presented as the mean ±
SEM of 4 mice per group. p<0.05 was taken to be significant.    * = p<0.05  ** = p<0.01
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Figure 3.16 S. pneumoniae infection results in a robust neutrophil recruitment to the 
airway. C57BL/6 and BALB/c mice (n=4) were infected intranasally with 1 x 104, 1 x 105 or 
1 x 106 cfu of S. pneumoniae on day 0. BAL was used to recover airway cells at specified 
time points post bacterial infection. Alveolar macrophage proportions (a & b) and 
neutrophil total numbers (c & d) were determined using differential FCM staining as 
previously described. Lung tissue levels of KC 12 h post infection (e) were also analysed 
by ELISA. Data are presented as the mean ± SEM of 4 mice per group. p<0.05 was taken 
to be significant. * = p<0.05  ** = p<0.01
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the airway and lungs of BALB/c mice remaining elevated up to and including day 7 
post infection. Further investigation into the composition of the cellular response to S. 
pneumoniae highlights that, at low doses of infection, alveolar macrophages 
constitute the major cell type present within the airway (Figure 3.16 a & b). However, 
as the inoculum dose of S. pneumoniae is increased, a correlated increase in 
neutrophil recruitment to the airway is observed in both C57BL/6 and BALB/c mice 
(Figure 3.16 c & d). This enhanced airway recruitment of neutrophils observed in 
BALB/c mice is more than 10 times the number seen in C57BL/6 mice. This is 
reflected by a significant elevation in the levels of KC, a murine homolog of IL-8, 
detected in the lung tissue of BALB/c mice in response to 1 x 106 cfu of S. 
pneumoniae compared to C57BL/6 mice (Figure 3.16 e). 
 
3.3 Discussion 
 
3.3.1 BALB/c mice demonstrate increased resistance to respiratory 
Streptococcal infections 
 
We demonstrate that BALB/c and C57BL/6 mice differ significantly in their 
susceptibility, as represented by survival time and numbers of bacteria present in 
peripheral blood, to both GBS and S. pneumoniae respiratory infections. Despite 
recovering comparable levels of bacteria from C57BL/76 and BALB/c mice following 
a non lethal dose of GBS, C57BL/6 mice succumbed when infected with a larger 
dose of GBS. The relative resistance to respiratory bacterial infection observed in 
BALB/c mice was more evident with a S. pneumoniae infection. The level of S. 
pneumoniae recovered from BALB/c mice was consistently lower, compared to 
C57BL/6, in all tissues analysed and was never detected in the lung tissue 
regardless of inoculum dose used. This result most likely explains the absence of 
bacteraemia in BALB/c mice and the 100 % survival regardless of S. pneumoniae 
dose used. These findings are largely supported by a number of recent studies that 
investigated the genetic resistance of some commonly used inbred mouse strains in 
response to S. pneumoniae infection 348;349. Using the exact strain of S. pneumoniae 
used in our study, Gingles et al demonstrate a large variation in S. pneumoniae 
resistance across several commonly used inbred mouse strains. The capacity to limit 
the development and progression of bacteraemia, specifically in BALB/c mice, is 
thought to be strongly dependent upon the ability to control the levels of bacteria in 
the lung and that this is affected by the amplitude of cells recruited to the site of 
infection. These observations are supported in another study that used a lobar 
pneumonia infection model, in which BALB/c mice demonstrated increased 
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resistance against a serotype 3 strain of S. pneumoniae compared to C57BL/6 mice 
325. Resistance in this case again depended on the intensity of cellular recruitment 
but also highlights a role for enhanced phagocytic activity and oxidative burst in 
alveolar macrophages and neutrophils. Similar innate defects in macrophage 
bactericidal capacity also contribute to the enhanced susceptibility of DBA/2 mice to 
Pseudomonas aeruginosa infection 350; though in the case of this organism the 
infiltration of neutrophils may play an important role in immunity 351. Our results also 
indicated that enhanced cellularity in BALB/c mice to both GBS and S. pneumoniae 
correlates with resistance and likely explains the reduction in bacterial titres and 
possibly the transient weight loss observed in BALB/c mice following S. pneumoniae 
infection. However, despite a more robust cellular response observed in BALB/c 
mice, there was no significant difference in GBS bacterial load observed between 
C57BL/6 mice and BALB/c. Assuming the absence of pre-existing anti-pneumococcal 
polysaccharide capsule antibodies, this suggests that both defects in the innate 
immune system that determines cellular recruitment and bactericidal capabilities play 
a critical role in determining mouse strain differences in susceptibility to respiratory 
bacterial infection.  
 
3.3.2 BALB/c mice elicit an enhanced neutrophil response to respiratory 
streptococcal infections 
 
Neutrophils were a dominant feature of both GBS and S. pneumoniae infection most 
notably in BALB/c mice following S. pneumoniae infection. This is particularly 
apparent at a high inoculum dose and correlates with elevated levels of KC, a 
neutrophil chemoattractant and murine homolog of human IL-8. Heightened 
recruitment may explain the control of S. pneumoniae infection in BALB/c mice, 
though at present we cannot rule out enhanced cellular anti-bacterial activity in 
BALB/c mice. An enhanced neutrophil response is consistent with the studies of 
Gingles et al and Preston et al, where both postulate that bacteraemia is avoided by 
neutrophil phagocytic and anti-bacterial activity. BALB/c mice also show greater 
recruitment of neutrophils into the airway in response to P. aeruginosa compared to 
susceptible DBA/2 mice that are unable to clear the infection 351;352. Protection has 
also been associated with a specific induction of IL-17 and MCP-1 in BALB/c mice, 
which in a recent study have been shown to enhance the recruitment and killing 
capacity of neutrophils in a nasopharyngeal S. pneumoniae colonization model 275. 
Furthermore, neutrophils are essential for the clearance of Staphylococcus aureus 
353. There is a swath of evidence highlighting the importance of the effector function 
of neutrophils in the clearance of bacteria rather than their mere presence alone. 
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Mice deficient in cathespin G, a serine protease produced by neutrophils, are more 
susceptible to infection with the gram positive bacteria Staphylococcus aureus and a 
deficiency of neutrophil elastase renders mice more susceptible to gram negative 
bacteria 354;355. Nonetheless, despite mounting evidence supporting the importance of 
neutrophils in anti-bacterial defence, there are a number of other studies that suggest 
an over exuberant neutrophil response can increase pathology to S .pneumoniae 
infection, resulting in increased mortality without affecting bacterial clearance 274. The 
dependence on neutrophils for clearance may depend on the respiratory site 
colonised. S. pneumoniae infection does not cause differential neutrophil recruitment 
in the nasal cavity of C57BL/7 and BALB/c mice 356. It would be interesting to test 
whether neutrophil depletion using an anti Ly6G, a neutrophil specific surface 
marker, antibody makes BALB/c mice as susceptible to S. pneumoniae as C57Bl/6 
mice or alters their nasopharyngeal commensal burden. 
 
Our observations, and those of others, raise a number of intriguing questions about 
what determines the amplitude and quality of a bacteria induced neutrophil response 
in an inbred mouse strain. For example, are there subtle differences in TLR 
expression in the respiratory tract that could in turn affect the production of neutrophil 
chemotactic factors? Is there a variation in the downstream signalling events and the 
machinery needed to produce neutrophil chemoattractants? A recent study highlights 
variations in chemokine production in C57BL/6 and BALB/c mice in response to 
infection with murine gammaherpesvirus-68 357. Are there innate differences in the 
migratory ability of neutrophils or even the ability to produce or release neutrophils 
from the bone marrow? Is a neutrophil response critical for all Streptococcaceae 
family members or even all Lactobacillales bacteria? 
 
3.3.3 MHC associations and bacterial susceptibility 
 
Attempts to map disease susceptibility to individual genes have been made for many 
years, however due to the complexity of the host‟s genetic components and the 
important role played by environmental factors, such as pathogenicity determinants 
of the microbe itself, progress has been slow. It was shown that mice with a tendency 
toward a Th1 or Th2 lymphocyte response manifest different reactions to inoculation 
with the parasite Leishmania major for example, however it is rare that susceptibility 
to an infectious agent is due to a single gene alone 358-360. Marley et al clearly show 
that the mouse H2 haplotype is responsible for the recruitment and function of 
neutrophils following a S. pneumoniae infection but that other non MHC genes were 
 CHAPTER 3: BACTERIAL INFECTION MODEL DEVELOPMENT 
88 
also required 361. Furthermore, within the H2κ haplotype, CBA/Ca mice are 
significantly more susceptible to S. pneumoniae infection than H2κ AKR mice and H2d 
BALB/c are more resistant than H2d DBA/2 strain. Thus H2 genes alone do not cause 
susceptibility to S. pneumoniae infection but may contribute with other susceptibility 
alleles 348. More recently, using linkage analysis of an F2 cross between resistant 
BALB/c and susceptible CBA/Ca strains, a region close to the locus D7Mit7, on 
chromosome 7, has been described that increases survival to S. pneumoniae 
infection. The identified locus lies within a region of chromosome 7 that includes 
several genes involved in inflammation and innate immunity, such as tyrosine kinase-
binding protein (Tyrobp), the platelet activating factor acetylhydrolase 1B gamma 
subunit gene (Pafah1b3) and the gene for nuclear factor–κB inhibition (IKB-b) 
amongst others 362. Evidence that inbred mouse strain differences in neutrophil 
recruitment explain innate susceptibility to infection also comes from other models of 
infection. For example, the differences in response of resistant BALB/c H2d and 
susceptible CBA/CaH mice to Candida albicans lies in short-lived cellular responses 
derived from the bone marrow, predominantly neutrophils 363. Furthermore, a recent 
investigation using a systems genetics approach identified a quantitative trait locus 
on chromosome 2 of mice that implicated the interleukin 1-α and prostaglandin E 
synthases pathways as key networks involved in modulating Group A streptococcus 
sepsis 364.  
 
By virtue of the variation in the distribution of phenotypes observed across commonly 
used inbred mouse strains, growing evidence from systems genetic linkage studies 
and the enormous complexity of host-pathogen interactions it is highly unlikely that a 
single gene will explain susceptibility or resistance to common respiratory bacterial 
pathogens such as GBS or S. pneumoniae. One can imagine a situation whereby a 
polymorphism in any of the detection and effector mechanisms involved in 
inflammation or resolution toward respiratory bacterial pathogens could provide a 
unique response that may or may not confer resistance.  
 
3.3.4 Alternative mechanisms in determining resistance to respiratory 
Streptococcal infections 
 
Having discussed the major phenotypic differences observed between C57BL/6 and 
BALB/c in response to two common respiratory bacterial infections, our results 
provided a number of other intriguing insights that warranted a brief discussion. We 
show that a GBS infection provokes a rapid infiltration of both NK and NK T cells into 
the airway and lung tissue. We also observe the development of a CD4+ dominated T 
 CHAPTER 3: BACTERIAL INFECTION MODEL DEVELOPMENT 
89 
cell response late in infection that could provide B cell help or seed a memory T cell 
population that provides enhanced immunity upon a GBS re-challenge. The role NK 
cells play in bacterial infection is not entirely clear, though once activated they 
release IFN-γ which may enhance APC activation and Th1 T cell development 
35;365. 
The presence of NK cells may therefore explain the development of the CD4+ Th1 T 
cell dominated response observed during a primary and secondary GBS infection. 
The presence of CD4+ T cells in response to a GBS re-challenge enhanced bacterial 
clearance, however, whether this was due to T cell dependent antibody production or 
the T cells themselves remains to be elucidated. The presence of NK T cells during a 
primary GBS infection also raised some interesting questions. Although NK T cells 
become activated early after challenge with both viral and bacterial pathogens, they 
are mainly thought to be critical for the clearance of viral infections. However, recent 
studies show that NK T cells play a critical role in both S. pneumoniae and P. 
aeruginosa infections 366;367. Invariant NK T cells (iNK) secrete cytokines, such as IL-
4, IFN-γ, TNF-α, IL13 and GM-CSF 368;369. Furthermore, a recent study investigating 
novel NK T cell populations shows that NK1.1neg iNK T lymphocytes represent a new 
population of IL-17 producing cells that contribute to neutrophil recruitment through 
preferential IL-17 secretion. Induction of these cells could therefore provide a quick 
response to infection and contribute anti-S. pneumoniae immunity. In addition to KC 
and MIP-3, TNF-α, together with IL-1 also stimulates neutrophil recruitment 370. NK T 
cells may therefore facilitate this in experimental S. pneumoniae models. Indeed 
rapid TNF-α activity within the airways has been shown to protect BALB/c mice from 
S. pneumoniae infection 371. The status of innate immunity prior to lung infection is 
also likely to determine the outcome of infection. A recent study demonstrates that 
protection against S. pneumoniae infection is achieved if the mice were previously 
primed using UV killed Haemophilus influenzae 372. This prior, irrelevant, bacterial 
challenge is likely to have primed the anti microbial lung microenvironment such that 
it responds better to subsequent unrelated organisms.  
 
The role of T cells in respiratory bacterial infection remains unclear and is highly 
dependant on the species of bacterial pathogen investigated. Mice that do not 
express MHC II, and thus fail to select CD4+ T cells in the thymus, show prolonged S. 
pneumoniae carriage 276. However, the CD4+ T cell dependent effector functions 
responsible are yet to be identified and as discussed above, there could also be 
other important immunity genes present within the mouse H2 locus that confers 
resistance to S. pneumoniae infection. One likely role of CD4+ T cells in mediating 
protection against S. pneumoniae is the assistance of antigen specific antibody 
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responses or the activation of macrophages via IFN-γ production. γδ T cells are 
prevalent in the murine intraepithelial compartment of the lung and it is postulated  
that they regulate pulmonary dendritic cells and alveolar macrophage and confer 
protection against S. pneumoniae bacteraemia by resolving over exuberant 
inflammation 373.  
 
3.4 Conclusion 
 
Animal models clearly establish a role for genetic factors in the predisposition to 
respiratory bacterial infections. There is also extensive data from humans that 
suggest the involvement of complex genetic and host/environment interactions.  
Understanding the molecular mechanisms responsible for successful protection 
against S. pneumoniae, and other common respiratory pathogens, is critical for the 
development of effective vaccines, but may also provide novel targets for 
immunomudulation and antimicrobial drug discovery. We have developed a GBS and 
a S. pneumoniae infection model in both C57Bl/6 and BALB/c mice within the 
laboratory. Both strains of mice become infected but differ in their susceptibility. 
Relative resistance is associated with increased neutrophil and NK T cell responses.  
For the purposes of the following chapter we will utilise BALB/c mice to develop a 
secondary bacterial infection model due to its inherent resistance to respiratory 
bacterial pathogens. 
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Chapter 4 
 
 
4.0 Influenza virus induced secondary bacterial pneumonias 
 
4.1 Introduction 
 
4.1.1 Infection history determines immune responsiveness    
 
Although continuously exposed to environmental antigens, the mucosal surfaces of 
the respiratory tract must restrain excessive inflammatory responses in order to fulfil 
its role of gaseous exchange and prevent bystander tissue damage. Powerful 
mechanical and immunosuppressive mechanisms protect the lungs against most 
external aggressions, yet repeat infections with variable immunopathological 
outcomes are common. In recent years, epidemiological and animal model data 
demonstrated that one respiratory tract infection alters immunity and pathology to a 
second unrelated pathogen, even long after the resolution of the first pathogen and in 
the absence of cross-reactive immunity 299;374. The outcome of successive infections 
may be beneficial for the host, as shown for some respiratory virus combinations, or 
significantly worse as illustrated by the increased susceptibly to life-threatening 
bacterial pneumonia in patients previously infected with influenza virus 299;375-377. 
Altogether, these data suggest that the lungs undergo some form of education 
process or maturation that alters the way it responds to subsequent challenges. 
 
In the absence of shared T and B cell epitopes what does this maturation or 
adaptation involve?  Bystander activation of unrelated memory T cells, known to be 
retained in the lungs long after resolution of respiratory viral infection, may modify the 
local cytokine balance and influence immunity and pathology to subsequent 
infections 299;378;379. Regulatory T cells and their associated immune suppressive 
cytokines, such as IL-10, may also be initiated by the first infection and reduce the 
amplitude of immunity to the next. We often attribute immune adaptation to acquired 
T and B lymphocytes and assume that innate immune compartments return to their 
pre-infection state even after multiple episodes of infection and inflammation.  
Nevertheless, the number of dendritic cells and their ability to prime T cells remain 
elevated in the murine lungs long after the resolution of an influenza or respiratory 
syncytial virus (RSV) infection 380;381. Influenza infection also leads to the long term 
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formation of inducible bronchus-associated lymphoid (iBALT) tissue in the lungs 
where these dendritic cells are located 382. 
 
4.1.2 Bacterial recognition and defence in the respiratory tract 
 
Conserved microbial associated molecular patterns (MAMPs), expressed on the 
surface of pathogens, are recognized by mucosal sentinel cells via pattern-
recognition receptors (PRRs) such as Toll-like receptors (TLRs). The engagement of 
TLRs results in the activation of nuclear factor (NF)-kB and the production of pro-
inflammatory and antimicrobial signals (as described in section 1.3) 16. An alteration 
in the level of PRR expression or cellular re-localization of these receptors as the 
result of an inflammatory episode can lead to abnormal innate signalling and 
associated inflammatory responses. For example, TLR expression and response are 
compartmentalized in the gut epithelium to prevent continual recognition of 
commensal flora although such compartmentalization has not been described thus 
far in the respiratory tract 383;384. Lung epithelial cells do, however, up-regulate TLRs, 
in particular TLR3 and TLR2 in response to respiratory syncitial virus (RSV) and 
influenza infection, which may be mediated by the release of interferons (IFN) by 
infected macrophages 385-387. Whether such up-regulation has an impact on 
secondary infection is unclear. Since many of these receptors share components of 
their signalling pathways, changes in the expression level or phosphorylation status 
of molecules within these pathways may also interfere with the recognition of 
subsequent pathogens.  
 
Enhanced adherence of bacteria in the context of viral infection has also been 
extensively studied 388. In the case of influenza and pneumococcus synergism, 
increased bacterial adherence is proposed to be mediated by influenza expressed 
neuraminidase which exposes cryptic receptors via the cleavage of sialic acids from 
surface glycoconjugates 389. Adenoviruses also enhance bacterial adherence 390. 
Various antimicrobial molecules are present in the lumen of the gut (beta-defensins) 
or in the airways (collectins) that have multifunctional properties, including the ability 
to suppress macrophage responses and to target different types of micro-organisms 
391-393. Most of them are produced at steady state but can also be up-regulated by 
TLR ligands 394;395. Altered expression of such molecules with a broad range of 
specificity could also explain how one infection can impact on multiple secondary 
pathogens independent of antigenic cross-reactivity. 
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Furthermore, it is well established that viral infection can affect the function and 
viability of host cells at the site of infection. Neutrophil apoptosis occurs during 
lympho choriomeningitis virus (LCMV) infection and suppression of monocyte and 
neutrophil chemotaxis occurs in humans and animal models of influenza and herpes 
simplex virus infection 396-399. Secondary infections may be further affected by the 
inhibition of macrophage activation and phagocytosis by influenza 400. It has been 
shown that RSV infection induces cytokine production and the up-regulation of co-
stimulatory molecules by alveolar macrophages, but also reduces their antimicrobial 
function upon bacterial challenge 401. In addition, innate cells, including macrophages 
and epithelium are susceptible to tolerance, which in the short term compromises 
subsequent inflammatory responses. A good example of this phenomenon is cross-
tolerance between TLR agonists, which could explain why patients with sepsis 
develop an immunosuppressive state characterized by the hypo-responsiveness of 
their monocytes and increased susceptibility to pulmonary bacteria 402-404. 
 
 
4.1.3 Hypothesis and aims 
Human epidemiological and clinical data clearly demonstrates a relationship between 
a primary influenza virus infection and the development of secondary bacterial 
pneumonias. Despite the existence of a number of possible explanations, the field 
remains ambiguous and the precise mechanism(s) by which influenza virus 
increases susceptibility to respiratory bacterial pathogens remains to be elucidated. 
On the basis of previous work within the laboratory, illustrating how a previous 
infection or inflammatory insult can modulate immunity to a second unrelated 
infection 298;299;405, we hypothesise that influenza virus infection pre-disposes to 
secondary bacterial pneumonia by modulating the capacity of the airway to detect 
and mount a sufficient innate cellular response. We investigate this hypothesis via 
the following aims:  
 
1. Develop a robust and reproducible model of influenza induced secondary 
bacterial infection that is physiologically significant but is non lethal.  
2. Determine the temporal relationship between the two disparate infections, 
and at what point the combination of virus/bacteria becomes more detrimental 
than either alone. 
3. Assess specific innate pathways and their role in controlling secondary 
bacterial pneumonia following influenza infection. 
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4.2 Results  
 
As discussed above, the precise mechanism(s) by which influenza increases 
susceptibility to respiratory bacterial infections remain to be fully elucidated. We 
therefore sought to develop a sequential secondary bacterial infection model and use 
this to investigate the temporal relationship that exists between the two infections and 
shed light on how influenza modulates immunity to increase susceptibility to a 
subsequent bacterial infection. Having previously developed and characterised both 
a GBS and S. pneumoniae single bacterial infection model, it was also necessary to 
understand a typical influenza virus infection in mice.  
 
4.2.1 Influenza infection induces weight loss and pulmonary inflammation in 
BALB/c and C57BL/6 mice  
 
A typical influenza virus infection protocol is illustrated in Figure 4.1 panel a, both 
BALB/c and C57BL/6 mice infected with 50 HAU of influenza virus, equivalent to 1.25 
x 105 pfu,  experienced acute weight loss that began on day 2-3 post infection and 
peaked on days 6-7. C57BL/6 mice lost less weight and recovered weight 
significantly quicker than BALB/c mice (Figure 4.1 b). The peak airway infiltrate 
coincided with maximal weight loss implying that illness severity, measured in part by 
weight loss, correlated directly with the exuberance of the host‟s immune response 
(Figure 4.1 b & c). By day 14 the observed pulmonary inflammation had largely 
subsided and mice had returned to their original body weight. Illness associated with 
influenza infection is also attributed to viral cytopathology. Analysis of influenza virus 
replication highlighted a rapid phase of viral replication with titres peaking on day 1-2 
post infection before declining gradually becoming undetectable by day 7 (Figure 4.1 
b). Peak viral load directly coincided with a transient neutrophil response observed in 
both the airway and lung tissue. Neutrophilia was more protracted in the lung tissue 
with levels elevated above naive levels up to and including day 14 post infection 
(Figure 4.1 d). T cells are also involved in viral clearance and are a significant 
component of the observed pathology, causing airway occlusion and producing 
inflammatory mediators that are responsible for the observed cachexia and fever. 
The extent of this cellular response is clearly evident with histology (Figure 4.2). The 
right azygous lobe was removed at days 2, 7 and 14 post influenza infection and 
examined using light microscopy. Perivascular and peribronchiolar infiltrates were 
visible 2 days after influenza infection. However, the extent of this infiltrate was most 
evident on day 7 post infection. At this time point there was also evidence of 
bronchiolar wall hypertrophy, bronchiolar oedema, epithelium hyperplasia and the  
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Figure 4.1 Influenza infection induces weight loss and pulmonary inflammation in 
BALB/c and C57BL/6 mice. A typical infection protocol uses BALB/c or C57BL/6 mice 
(n=4) infected intranasally with 50 HAU HK/X31 influenza A virus or PBS naïve control (a). 
Weight loss (b, left axis) was monitored daily and expressed as mean % of original body 
mass. BAL was performed and lung tissue removed at 6 hrs, 1, 2, 3, 4, 7 and 14 days 
after infection. Total viable airway (c - right axis) and lung (c - left axis) cells were 
enumerated using Trypan blue exclusion. Flow cytometry was utilised to determine the 
number of neutrophils present in the airway and lung tissue (d). Viral titres were also 
analysed from snap frozen BALB/c lung lobe (b, right axis). Data are presented as the 
mean ± SEM of 4 mice per group. 
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Time (d) post influenza infection
Naive Day 2 
Day 14 Day 7 
BALB/c mice lung histology 
Figure 4.2 Progressive lung pathology and injury in the lungs of BALB/c mice 
during an influenza infection. BALB/c mice (n=5) were infected intranasally with 50 HAU 
HK/X31 influenza A virus on day 0. Mice were subsequently harvested on days 2, 7 and 
14 days post infection. Processing of mouse lungs for histology and light microscopy of H 
& E stained sections were carried out as described in section 2.7.1. Magnification was x 
10. Sections are representative of five mice studied at each time point. 
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presence of cellular debris in the larger airways. By day 14, the excessive cellular 
infiltrate had subsided leaving a small number of isolated foci of peribronchiolar 
infiltrate surrounding the larger airways. At this time point an improvement in alveoli 
architecture was also clearly visible (Figure 4.2).  
 
4.2.2 Simultaneous infection of BALB/c mice with influenza virus and GBS 
results in reduced associated viral weight loss  
 
Extensive clinical evidence suggests that during, or shortly after, an influenza 
infection a „window of opportunity‟ exists in which the lung becomes highly 
susceptible to invasive bacterial infection. Epidemiological evidence from the 1918 
influenza pandemic clearly demonstrates this temporal relationship (Figure 4.3 a). 
The appearance of secondary bacterial pneumonias begins approximately 7 days 
after the first cases of influenza virus infection. To investigate this temporal 
relationship an awareness of the distinct phases of an influenza infection in mice is 
necessary (Figure 4.3 b). Using this as a rudimentary guide, we developed a 
secondary bacterial infection model in which a pre-determined non lethal dose of 
GBS was intranasally administered at various time points post influenza infection 
(Figure 4.4). Bacterial titres in the nasopharyngeal cavity, distal airway, lung tissue 
and peripheral blood were measured along with other immune parameters to 
determine whether or not a concurrent or previous influenza infection affects the 
host‟s susceptibility to a respiratory bacterial infection.  
 
Initially, BALB/c mice were simultaneously infected intranasally with 50 HAU of 
influenza virus and 5 x 106 cfu GBS. Mice were subsequently followed over 14 days 
and at specified time points post GBS infection, harvested and analysed. As was 
described previously, mice infected with GBS alone showed no outward signs of 
clinical illness and followed the same weight profile as vehicle control mice (Figure 
4.5 a). Both groups of mice infected with influenza followed a typical weight loss 
profile, however mice co-infected with influenza and GBS recovered weight 
significantly faster than those infected with influenza alone (Figure 4.5 a). On 
comparison of viable bacterial titres recovered from co-infected and GBS alone 
infected mice, no significant difference was observed in the airway, lung tissue and 
nasopharyngeal cavity up to and including day 3 post GBS infection. However, on 
day 5, viable GBS bacterial titres were observed in the lung tissue of 50 % of those 
mice simultaneously infected with influenza and GBS (Figure 4.5 c). GBS cfu also  
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Figure 4.3 Epidemiological data suggests that secondary bacterial infections occur 
within a certain time frame after an initial influenza virus infection. (a) Human 
epidemiological data from the 1918 Spanish Flu pandemic highlighting the temporal 
relationship between influenza virus infection and a wave of secondary bacterial 
infections. (b) A representation of a typical murine influenza infection using weight loss to 
demonstrate three distinct phases of infection. 
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Figure 4.4 An illustration of a standard secondary bacterial infection protocol. 
BALB/c mice (n=4) are inoculated intranasally (i.n.) with 50 HAU HK/X31 influenza A 
virus. On a pre specified day after influenza infection mice are infected i.n. with 5 x 106 cfu
mid log phase Group B streptococcus (GBS), unless otherwise stated. Mice are followed 
over the course of the infection and harvested on days specified in the results. Designated 
tissues were removed and analysed subsequently. 
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Figure 4.5 Simultaneous infection of BALB/c mice with influenza and GBS alleviates 
viral induced weight loss but reduces bacterial clearance. BALB/c mice (n=4) were 
intranasally infected simultaneously with 50 HAU HK/X31 influenza A virus and 5 x 106 cfu
GBS or GBS and influenza on there own. Weight loss (a) was monitored daily and 
expressed as mean % of original body mass. On days post GBS infection lung tissue was 
removed and BAL and nasal wash was performed. Colony forming units (cfu) were 
calculated using serial dilutions of single cell suspensions of each tissue sample and 
plated on THB agar. GBS cfu titre recovered from airway (b), lung (c) and nasopharynx 
(d). Data are presented as the mean ± SEM of 4 mice per group. p<0.05 was taken to be 
significant. * = p<0.05  ** = p<0.01
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remained in the airway until day 7 and were significantly higher in the 
nasopharyngeal cavity of mice simultaneously infected with influenza and GBS  
(Figure 4.5 b & d). The level of GBS recovered from the nasopharynx was 
significantly greater than observed in the airway or lung at all time points analysed. 
There was no recorded difference in the outward appearance and clinical illness 
score of mice simultaneously infected with influenza and GBS compared to mice 
infected with GBS alone (data not shown).  
 
4.2.3 Mice infected with GBS 3 days after influenza virus infection contain 
heightened bacterial titres in all tissues analysed 
 
We have previously shown that infection of BALB/c mice with 5 x 106 cfu of GBS 
resulted in the clearance of bacteria in all tissues by day 5 post infection, with no 
associated weight loss. This is driven by a transient neutrophil and macrophage 
response which effectively primes an adaptive response capable of establishing 
immunological memory. We have also demonstrated that a simultaneous infection of 
influenza and GBS resulted in reduced influenza induced weight loss and a small, yet 
significant, delay in bacterial clearance from the airway and lung tissue. Therefore, 
we next investigated whether a previous influenza virus infection alters the 
susceptibility to a GBS infection. BALB/c mice were intranasally infected with 
influenza or vehicle control, as previously described, and subsequently infected with 
5 x 106 cfu of GBS 3 days later. Mice were harvested on days 1, 3, 5, 7 and 11 days 
post GBS infection. Mice infected with GBS after a primary influenza infection did not 
demonstrate additional weight loss compared to mice infected with influenza alone 
(Fig. 4.6 a). The absence of weight loss to GBS infection alone was again confirmed. 
Existing theories suggest the increased susceptibility to bacterial infections after a 
primary influenza infection can be attributed, in part, to a reduction in respiratory 
epithelial integrity. We previously demonstrated that mice infected with GBS alone 
had no detectable cfu in the airway or lung tissue after 3 days. In contrast, mice 
infected with GBS 3 days after an influenza virus infection demonstrated a significant 
increase in bacterial titre recovered from both the airway and lung, when compared 
to GBS infected alone mice, and a reduction in the rate of bacterial clearance (Figure 
4.6 b & c). The levels of GBS recovered from the nasopharynx were also elevated in 
mice infected with influenza virus 3 days prior to GBS infection (Figure 4.6 d). 
Interestingly, although bacterial titres were increased in mice previously infected with 
influenza virus, the administration of GBS 3 days after a primary influenza infection 
reduced viral load compared to mice infected with influenza virus alone (Figure 4.6 
e). 
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4.2.4 GBS infection during peak influenza illness results in additional weight 
loss and a significant increase in bacterial susceptibility 
 
After demonstrating that BALB/c mice have enhanced susceptibility to a GBS 
infection 3 days after infection with influenza virus, coinciding with peak viral load, we 
next investigated the effects on bacterial susceptibility during the peak illness phase 
of an influenza infection. As previously described, BALB/c mice were infected with 50 
HAU of influenza or vehicle control and subsequently infected with 5 x 106 cfu of GBS 
5 days later. The addition of GBS on day 5 of an influenza infection resulted in 
additional weight loss (Figure 4.7 a). The additive effect of a GBS infection on weight 
loss was accompanied by a substantial increase in GBS cfu recovered from the 
airway, lung tissue and nasopharynx (Figure 4.7 b-d). The bacterial titres recovered 
from all three compartments were 10 times greater than those recovered from the 
corresponding tissue at the same time post GBS infection when GBS was 
administered 3 after influenza infection. However, despite these significant 
differences bacteria were cleared from the airway and lung tissue by day 7 and had 
returned to levels observed in GBS alone infected mice in the nasopharynx (Figure 
4.7 b-d). Additionally, mice infected with GBS on day 5 of an influenza infection 
appeared more sedentary and hunched compared to mice infected with GBS alone 
(data not shown). 
 
4.2.5 Influenza induced susceptibility to respiratory GBS infection remains for 
several weeks  
 
After demonstrating that susceptibility to a respiratory GBS infection increases as an 
influenza illness proceeds, we next examined whether the enhanced susceptibility 
continues or abates on resolution of influenza illness. BALB/c mice were again 
infected with 50 HAU of influenza virus, or vehicle control, and allowed to recover for 
14, 28 or 42 days. All mice returned to day 0 weight by day 14-16 post infection and 
total airway and lung cellularity was equal to naive levels by day 28 post influenza 
infection (data not shown). All recovered mice were subsequently infected with 5 x 
106 cfu of GBS and harvested at specified time points post GBS to compare bacterial 
susceptibility. Mice infected with influenza and allowed to recover for 14 days 
demonstrated elevated GBS bacterial titres in both the airway and lung 3 days post 
GBS infection compared to vehicle (no influenza virus) control mice (Figure 4.8 a). 
There was no significant difference observed in the nasopharyngeal bacterial load. 
Mice allowed to recover from influenza infection for 28 days also showed enhanced 
susceptibility to GBS infection, with elevated GBS bacterial titres recovered from both 
the airway and lung compartments (Figure 4.8 b). Once more there was no difference 
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observed in the nasopharyngeal carriage rates between the two groups. Finally, mice 
infected with influenza virus 42 days (6 weeks) prior to infection with GBS also 
displayed enhanced GBS susceptibility (Figure 4.8 c).  
 
Before investigating possible mechanisms for how a primary influenza infection 
increased susceptibility to a subsequent bacterial infection, we investigated whether 
a primary GBS infection could alter subsequent influenza immunity and whether GBS 
can colonise the nasopharynx and upon subsequent influenza infection propagate 
and develop into an invasive bacterial infection. To examine this, we infected BALB/c 
mice with GBS and allowed them to resolve the infection for 28 days. Mice were 
subsequently infected with influenza virus, as previously described, and harvested at 
specified time points post influenza to investigate influenza immunity and GBS titre 
(Figure 4.9 a). No recoverable GBS cfu were detected in any tissue at the time of 
influenza infection (data not shown). A previous GBS infection did not affect total cell  
recruitment in response to influenza (Figure 4.9 b & c). However, despite the 
presence of a residual CD4+ T cell population in the airway of mice infected with GBS 
28 days previously (Figure 4.9 d), there was no significant difference in the proportion 
or total number of CD8+ or CD4+ T cells in response to influenza infection between 
the two groups (data not shown). No detectable GBS cfu were recovered from any 
tissue at all time points analysed post influenza infection (Figure 4.9 e). 
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Figure 4.6 BALB/c mice infected with GBS 3 days after influenza virus have a 
reduced ability to clear bacteria. BALB/c mice (n=4) were infected intranasally with 50 
HAU HK/X31 influenza A virus or PBS control. After three days, mice were challenged 
with either 5 x 106 cfu GBS i.n or PBS control. Weight loss (a) was monitored daily and 
expressed as a % of original body mass. On days post GBS infection lung tissue was 
removed and BAL and nasal wash was performed. Airway (b), lung (c) and nasopharynx 
(d) bacterial titres were calculated using serial dilutions of single cell suspensions of each 
tissue sample and plated on THB agar. Viral titre (e) was also analysed from snap frozen 
lung lobe. Data are presented as the mean ± SEM of 4 mice per group. p<0.05 was taken 
to be significant. * = p<0.05  ** = p<0.01
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Figure 4.7 GBS infection during peak influenza illness results in increased weight 
loss and bacterial burden. BALB/c mice (n=4) were infected intranasally with 50 HAU 
HK/X31 influenza A virus or PBS control. Five days after influenza infection mice were 
challenged with 5 x 106 cfu GBS or PBS control. Weight loss (a) was monitored daily and 
expressed as % of original body mass. On days post GBS infection lung tissue was 
removed and BAL and nasal wash was performed. CFUs were calculated using serial 
dilutions of single cell suspensions of each tissue sample and plated on THB agar. GBS 
cfu titre recovered from airway (b), lung (c) and nasopharynx (d). Data are presented as 
the mean ± SEM of 4 mice per group. p<0.05 was taken to be significant. * = p<0.05  ** = 
p<0.01
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Figure 4.8 Influenza virus infection has a long lasting effect on the lung’s ability to 
clear a GBS infection. BALB/c mice (n=4) were infected intranasally with 50 HAU 
HK/X31 influenza A virus or PBS control. 14 days (a), 28 days (b) or 42 days (c) after 
influenza infection all mice were challenged with 5 x 106 cfu GBS. On days specified, post 
GBS infection, BAL, lung and nasal wash was performed and collected. CFUs were 
calculated using serial dilutions of single cell suspensions of each tissue sample and 
plated on THB agar. Data are presented as the mean ± SEM of 4 mice per group. p<0.05 
was taken to be significant. * = p<0.05  ** = p<0.01
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4.2.6 Co-infection with influenza virus and GBS does not significantly increase 
airway cellularity but enhances total lung cell numbers 
 
We have demonstrated that susceptibility to a respiratory GBS infection begins as 
early as 3 days after the primary influenza infection and continues for at least 6 
weeks. To investigate possible mechanism(s) responsible for this phenomenon, we 
next examined differences in the innate cellular response to a GBS infection in mice 
previously infected with influenza virus in comparison to naive mice. By analysing the 
total cellular response at time points after GBS infection it was apparent that a GBS 
infection at the same time as, or up to 5 days after, an influenza infection resulted in 
an additive increase in the total number of cells present in the airway 12-24 hours 
post GBS infection (Figure 4.10 a, c & e). This increase was most evident at 24 
hours, in mice infected with GBS at the same time as or 5 days after influenza 
infection, and at 72 hours when mice were infected with GBS 3 days after the primary 
influenza infection. However, due to a large standard deviation, there was no 
statistically significant increase at any time point. However, at all time points 
analysed, mice co-infected with GBS and influenza consistently contained more total 
cells in the airway compared to mice infected with GBS alone. On comparison of total 
lung cellularity, there was a significant increase in total numbers 24 hours after GBS 
infection in mice simultaneously infected with influenza and GBS (control, 1.7 ± 0.4 x 
106; + influenza 4.6 ± 0.6 x 106; n=4; p 0.03) and on day 3 in mice infected with GBS 
3 days after the primary influenza infection (control; 5.4 ± 0.7  x 106; post influenza  
1.0 ± 0.3 x 107; n=4; p 0.02) (Figure 4.9 b & d). However, this significant increase in 
cellularity was not observed in mice infected with GBS on day 5 of an influenza 
infection compared to mice infected with influenza alone (Figure 4.10 f).  
 
In contrast, mice allowed to completely recover from the primary influenza infection 
for 28 and 42 days displayed a reduction in cellular recruitment to the airway in 
response to a GBS infection (Figure 4.11 a ). This was statistically significant in mice 
allowed to recover from influenza for 42 days. There is no statistical significance 
when comparing lung cellular recruitment between influenza recovered mice and 
PBS control mice (Figure 4.11 b). Table 4.0 summarises the outcome of a GBS 
respiratory infection when administered at varying times post influenza virus 
infection.   
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4.2.7 A previous influenza virus infection reduces the number of airway 
neutrophils present following a respiratory bacterial infection   
 
Investigating the total cellular infiltrate elicited in response to GBS only provides a 
small insight into the cellular responsiveness of naive and influenza infected/resolved 
mice. Further interrogation of the composition of the cellular response was needed to 
determine the potential effects influenza infection had on specific leukocyte subsets. 
We have previously demonstrated that neutrophils are rapidly recruited to both the 
airway and lung tissue during an influenza infection (Figure 4.1 d). Their precise 
function during an influenza infection remains open to debate, however the evidence 
for their role in anti-bacterial defence is much more compelling. There is abundant in 
vitro evidence highlighting synergistic effects of influenza virus and bacteria in 
detrimentally affecting both the function and viability of neutrophils 287;406. Therefore, 
we next examined the exact composition of the cellular response to GBS in naive 
mice and mice previously infected with influenza. Using FCM and differentially 
expressed surface antigens, the proportions of neutrophils, macrophages and their 
activation status were measured. Mice simultaneously infected with influenza and 
GBS showed similar proportions of neutrophils in the airway at all time points 
analysed as those mice infected with GBS alone (Figure 4.12 a).  
 
On calculating the actual numbers of neutrophils in the airway there appeared to be 
an increase in total numbers on day 1 post infection in mice simultaneously infected 
with influenza and GBS compared to mice infected with GBS alone, however this 
increase was statistically insignificant (Figure 4.12 b). There was an increase in the 
number of neutrophils in the lung tissue on day 1 in mice simultaneously infected with 
influenza and GBS compared to mice infected with GBS alone (p 0.025 data not 
shown). In contrast, mice infected with GBS on day 3 of an influenza infection 
displayed a reduction in the proportion and total numbers of neutrophils 1 day post 
GBS infection compared to mice infected with GBS alone (Figure 4.12 c & d). This 
reduction was also observed in the lung tissue of mice infected with GBS on day 3 of 
an influenza infection (Figure 4.13 a-c). Mice infected with GBS on day 5 of an 
influenza infection also showed a significant reduction in total neutrophil numbers 
and proportion in the lung tissue (data not shown). In mice allowed to recover from 
an influenza infection for 42 days, a similar reduction in total number and the 
proportion of airway neutrophils 24 hours post GBS infection was observed (Figure 
4.12 e & f). This trend was also seen in the lung tissue but was statistically 
insignificant (data not shown).  
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Figure 4.9 Influenza infection does not reactivate a previous GBS infection. BALB/c 
mice (n=4) were infected intranasally (i.n.) with 5 x 106 cfu GBS or PBS control. Mice were 
subsequently infected i.n. with  50 HAU HK/X31 influenza A virus 28 days later (a). On 
days specified, post influenza infection, airway cells (b) and lung cells (c) were removed 
and total viable cell counts were determined using Trypan Blue exclusion. Flow cytometry
was used to determine the total number of airway CD4+ T cells at the time of influenza 
infection (d). CFUs were also measured in the airway, lung and nasopharynx by using
serial dilutions of single cell suspensions and plated on THB agar (e). Data are presented 
as the mean ± SEM of 4 mice per group. p<0.05 was taken to be significant. * = p<0.05  ** 
= p<0.01
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Figure 4.10 Co-infection with influenza virus and GBS does not significantly 
increase airway cellularity but enhances lung total cell numbers. BALB/c mice (n=4) 
were infected intranasally with 50 HAU HK/X31 influenza A virus or PBS control. 5 x 106
cfu GBS was intranasally administered at the same time (a-b), 3 days after (c-d) or 5 days 
after (e-f) the primary influenza infection. On days specified, post GBS infection, BAL was 
performed and lung tissue was removed, homogenised and total viable cell counts were 
determined using Trypan Blue exclusion. Data are presented as the mean ± SEM of 4 
mice per group. p<0.05 was taken to be significant. * = p<0.05  ** = p<0.01 ns = no 
significance
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Figure 4.11 Infection with GBS after influenza resolution results in reduced cell 
recruitment to the airway. BALB/c mice (n=4) were infected intranasally  with 50 HAU 
HK/X31 influenza A virus or PBS control. 5 x 106 cfu GBS was administered 28 or 42 days 
after the primary influenza infection. On days specified, post GBS infection, airway cells 
(a) and lung cells (b) were removed and total viable cell counts were determined using 
Trypan Blue exclusion. Table 4.0 summarises the cfu and cellularity data from different 
secondary infection protocols Data are presented as the mean ± SEM of 4 mice per group. 
p<0.05 was taken to be significant. * = p<0.05  ** = p<0.01
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Figure 4.12 Influenza infection reduces airway neutrophil recruitment to a bacterial 
infection that remains for at least 6 weeks. BALB/c mice (n=4) were infected i.n with 50 
HA HK/X31 influenza A virus or PBS control. 5 x 106 cfu GBS was administered i.n. at day 
0 (a-b), 3 days (c-d) or 42 days (e-f) after influenza infection. Mice were harvested on 
specified days after GBS infection and BAL was performed to quantify total viable cells 
using Trypan blue exclusion. Total neutrophils were determined from the % of CD11b+
Ly6G+ MHC II low cells multiplied by the total airway viable cell count. Data are presented 
as the mean ± SEM of 4 mice per group and represent two separate experiments. p<0.05 
was taken to be significant. * = p<0.05  ** = p<0.01 *** = p<0.001
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Despite seeing a reduction in innate cellular responses in influenza recovered mice 
following a GBS infection, there was no comparable decrease in adaptive immunity. 
A comparison of the lymphocyte response to GBS in influenza resolved mice 
demonstrated a significant increase in percentage and total number of lymphocytes 
in the lung compared to vehicle infected controls. This was also reflected with 
increased levels and activity of CD4+ T cells and CD8+ T cells in terms of percentage 
and total number 3 days post GBS infection. This increase in lymphocyte numbers 
observed in influenza recovered mice was also seen in the airway (data not shown). 
 
4.2.8 TLR receptor expression is transiently altered in mice infected with 
influenza  
 
All cells that have the ability to migrate from one site of the body to another 
accomplish this by responding to chemotactic gradients setup by the release of 
cytokines and chemokines from cells at peripheral effector sites. However, the 
production of chemoattractant mediators is dependent upon the detection of the 
presence of an object or organism foreign to the host. Multiple cells at mucosal sites 
of the body express a wide variety of PRRs that are responsible for detecting the 
presence of invading pathogens through interactions with MAMPs. Two such PRRs, 
TLR 2 and MARCO have been suggested to play critical roles in bacterial detection 
and defence in numerous respiratory infection models 407;408. TLR 2 is responsible for 
the detection of peptidoglycans (PGN) and lipoteichoic acids (LTA) both of which are 
present in the cell wall of Gram positive bacteria such as GBS. However, their 
involvement in respiratory viral and secondary bacterial infection models has not 
been comprehensively elucidated. Therefore we next examined the total number of 
TLR2 and MARCO positive cells and their respective expression level in our 
secondary infection model. Analysis of myeloid cell subsets highlighted that although 
the proportion of TLR2+ CD11c+ macrophages was significantly reduced in the airway 
and lungs of mice infected with influenza virus 3 days prior to GBS, their total 
numbers were elevated (Figure 4.14 a+c). There was no significant difference in total 
numbers of lung TLR2+ CD11c+ macrophages at any time point analysed (Figure 
4.14 d). In contrast, the proportion and total number of TLR2+ CD11c– cells, 
comprising of both neutrophils and infiltrating exudate monocytes, was significantly 
greater in both the airway and lung tissue of mice infected with influenza virus 
compared to GBS alone infection (Figure 4.15 a-d). Analysis of TLR 2 expressed on 
the surface of myeloid subsets showed no alteration over the course of both 
influenza and GBS infection.   
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Figure 4.13 Influenza infection reduces neutrophil numbers and percentage in the 
lung in response to bacterial infection. BALB/c mice (n=4) were infected intranasally 
with 50 HAU HK/X31 influenza A virus or PBS control. Three days after influenza infection 
mice were challenged with 5 x 106 cfu GBS or PBS control. Mice were subsequently 
harvested on days 1, 3, 5, 7 and 11 days post GBS infection. Lung tissue was removed, 
homogenised and total viable cell counts were determined using Trypan Blue exclusion. 
Percentage (a) and total number (b) of lung neutrophils were discriminated as CD11b+
Ly6G+ MHCIIlo. (c) represents relative lung neutrophil percentages in all groups on day 1 
and day 3 post GBS infection. Data are presented as the mean ± SEM of 4 mice per 
group. p<0.05 was taken to be significant. * = p<0.05  ** = p<0.01
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Influenza virus infection also altered the proportion and total numbers of MARCO+ 
cells in both the airway and lung and was greatest in mice infected with GBS 3 days 
after infection with influenza virus (Figure 4.16 & 4.17). The geometric mean of 
intensity MARCO expression on airway CD11c+ macrophages also did not alter 
significantly over the course of infection, but peaked in the lung tissue on day 8 post 
influenza infection (peak illness) (Figure 4.16 d).   
 
4.2.9 Mice infected with GBS on day 3 of an influenza infection elicit a normal 
chemokine response but have heightened airway apoptosis 
 
The reduction in neutrophils in mice infected with GBS following influenza virus could 
be the result of:  
 
1. A reduced ability of neutrophils to migrate to the airway and lungs from the 
peripheral blood or the bone marrow. This could be due to a reduction in 
neutrophil chemotactic factors, such as KC or MIP-2α, or a reduced ability of 
neutrophils to extravasate from peripheral blood and into the lung tissue and 
subsequently the air spaces. 
2. The apoptosis or necrosis of neutrophils recruited as a result of the primary 
influenza infection, therefore reducing the apparent proportions and total numbers 
of neutrophils in response to a secondary bacterial infection.  
 
To investigate these two possible scenarios we measured the levels of neutrophil 
chemotactic factors and the proportions of apoptotic cells in the airway and lungs of 
mice infected with GBS alone and on day 3 of an ongoing influenza infection. There 
was no significant differences in the level of lung (data not shown) or airway KC and 
MIP-2α between the two groups (Figure 4.18 a & b). However, a greater proportion 
and total number of CD11b+ F480– TUNEL+ (neutrophils) apoptotic cells was 
observed in the co-infected group compared to GBS alone. Thus the fewer 
neutrophils observed may be due to enhanced cell death (Figure 4.18 c &d).  
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Figure 4.14 Influenza virus alters the proportion of TLR 2+ myeloid cells. BALB/c 
mice (n=4) were infected intranasally with 50 HAU HK/X31 influenza A virus or PBS 
control. Three days after influenza infection mice were challenged with 5 x 106 cfu GBS or 
PBS control. Mice were subsequently harvested on specified days post bacterial infection. 
BAL was performed and lung tissue was removed, homogenised and total viable cell 
counts enumerated. Differential antibody staining was used to derive the proportions of 
airway (a & c) and  lung (b & d) CD11c+ TLR2+ cells. Data are presented as the mean ±
SEM of 4 mice per group. p<0.05 was taken to be significant. * = p<0.05  ** = p<0.01
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Figure 4.15 Influenza increases the number of CD11c– TLR2+ cells in both the lung 
and airway. BALB/c mice (n=4) were infected intranasally (i.n.) with 50HA HK/X31 
influenza A virus or PBS control. Three days after influenza infection mice were 
challenged with 5 x 106 cfu GBS i.n or PBS control. Mice were subsequently harvested on 
specified days post GBS infection. BAL was performed and lung tissue was removed, 
homogenised and total viable cell counts were determined using Trypan Blue exclusion. A 
differential stain was used to derive the total numbers of airway (a & c) and lung (b & d) 
CD11c– TLR2+ cells. Data are presented as the mean ± SEM of 4 mice per group. p<0.05 
was taken to be significant. * = p<0.05  ** = p<0.01
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Figure 4.16 Influenza increases the total number of MARCO expressing macrophage 
in the airway and lung compartments. BALB/c mice (n=4) were infected intranasally 
with 50 HAU HK/X31 influenza A virus or PBS control. Three days after influenza infection 
mice were challenged with 5 x 106 cfu GBS or PBS control. Mice were subsequently 
harvested on specified days post bacterial infection. BAL was performed and lung was 
removed, homogenised and analysed using flow cytometry (FCM). Myeloid cell types 
were discriminated using forward and side scatter. Total number of airway (a) and lung (b) 
cells expressing CD11c+ MARCO+ were enumerated. The geometric mean of MARCO 
expression on airway (c) and lung (d) cells was also determined. Data are presented as 
the mean ± SEM of 4 mice per group. p<0.05 was taken to be significant. * = p<0.05  ** = 
p<0.01
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Figure 4.17 Influenza increases the proportion of lung macrophage expressing 
MARCO. BALB/c mice (n=4) were infected intranasally with 50 HAU HK/X31 influenza A 
virus or PBS control. Three days after influenza infection mice were challenged with 5 x 
106 cfu GBS or PBS control. Mice were subsequently harvested on specified days post 
GBS infection. Lung was removed, homogenised and analysed using flow cytometry. 
Myeloid cell subtypes were discriminated using forward and side scatter. A comparison of 
the proportion of lung myeloid cells positive for MARCO and CD11c between the different 
infection states are represented in (a). Representative plots for naïve and negative stained 
samples are also shown. 
a
Day 1 Day 3 Day 5 Day 7 Day 11
F
lu
+
 G
B
S
F
lu
 a
lo
n
e
G
B
S
 a
lo
n
e
Time (d) post infection
MARCO
C
D
1
1
c
Naive CD11c+ MARCO– CD11c+ MARCO+
0.2% 2.4% 9.1% 2.8% 1.6%
0.2% 1.6% 5.7% 6.9% 0.3%
0.2% 0.1% 0.1% 0.1% 0.02%
0.1%
Lung macrophages
 CHAPTER 4: VIRUS INDUCED SECONDARY BACTERIAL PNEUMONIAS 
120 
4.2.10 The long term effect on airway cellular recruitment observed in mice 
previously infected with influenza is not GBS specific 
 
We next examined how specific, in terms of bacterial species and TLR ligands, the 
detrimental effect of influenza viral infection had on the host‟s anti bacterial defence. 
Utilising mice that had been allowed to recover from an influenza infection for 42 
days (6 weeks) and vehicle matched controls; we challenged mice with the Gram 
positive bacterium Streptococcus pneumoniae and the Gram negative bacterium 
Pseudomonas aeruginosa. As before a previous influenza virus infection significantly 
increased S. pneumoniae and P. aeruginosa titres 4 and 24 hours post infection 
(Figure 4.19 a & b). These results coincided with a significant reduction in recruited 
airway neutrophils (Figure 4.19 a & b). To investigate whether this decrease in 
neutrophil numbers was a consequence of bacterial virulence factors, we next 
intranasally challenged mice, previously infected with influenza virus or vehicle 
control 42 days previously, with a selection of purified recombinant bacterial toll 
receptor ligands. Again reduced neutrophils were observed (Figure 4.19 c). 
 
4.2.11 The influenza induced defect in neutrophil recruitment is associated with 
impaired TLR induced cytokine production 
 
Results so far suggest a reduction in neutrophils may reflect a reduction in 
chemotactic signals. Indeed this was the case 42 days post influenza infection when 
mice were challenged with bacterial TLR ligand flagellin (FliC) neutrophils were 
reduced (Figure 4.20 a). This did not reflect a reduction in the ability of neutrophils to 
migrate since intranasal administration of KC (CXCL1) and MIP-2α (CXCL2) resulted 
in equivalent numbers of neutrophils being recruited to the airway and lung tissue of 
mice previously infected with influenza compared to vehicle controls (Figure 4.20 a). 
In addition, both KC and MIP-2α protein levels were reduced in the airway and lung 
tissue of mice previously infected with influenza compared to vehicle controls (Figure 
4.20 b). KC and MIP-2α mRNA transcripts were also reduced in mice previously 
infected with influenza (Figure 21 a). Thus, chemotactic signals are reduced in the 
influenza experienced lungs possibly via a desensitisation to TLR signalling.  
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Figure 4.18 Influenza infection 3 days prior to GBS infection does not alter 
neutrophil chemoattractant levels but enhances apoptosis. BALB/c mice (n=4) were 
infected intranasally with 50HAU HK/X31 influenza A virus or PBS control. Three days 
after influenza infection mice were challenged with 5 x 106 cfu GBS or PBS control. Mice 
were subsequently harvested on specified days post GBS infection. BAL was performed 
and subsequently purified using centrifugation and analysed for levels of murine KC (a) 
and MIP-2α (b) using ELISA. Airway cells recovered 24 hours after GBS infection were 
assayed for apoptosis using TUNEL staining (c-d). Data are presented as the mean ±
SEM of 4 mice per group. p<0.05 was taken to be significant. * = p<0.05  ** = p<0.01
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Figure 4.19 Influenza induced defect in airway neutrophil recruitment is not GBS 
specific. BALB/c mice (n=4) were infected intranasally (i.n.) with 50HAU HK/X31 
influenza A virus or PBS control. 42 days after influenza infection mice were challenged 
i.n. with 1 x 104 cfu S. pneumoniae (a),  5 x 106 cfu P. aeruginosa PAK strain (b), 1μg LPS 
(c), 25μg LTA (c) or 1μg flagellin FliC (c). The total number of neutrophils in the airways at 
specified time points after stimulation was determined by flow cytometric analysis. 
Bacterial cfus were determined by serial dilution of BALF in PBS and plated on non 
selective agar. Data are presented ± SEM as the combination of 2 separate experiments. 
p<0.05 was taken to be significant. * = p<0.05  ** = p<0.01
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Figure 4.20 Defective neutrophil recruitment in post influenza infected mice is 
associated with impaired TLR mediated cytokine production. Airway and lung 
neutrophil recruitment in BALB/c mice intranasally (i.n.) infected with 50HAU HK/X31 
influenza or PBS 42 days previously were compared 6 hours after i.n administration of 
1μg flagellin FliC, or co-instillation of 1μg of recombinant KC and MIP-2α (a). MIP-2α and 
KC levels were measured in the BAL fluid and lung homogenates of post influenza or 
control mice 6 and 24 hrs post FliC administration (b). Data are presented as the mean ±
SEM of 4 mice per group. p<0.05 was taken to be significant. * = p<0.05  ** = p<0.01
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4.2.12 Translocation of NF-κβ subunits by TLR stimulation is inhibited in 
alveolar macrophage isolated from influenza resolved mice 
 
Both alveolar macrophages and non-haematopoietic resident cells, such as type 1 
and type 2 epithelial cells are instrumental in inducing TLR dependant signals early 
during infection. Mice were infected with influenza or vehicle control and allowed to 
recover for 42 days. FliC was then intranasally administered and alveolar 
macrophage collected and analysed. Alveolar macrophages isolated from influenza 
recovered mice 1 hour after intranasal FliC challenge displayed reduced levels of KC, 
MIP-2α and TNF-α mRNA transcripts (Figure 4.21 a); a reduction consistent across 
varying doses of FliC (Figure 4.21 b). Importantly we also observed a reduction in 
p65, a sub unit of NF-κβ, translocation to the nucleus after FliC stimulation (Figure 
4.21 c). This reduction in NF-κβ signalling activation was also observed in isolated 
epithelium cells from influenza exposed mice (data not shown). However, we could 
only purify them to 65 %. They were difficult to isolate and the difference was only 2-
4 fold, therefore we cannot say with certainty that TLR responsiveness by these cells 
was also affected.  
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Figure 4.21 Alveolar macrophage NF-κβ signal transduction is altered after 
influenza infection. BALB/c mice (n=5) intranasally (i.n.) infected with 50 HAU HK/X31 
influenza or PBS 42 days previous were challenged i.n. with 1μg FliC. Alveolar 
macrophage (AM) were purified after 1 h and RNA transcript level was measure by real 
time PCR. Results are expressed as a ratio between the gene of interest and 18s rRNA
(a). AM were also stimulated overnight with Flic and LPS and resulting supernatant KC 
and MIP-2α levels were measured (b). Results are expressed as fold increase compared 
with stimulation with medium alone (n = 10). AM isolated from control and post-influenza 
mice were stimulated with 1 μg/ml FliC and stained for p65 (green). A nuclear stain is 
shown in red (c). Data are presented as the mean ± SEM of 4 mice per group. p<0.05 was 
taken to be significant. * = p<0.05  ** = p<0.01
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4.3 Discussion 
4.3.1 The timing of a secondary bacterial infection is critical in determining 
illness outcome  
 
Susceptibility to a secondary GBS infection begins as early as 3 days after the 
primary influenza infection and continues for at least 6 weeks. We show that maximal 
susceptibility, measured by bacterial outgrowth and outward signs of disease occur 
during peak illness and early resolution phase of an influenza infection. We also 
demonstrate that the mechanisms leading to secondary bacterial infection are 
dependent on the time at which GBS infection occurs after the primary influenza 
infection. Existing in vivo mouse models, investigating the mechanisms involved in 
influenza induced secondary bacterial infections, also demonstrate peak 
susceptibility to bacterial infection between 7 and 14 days post influenza infection 
279;409-411. Furthermore, epidemiological and clinical evidence also suggests that 
susceptibility to secondary bacterial infection is greatest 5-10 days post the onset of 
influenza symptoms 375;412. Assuming an incubation period of 2-4 days this would 
equate to the same period of susceptibility determined in our secondary infection 
model.  
 
As described earlier in this thesis, the majority of existing concepts surrounding 
mechanisms of virus induced bacterial susceptibility centre around respiratory 
epithelial damage, effector cell dysfunction and enhanced bacterial adhesion. 
Previous studies highlight enhanced bacterial titre and mortality in secondary 
infection models in which bacteria are administered during peak viral illness 413;414. 
Heightened bacterial adherence and invasion at sites of viral induced cell death is 
also observed in human specimens obtained from post mortems 290;415;416. We 
however demonstrate that susceptibility to bacterial infection remains long after the 
virus has been cleared and is associated with a reduction in airway cell recruitment, 
in particular neutrophils. Pulmonary epithelial damage from primary influenza 
infection peaks around day 5, and is restored by day 12-14 post influenza, however 
this is likely to be determined by viral strain, viral replication propensity and amplitude 
of host cellular response. Susceptibility to secondary bacterial infection does 
therefore not entirely depend on epithelial damage. The extent to which each of 
these mechanism influences susceptibility is likely to be dependent upon the precise 
phase of influenza infection at which the bacteria gain access to the airways. For 
example, the ability of influenza virus associated neuraminidase to expose putative 
bacterial binding sites most likely contributes to bacterial infection susceptibility 
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during peak viral load 25. We show that the greatest susceptibility to GBS occurs from 
5-14 days post influenza infection suggesting epithelial damage, immune 
suppression and/or alternative unknown mechanisms are responsible. Recent 
evidence highlights tumour necrosis factor-related apoptosis inducing ligand (TRAIL), 
produced by airway infiltrating exudates monocytes, as a key mechanism involved in 
epithelial leakage that is maximal on day 7 of a murine influenza infection. However, 
this evidence was obtained using the A/PR/8 strain of influenza and was less evident 
when A/HK/X31 was used 417. Alternative experimental models utilising ozone and 
bleomycin, also highlight the importance of epithelial integrity in protecting against 
opportunistic respiratory bacterial pathogens 418-420. Nevertheless, the loss of 
respiratory epithelium integrity is less likely to explain the log increase in airway and 
nasopharynx GBS titres at the longer time points after an influenza infection.  
 
A long term increase in susceptibility to subsequent bacterial infections is also 
observed with meningococcal bacteria several weeks after the resolution of an 
influenza virus infection 421;422. Some infections improve host immunity to a second 
unrelated pathogen through cross reactive T cell and antibody epitopes whilst others 
attenuate excessive inflammation and pathology 423-426. For example RSV or 
Cryptococcus neoformans infection is attenuated in mice previously infected with 
influenza virus, the effect is independent of cross-reactive adaptive immunity and 
occurs up to 6 months after influenza infection 299. These data taken together with a 
large amount of evidence from invertebrate infection models allude to long term 
modifications in innate immune pathways 427;428. 
 
Alternative explanations for increased bacterial susceptibility include modifications to 
the overall structure of the lung, such as collagen and fibronectin deposition, which 
may provide additional binding sites for bacteria 429. Airway remodelling, common in 
chronic conditions such as asthma or fibrosis, also occurs after acute viral infection. 
These effects are mediated in part by matrix metalloproteinases (MMPs), induced by 
infection or injury, that are important mediators of resolution of infection. Indeed, they 
play a dual role by participating in repair mechanisms, for example by activating 
TGF-β but also by modulating inflammatory responses 430;431. For instance, matrilysin 
(MMP7) is necessary for the regeneration of the airway epithelium after mucosal 
injury but also directly activates defensins and modulates the chemokine gradient 
and neutrophil transmigration. Whether MMP expression is sustained after resolution 
of one infection in order to modulate successive infections remains to be elucidated 
432-434. Respiratory infection can also induce lymphatic vessel hyperplasia 435. 
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Mycoplasma pulmonis infection induces robust lymphangiogenesis driven by 
vascular endothelial growth factor (VEGF) produced by infiltrating inflammatory cells. 
After inflammation resolution, the network of newly synthesized lymphatic vessels 
persists in the airways for several weeks. Therefore an alteration in the lymphatic 
network could alter subsequent immunity to infection as this provides conduits for 
enhanced drainage and migration of activated APCs to the draining lymph nodes. 
Further studies are needed to look at the role of angiogenesis and 
lymphangiogenesis in sequential infection models. Furthermore, the maintenance of 
minor populations of CD8+ T cells, CD11c+ cells and isolated lymphoid aggregates 
(iBALT) in the influenza resolved lung could also contribute to altered immunity to 
subsequent infections 436;437.  
 
Finally, we also observed that mice infected with GBS simultaneously or 3 days after 
influenza infection showed accelerated weight recovery and a reduction in influenza 
viral load, respectively. This is an intriguing result that is difficult to explain but 
warrants a brief discussion. Our data is contrary to existing in vitro and in vivo  
evidence that postulate the presence of bacterial proteases, produced by bacteria 
such as GBS, increase the cleavage of influenza HA0 to HA1 resulting in increased 
viral infectivity and load 279;438;439. It is likely that increased levels of IFN-γ producing 
NK and NK T cells observed in co-infected mice account for the improved viral 
clearance in our study. Anti viral properties of NK cells in influenza virus clearance is 
well documented and essential for viral eradication 440-442. Further investigation in 
alternative antiviral mechanisms, such as IFN responses, is needed to shed more 
light on this affect.   
 
4.3.2 Desensitization to TLR mediated signals represents a novel long term 
modification to innate immune responsiveness  
 
In this study we show that a previous influenza virus infection reduces neutrophil 
numbers and enhances bacterial titer. The reduction in neutrophil numbers results 
from two mechanisms depending on what stage of influenza illness bacteria gain 
access to the lungs. Apoptosis accounts for the early reduction whereas a 
recruitment problem dominates later 287. A similar defect in neutrophil recruitment 
occurs in response to S. pneumoniae and P. aeruginosa infection following influenza 
infection. Previous studies have implicated altered chemotaxis of neutrophils in mice 
previously infected with influenza 443;444. Furthermore, IFN-γ produced in response to 
many viral infections can result in increased apoptosis of neutrophils in the bone 
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marrow and could therefore result in reduced neutrophil numbers at the site of 
infection 445.  
 
In spite of these suggestions, the long term decrease in neutrophil transmigration 
requires a different mechanism as influenza virus is no longer present in the host. 
Long term functional alteration in neutrophils was ruled out by showing unimpaired 
neutrophil airway recruitment in influenza recovered mice after intranasal 
administration of the neutrophil chemoattractants, KC (CXCL1) and MIP-2α (CXCL2). 
Furthermore, neutrophil recruitment is reduced in response to purified TLR agonists 
in influenza resolved lung. Therefore, it appears that the cells that produce neutrophil 
chemoattractants are impaired and indeed isolated cells stimulated ex vivo also 
produce less neutrophil chemoattractants. However, removal and analysis of cells ex 
vivo does not indicate whether transcriptional regulation occurs independently in this 
cell type or as a result of co-operation with others. Cross talk between alveolar 
macrophage and alveolar epithelial cells (AECs) has been shown to occur in vivo 446. 
By isolating these populations from naïve and influenza recovered mice we show in 
vitro that nuclear translocation of the p65 subunit of NF-kB in response to flagellin is 
inhibited in alveolar macrophage isolated from mice previously infected with 
influenza, which is associated with a defect in cytokine production. We therefore 
propose a model whereby sustained reduction of NF-kB activation in alveolar 
macrophage after the initial viral infection leads to reduced inflammatory response 
and neutrophil recruitment. Though we have examined macrophages we cannot 
exclude an indirect role for other cell populations such as DCs, exudate monocytes 
and tissue (interstitial) macrophages. It remains to be determined whether alveolar 
macrophages are directly affected by infection, or their phenotype altered by 
interaction with recruited inflammatory cells.  
 
Furthermore, whether the pool of lung macrophages that give rise to alveolar 
macrophages is also affected by previous infection warrants further investigation 447. 
The molecular mechanisms responsible for prolonged TLR desensitization remain to 
be resolved. Because many of these receptors share components of their signalling 
pathways, changes in the expression level or phosphorylation status of molecules 
within these pathways may also interfere with the recognition of subsequent 
pathogens. TLR signalling is inhibited by several negative regulators downstream of 
the receptor 448. For example, increased expression of IL-1 receptor associated 
kinase M (IRAK-M) correlates with the unresponsiveness of alveolar macrophages to 
LPS in a mouse model of abdominal sepsis 449. Intestinal commensals also inhibit 
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TLR responses by directly interfering with the signalling pathways in epithelial cells 
450;451. Lung epithelial cells do, however, up-regulate TLRs, in particular TLR3 and 
TLR2, upon respiratory syncitial virus (RSV) and influenza infection, which may be 
mediated by the release of IFN by infected macrophages, whether such up-regulation 
has an impact on secondary infection is unclear 387;452. We do show an increase in 
the number of TLR 2+ myeloid cells in the airway and lungs of influenza infected 
mice. Clearly, a previous infectious event could impact significantly on 
responsiveness to the next, depending on how long the first influence lasts and 
whether the subsequent pathogen triggers similar signalling pathways.  
 
The pertinent question is why would the lung leave itself vulnerable to a secondary 
bacterial infection in this manner? In certain compartments, such as the lung, 
inflammatory cascades need to be regulated in order to prevent bystander tissue 
damage, which itself can be life threatening to the host. The lung contains a heavy 
microbial load in the upper respiratory tract and certain species in the lower 
respiratory tract (see Chapter 6) but is devoid of any significant resident organized 
lymphoid tissue. Pathogens bypassing passive anti-microbial strategies can cause 
significant indirect pathology in the lungs due to the recruitment of excessive 
numbers of immune cells that occlude the airspaces. An alteration in TLR 
responsiveness therefore is beneficial for those infections associated with excessive 
immunity but at the expense of other pathogens such as bacteria. This phenomenon, 
though detrimental in a sub-population of co-infected individuals, is likely to represent 
an evolutionary advantage for the respiratory tract and shares interesting similarities 
with immunosuppressive mechanisms operating at other mucosal sites.  
 
 
4.4 Conclusion  
 
Many mechanisms can explain why the host responds differently to heterologous 
pathogens, from a simple breach of the mucosal barrier to subtle alterations in 
immune modulatory mechanisms. However, evidence produced herein reveals that a 
crucial pathway of innate immunity does not return to a pre-infection state therefore 
providing a novel mechanism which may contribute to increased susceptibility to 
bacterial infection observed after respiratory viral infection. The challenge in this field 
is to investigate the cellular and molecular mechanisms at mucosal sites, where the 
education of the immune system is crucial for efficient protection against pathogens. 
In particular, identifying the molecules involved in increasing susceptibility or 
protection against subsequent infection may have a significant impact on therapeutic 
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strategies to tackle infectious diseases. To summarise our findings Figure 4.22 
highlights how the mechanism(s) responsible for enhancing susceptibility to 
secondary bacterial infection alters depending on the phase of influenza infection the 
bacteria gain access to the distal airways.  
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Figure 4.22 Model of secondary bacterial infection at different stages after influenza 
infection. In homeostasis, bacteria are cleared from the airway by alveolar macrophages, 
recruited neutrophils and AMPs. Epithelium integrity is intact and prevents bacterial invasion 
and dissemination (a). During influenza infection (day 5-8 post infection), epithelial damage, 
exposure of bacterial binding sites and apoptosis of infiltrating neutrophils facilitates bacteria 
tissue invasion and subsequent dissemination (b). After resolution of influenza infection, 
alveolar macrophages and epithelial responsiveness is attenuated, resulting in impaired 
neutrophil recruitment and consequently decreased antibacterial capacity. In addition the 
presence of IL-10 and TGF-β produced during inflammation resolution maintains an anti-
inflammatory environment.  
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 Chapter 5 
 
 
5.0 Innate immune homeostasis and inhibitory myeloid receptors 
 
5.1 Introduction 
In the previous chapter, we developed a robust in vivo secondary bacterial infection 
model that highlighted the temporal relationship between influenza infection and 
secondary bacterial pneumonias. Furthermore, we described a novel viral mediated 
immune suppression mechanism in which alveolar macrophages become hypo-
responsive to bacterial Toll ligands and consequently less capable of initiating 
subsequent immune responses. This evidence demonstrates that a self limiting acute 
inflammatory insult can alter tissue-specific immune responsiveness over a 
prolonged period of time, suggesting that infection history can influence the way in 
which a specific tissue responds to subsequent immune stimulation. 
 
The lung, similar to the intestinal tract, must maintain a high threshold of ignorance to 
innocuous antigen to avoid unwarranted inflammation and bystander tissue damage 
169;453-455. This high level of immune regulation depends upon the delicate balance 
between positive inflammatory signals, such as Toll-like receptors, and regulatory 
repressor pathways. An example of this is the restraint of alveolar macrophages by 
epithelial v6 integrin tethered TGF- 
456;457. Progression of an inflammatory 
response requires down regulation of the v6 integrin, which is initiated by exposure 
to Toll-like receptor ligands 456. Equally important, especially within mucosal sites, is 
resolution of the immune response, without which excessive tissue damage can 
occur. The mechanisms mediating resolution are likely to be similar to those that 
maintain homeostasis. TGF- mediated suppression of alveolar macrophages, for 
example, is restored by cleavage of latent TGF- by matrix metalloproteinase (MMP)-
9 produced by activated alveolar macrophages 456. Recent work within the laboratory 
has uncovered a novel regulatory mechanism that suppresses alveolar macrophages 
activity in homeostasis and during resolution of acute inflammation 458. Further details 
of this mechanism and other integral regulatory pathways are described below. 
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5.1.1 Paired activating and inhibitory myeloid receptors  
 
Lung and airway resident myeloid cells are not only critical effector cells involved in 
protecting the host from invading pathogens, but also play an integral part in 
governing the initiation, maintenance and resolution of inflammation. The 
development of an efficient and robust immune response is critical to the successful 
resolution of infection; however, a degree of control and tolerance is needed to 
prevent bystander tissue damage and to distinguish self from non-self 107;459. This 
control is achieved through receptor ligation of soluble mediators as well as cognate 
cell-cell interactions 108;460-462. The role of such signals in dictating immunity and 
tolerance at the level of the T cell are well characterised, but comparatively little is 
known regarding the interactions that govern cells of the myeloid lineage, despite 
their central role in immunity and immunopathology 463-465.  
 
Myeloid cells are an extremely heterogeneous population and can be individually 
defined by their complex combinations of surface receptors that determine specific 
phenotype and function 108. These receptors include pattern recognition receptors 
(PRR), cytokine, complement and Fc receptors, which facilitate pathogen clearance 
and phagocytosis, accessory molecules that promote T cell activation and those that 
dictate the migration of cells from the circulation and into tissues. An important family 
of receptors that dictate myeloid cell function are paired activating and inhibitory 
receptors. These include paired immunoglobulin-like receptors (PIRs), signal 
regulatory proteins (SIRPs), triggering receptors expressed by myeloid cells (TREMs) 
and the CD200 receptor family 107;108;110;111;466;467. There remains a large gap in our 
knowledge of these receptors and in many cases the physiological ligand remains 
unknown. However, the CD200 (OX 2)-CD200R (OX2-receptor) interaction has 
recently gained considerable interest in infectious disease models with a growing 
appreciation of its inhibitory effects on the myeloid immune compartment. 
Furthermore, continued research into this myeloid inhibitory interaction has 
highlighted clear immunotherapeutic potential in the treatment of tumours and in 
alleviation of autoimmunity, allergy and immunopathology 111;128;142;144;145. However, 
much of the existing knowledge is contradictory and the role they play in human 
disease remains to be revealed.   
 
5.1.2 CD200-CD200R and their role in respiratory tract homeostasis  
 
CD200 is a type 1 transmembrane glycoprotein with two immunoglobulin superfamily 
(IgSF) domains 114;468. The expression of CD200 is varied, being detected in 
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thymocytes, recirculating B cells, some peripheral T cells, follicular dendritic cells, 
neurons in the central nervous system, endothelium, trophoblasts and smooth 
muscle 114;118;119;121;128. This unusual and specific distribution was found to be highly 
conserved in mice and humans 118;131;469. This conserved expression of CD200 on 
specific cellular populations suggests a significant biological role for this molecule. 
Conversely the expression of CD200 receptor (CD200R) is limited to myeloid cells, 
including macrophages, dendritic cells, neutrophils, basophils and mast cells 110;123-
125;144 although expression on peripheral CD4+ T cells in mice and humans and high 
levels of CD200R mRNA expression in Th2 polarised T cells has been described in 
one study 123.  
 
Further investigation into the structure of CD200R demonstrated high homology to its 
ligand CD200, but in addition, the existence of a cytoplasmic tail with signalling 
capacity 110;122;123. The generation of CD200 and CD200R KO mice by Sedgwick et al 
illustrated that the vast majority of the altered phenotypic traits present in these mice 
were focused in the leukocyte compartments, for example the enlarged spleens 
present in CD200 KO mice contain twice the number of CD11b+ myeloid cells and 
have elevated numbers of macrophages and granulocytes 128. Marginal zone 
macrophages and dendritic cells within T cell areas of the white pulp express higher 
levels of the ITAM containing DAP12 molecule, implying heightened cellular 
activation. Distinct phenotypes are also observed in peripheral lymph nodes. The fact 
that the phenotype is observed in those cells that express the CD200R rather than 
those that express CD200 led Hoek et al to postulate that the CD200 KO phenotype 
was a consequence of a loss in an inhibitory signal to the myeloid cells 128. Additional 
studies added strength to this hypothesis by illustrating that CD200 ligation of 
CD200R imparts a uni-directional negative signal to cells that express CD200R 
110;114;125;132;144. The absence of an effect on CD200-expressing cells is likely due to 
the lack of intracellular signalling motifs or docking domains on the short cytoplasmic 
tail of CD200 115;116. All cells expressing CD200 ligand can therefore potentially 
negatively regulate innate myeloid responses. Subsequently, CD200 knock out mice 
have been demonstrated to exhibit a more severe or accelerated disease phenotype 
in a variety of conditions where macrophage function are critical elements of the 
disease process, such as experimental autoimmune encephalitis (EAE) and collagen 
induced arthritis (CIA) 128. However, much of the evidence concerning the role of 
CD200 in immune regulation are observational and there is little in the literature to 
divulge the mechanisms by which CD200 exerts a suppressive signal to the myeloid 
compartment. A recent study demonstrates the potential of signalling through 
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CD200-CD200R to suppress cytokine production in CD200R transfected U937 cells, 
and the potency of this suppression correlates with density of CD200R expression 
470. Furthermore, the same study demonstrates CD200R ligation suppresses IFN-γ 
and IL-17 induced secretion of IL-6 by peritoneal macrophages. Similarly, 
engagement of CD200R in murine bone marrow derived mast cells over-expressing 
the receptor reduces degranulation and secretion of IL-13 and TNF 144. Similar 
findings were subsequently confirmed in human mast cells. Finally, some evidence 
supports a role for CD200R ligation in up-regulating indoleamine 2,3-dioxygenase 
(IDO) in plasmacytoid dendritic cells resulting in heightened tryptophan catabolism 
and tolerance 146.  
 
5.1.3 Hypothesis and Aims 
 
In this chapter, we investigate the impact of manipulating the CD200-CD200R axis 
during influenza virus infection and its impact on susceptibility to secondary bacterial 
pneumonias. We postulate that in some circumstances, an attempt to restore the 
lung to homeostasis after an acute inflammatory insult leads to a period of immune 
over regulation that results in immune hypo-responsiveness and hence susceptibility 
to bacterial infection. To address this we will: 
 
1. Demonstrate that a previous influenza virus infection increases susceptibility 
of C57BL/6 mice to S. pneumoniae infection. 
2. Determine the expression and role of CD200R in lung immunity during 
homeostasis and in response to single influenza and S. pneumoniae 
infection. 
3. Investigate the role of CD200R in a secondary bacterial infection model. 
 
5.2 Results 
5.2.1 Influenza significantly increases S. pneumoniae susceptibility and results 
in lethal bacteraemia 
 
Before investigating whether the CD200R-CD200 axis plays a role in susceptibility to 
bacterial infections following influenza virus infection, we first needed to examine a S. 
pneumoniae infection in C57BL/6 mice as the CD200 and CD200R KO mice are bred 
onto this mouse background. Utilising both the non lethal intranasal dose of S. 
pneumoniae, determined in section 3.2.8 and the secondary bacterial infection 
protocol developed in Chapter 4, we examined the effects of a preceding influenza 
virus infection on S. pneumoniae clearance in wild type C57BL/6 mice. As with 
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BALB/c mice, intranasal infection with 1 x 104 cfu S. pneumoniae does not result in 
significant weight loss in C57BL/6 mice compared to vehicle infected control mice. 
However, C57BL/6 mice infected with 1 x 104 cfu S. pneumoniae three days after an 
influenza virus infection demonstrated enhanced weight loss compared to mice 
infected with influenza alone (Figure 5.1 a). In addition to the observed weight loss, 
mice infected with both influenza and S. pneumoniae appeared less mobile, hunched 
and developed hypothermic shock 48-72 hours post S. pneumoniae infection. This 
was not observed in mice infected with S. pneumoniae alone (data not shown). 
These clinical manifestations were highlighted by a significant increase in mortality 
observed in mice infected with S. pneumonia and influenza virus compared to those 
infected with S. pneumoniae alone (Figure 5.1 b). Similar to a secondary GBS 
infection, S. pneumoniae infection in mice previously infected with influenza resulted 
in a significant increase in bacterial titres recovered from the airways, lung tissue and 
nasopharynx compared to mice infected with S. pneumoniae alone (Figure 5.1 c-e). 
Systemic bacteraemia in influenza infected mice occurred 48 hours after S. 
pneumoniae infection, demonstrated by the presence of viable bacteria in peripheral 
blood (Figure 5.1 f).  
 
We next established whether cellular recruitment was altered in C57BL/6 mice, as 
was seen in BALB/c mice, when challenged with S. pneumoniae following influenza 
infection. Infection of naive C57BL/6 mice with 1 x 104 cfu of S. pneumoniae elicited a 
modest, but statistically insignificant, increase in the total number of cells observed in 
the airways 48 hours post infection compared to naive and vehicle infected control 
mice (Table 5.1). Infection with S. pneumoniae on day 3 of an influenza virus 
infection also failed to increase total cellularity in the airway and lung tissue 
compared to mice infected with influenza alone. Of the cells recruited in response to 
S. pneumoniae a small number of neutrophils were observed in the airway and lung 
tissue of naive mice (Figure 5.2 a-d). In contrast to BALB/c mice, a preceding 
influenza infection in C57BL/6 mice resulted in enhanced total neutrophil numbers in 
response to S. pneumoniae infection compared to mice infected with S. pneumoniae 
alone (Figure 5.2 b & d). This is likely a consequence of the elevated bacterial titres 
observed in both the airway and lung tissue of co-infected mice.  
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Figure 5.1 Influenza significantly increases susceptibility to S. pneumoniae and 
results in bacteraemia. C57BL/6 mice (n=5) were intranasally (i.n.) infected with 
either 50 HAU HK/X31 influenza A virus or PBS control on day 0. Three days later 1 x 
104 cfu S. pneumoniae were administered i.n. Weight loss (a) and survival (b) was 
monitored daily and expressed as mean % of original body mass and % survival, 
respectively. BAL (c), lung (d), nasal wash (e) and peripheral blood (f) samples were 
collected at specified time points and cfu calculated using serial dilutions of single cell 
suspensions of each tissue sample plated on blood Columbia agar. Data represent the 
mean ± SEM. p<0.05 was taken to be significant. * = p<0.05  ** = p<0.01
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Figure 5.2 S. pneumoniae induced a modest recruitment of neutrophils to the 
airway and lungs. C57BL/6 mice (n=5) were intranasally (i.n.) infected with either 50 
HAU HK/X31 influenza A virus or PBS control on day 0. Three days later 1 x 104 cfu S. 
pneumoniae (D39) were administered i.n. BAL and lung tissue were removed and total 
cells were quantified using trypan blue to differentiate between viable and non viable 
cells. Total airway and lung cell numbers 48 hours post S. pneumoniae infection are 
illustrated in Table 5.1. Neutrophil % and total numbers in both the airway and lung 
compartments were quantified using differential flow cytometric staining (a – d). Data 
represents mean ± SEM. p<0.05 was taken to be significant. * = p<0.05  ** = p<0.01
Condition Airway cellularity Lung cellularity
Vehicle control/Naive 1.7 ± 0.7 x105 1.0 ±0.4 x 106
S. pneumoniae 3.2 ± 3.9 x 105 8.0 ±3.1 x 105
Flu d3 + PBS 9.4 ± 3.9 x 105 6.8 ±4.2 x 106
Flu d3 + S. pneumoniae 8.9 ± 2.5 x 105 7.0 ±1.8 x 106
Table 5.1 Total cells 48 hours post S. pneumoniae infection
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5.2.2 CD200R and CD200 expression during homeostasis and influenza 
infection in C57BL/6 mice 
 
After demonstrating that a prior influenza infection increases susceptibility to S. 
pneumoniae infection in C57BL/6 mice we next investigated the distribution of 
CD200R and CD200 expression on specific cell subsets in homeostasis and during 
an influenza virus infection in C57BL/6 mice. An in depth understanding of CD200R 
expression profile may provide information on its role during homeostasis and 
infection. We revealed that alveolar macrophages expressed unusually high basal 
levels of CD200R compared to non mucosal splenic macrophages, lung interstitial 
monocytes and macrophages (Figure 5.3 a). In addition, it was noted that BALB/c 
alveolar macrophages expressed significantly lower levels of CD200R than alveolar 
macrophages isolated form C57BL/6 mice during homeostasis, though this was still 
higher than splenic counterparts (Figure 5.3 a upper left panel-purple). Dendritic cells 
are not present in the airways but those in the lung interstitium have been shown to 
sample airway lumen content using dendrites 471. We observed bimodal expression 
of CD200R expression on lung DCs, the reason for this may represent different DC 
populations or differences depending on their location within the lung parenchyma, 
for example adjacent to the respiratory epithelium or contained within iBALT. 
Interstitial neutrophils expressed low amounts of CD200R (Figure 5.3 a-bottom right 
panel). Therefore, high CD200R expression was observed on myeloid cells in contact 
or within the airway lumen at this mucosal site. For CD200R to be functional in the 
airway and lung however, cells expressing CD200 are required.  In addition to 
previously described expression on hematopoietic cells, including B cells and some 
CD4+ and CD8+ T cells (Figure 5.3 b), lung endothelial cells, identified as CD45– 
CD31+, also exhibited high CD200 expression (Figure 5.3 c). Importantly, type II 
epithelial cells that dominate in the lung alveoli, isolated from collagenase/dispase 
digested lungs as described in section 2.5.2, were also positive for CD200 (Figure 
5.3 d). Immunohistology on OCT inflated lungs further verified CD200 expression on 
the luminal aspect of epithelial cells (Figure 5.3 e). The demonstration of CD200 
expression on epithelial and endothelial cells was done in conjunction with Dr R. 
Snelgrove (see acknowledgements).   
 
After illustrating that alveolar macrophages expressed high levels of CD200R in 
homeostasis and that CD200 is expressed on T cells and respiratory epithelium, we 
hypothesised that CD200R may limit the amplitude of innate immunity through 
interaction of recruited leukocytes needed to clear influenza infected cells. We 
therefore investigated the temporal and spatial expression profile of CD200R and 
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CD200 during an influenza infection. Despite high basal expression levels of 
CD200R on alveolar macrophages, influenza virus infection exponentially increased 
CD200R expression levels on alveolar macrophages and lung 
monocytes/macrophages (Figure 5.4 a & b). The level of CD200R expression 
remained elevated above basal levels up to and including 14 days post infection. 
Influenza virus infection also increased the % and total number of CD200+ CD4+ and 
CD8+ T cells in the lung tissue (Figure 5.4 c & d). However, CD200 intensity of 
expression was reduced on both CD4+ and CD8+ T cells recruited to the airway 
(Figure 5.4 e & f). Furthermore, endothelial and epithelial expression of CD200 
remained constant throughout the course of infection, although the intensity of 
expression was reduced on endothelial and epithelial cells at day 7, the time of peak 
inflammation (data not shown). The temporal expression of CD200 and CD200R 
during an influenza infection was also investigated in conjunction with Dr R. 
Snelgrove (see acknowledgements).   
 
5.2.2 A lack of CD200R increases resistance to a S. pneumoniae infection 
 
We next investigated whether a lack of CD200R altered innate immunity against an 
intranasal S. pneumoniae infection. To investigate this we intranasally infected 
CD200R KO mice and wild type controls with 1 x 104 cfu S. pneumoniae and 
evaluated survival and bacterial clearance. As previously demonstrated, no 
significant weight loss was observed over the course of infection (data not shown). 
There was no significant difference in survival rates between the two groups (Figure 
5.5 a). However, CD200R KO mice had reduced bacterial titres in both the airway 
and lung compartments at 12 hours post S. pneumoniae infection compared to wild 
type controls (Figure 5.5 b & c). No S. pneumoniae was detected in peripheral blood 
of either CD200R KO or wild type mice at any time point analysed (data not shown). 
Interestingly the bacterial titres observed in the nasopharyngeal cavity were identical 
between both groups of mice at all time points analysed (Figure 5.5 d). In a separate 
experiment looking at later time points (day 7), no bacteria were observed in wild 
type or CD200R KO mice in the lung or airways though they remained in the 
nasopharynx (data not shown). This implies that an absence of CD200R limits the 
extent of bacterial load but does not affect its ultimate clearance.  
 
CD200R KO mice had greater airway cell recruitment to S. pneumoniae compared to 
wild type controls (Figure 5.6 a). Despite a significant increase in lung cellularity over 
the course of infection in both wild type and CD200R KO, there was no difference  
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Figure 5.3 Airway and lung expression of CD200R and CD200. Lung and BAL cells 
from naïve C57BL/6 mice (n=5) were stained for CD200R expression (a). 
Representative histogram overlays of CD200R expression on alveolar (blue), splenic
(red), isotype control (orange) and BALB/c alveolar macrophages (purple) (upper left). 
Upper right and lower panels show CD200R expression on other lung myeloid 
populations (orange, isotype control; black, anti-CD200R). The % CD200 expression 
on lung CD4+, CD8+ and B220+ cells was assessed by flow cytometry (b). CD200 
expression on lung endothelium (CD31+, CD45-, pro-surfactant protein c-) (c) and lung 
epithelium (CD31+, CD45-, pro-surfactant protein c+) (d) is shown in representative 
histogram overlays (black, isotype control; grey, anti-CD200). OCT inflated lungs were 
sectioned and stained for CD200 as described in section 2.7.2 (e). Original 
magnification, x 400; BV, blood vessel; B, bronchiole. Representative of 3 
experiments.
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Figure 5.4 CD200R and CD200 expression alters during an influenza virus 
infection. C57BL/6 mice (n=5) were infected intranasally with 50 HAU HK/X31
influenza A virus on day 0. BAL and lung tissue was removed at specified time points 
post infection. CD200R expression on alveolar macrophages (a) and lung 
monocyte/macrophage (b) was determined using flow cytometry (black, isotype 
control; blue, day 0; yellow, day 4; green, day 7 and red, day 14 post influenza 
infection). The percentage (c) and total number (d) of CD200+ CD4+ T cells 
(diamonds), CD8+ T cells (squares) and B cells (triangles) in lung tissue was also 
determined. The difference in CD200 expression on airway (grey) and lung (black) T 
cells 7 days post infection is shown in (e). Data represents mean ± SEM and 
representative of three independent experiments. 
a b
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CD200CD200
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Figure 5.5 CD200R KO mice limit bacterial titres in both the airway and lung 
compartments. CD200R KO and wild type C57BL/6 (WT) litter mates (n=4) were 
intranasally (i.n.) infected 1 x 104 cfus S. pneumoniae and subsequently harvested 12, 
72 hours and 7 days post infection. Survival (a) was monitored daily. BAL (b), lung (c), 
nasal wash (d) samples were collected at specified time points cfu calculated using 
serial dilutions of single cell suspensions of each tissue sample plated on blood 
Columbia agar. Data represent the mean ± SEM of two separate experiments. p<0.05 
was taken to be significant. * = p<0.05  ** = p<0.01
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Figure 5.6 CD200R KO demonstrate heightened airway cellular recruitment and 
inflammatory cytokine production. CD200R KO and WT controls (n=4) were 
intranasally (i.n.) infected with 1 x 104 cfu S. pneumoniae and subsequently harvested 
12 and 72 hours post infection. Total airway (a) and lung (b) cell numbers were 
enumerated using Trypan blue exclusion. Airway IL-6 and TNFα cytokine levels were 
analysed using ELISA. Alveolar macrophage from naive wild type and CD200R KO 
mice were enumerated (e) as described and MHC II expression was determined using 
flow cytometry (f). Data represent the mean ± SEM. p<0.05 was taken to be significant. 
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between the two groups (Figure 5.6 b). The constituents of the airway and lung 
infiltrates did not differ between the two groups other than in amplitude, comprising of 
neutrophils and MHC II expressing F480+ monocytes (data not shown). The 
proportions and total numbers of CD4+ T cells did not significantly alter over the 
course of infection in either the airway of lung tissue (data not shown). There was, 
however, an increase in inflammatory cytokine levels measured in the airways of 
CD200R KO mice (Figure 5.6 c & d). This was statistically significant for TNF-α levels 
at 12 and 72 hours post infection.  
 
5.2.3 CD200R KO alveolar macrophage show heightened activity during 
homeostasis    
 
Cellular analysis of BALF during homeostasis revealed no inherent difference in the 
proportion or total number of alveolar macrophage between CD200R KO and wild 
type mice (Figure 5.6 e). However, their expression of MHC II was elevated 
suggesting at least partial activation (Figure 5.6 f). To further interrogate the role 
CD200R plays in determining alveolar macrophages responsiveness, we isolated 
alveolar macrophages from wild type and CD200R KO mice and exposed them to 
various stimuli, ex vivo, and measured their inflammatory response. Alveolar 
macrophages lacking CD200R demonstrated enhanced production of both TNF-α 
and IL-6 in response to LPS and S. pneumoniae stimulation (Figure 5.7 a-d). In order 
to confirm these findings, we stimulated wild type, CD200R expressing, bone marrow 
(BM) derived macrophages in the presence or absence of an agonistic antibody to 
CD200R (OX110). The results demonstrated that signaling through CD200R reduces 
inflammatory cytokine and nitric oxide production by BM macrophages in response to 
IFN-γ, LPS and influenza virus (Figure 5.8 a-d). 
 
5.2.4 CD200R KO mice are protected against influenza induced secondary 
bacterial pneumonia  
 
After demonstrating that influenza virus infection increased CD200R expression 
levels on myeloid cells and that signalling through CD200R regulated inflammatory 
cytokine production, we hypothesised that increasing CD200R expression over the 
course of an influenza infection inhibits macrophage responsiveness to bacterial 
infection. In order to test this hypothesis we infected wild type and CD200R KO mice 
with a non lethal dose of S. pneumoniae at varying time points after influenza virus 
infection and measured survival, bacterial clearance, inflammatory cytokine 
production and cellular responses.  
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Figure 5.7 Alveolar macrophage from CD200R KO mice show enhanced
inflammatory cytokine production in response to stimuli ex vivo. Alveolar 
macrophages were isolated from CD200R KO and WT controls (n=4) by adherence of 
BALF to plastic for 1 h at 37 0C in 5% CO2 . 5 x 10
4 of purified alveolar macrophage were 
then stimulated with medium alone, LPS (a & b) and varying multiplicity of infection (MOI) 
of S. pneumoniae (c & d). The supernatants were removed 24 hours later and analysed 
for TNF-α and IL-6 by ELISA. Data are presented as the mean ± SEM and are 
representative of three separate experiments. p<0.05 was taken to be significant. * = 
p<0.05  ** = p<0.01
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Figure 5.8 Signaling through CD200R reduces pro-inflammatory cytokine 
production by BM macrophages. WT bone marrow (BM) derived macrophages were 
stimulated with 10 ng/ml IFN–γ, 100 ng/ml LPS or 5 HAU influenza in the presence of 10 
µg/ml of an isotype control antibody (open) or a CD200R agonistic antibody (OX110; 
closed). At 48 hours after stimulation, culture supernatants were removed and TNF-α (a), 
IL-6 (b) and MCP-1 (c) cytokine concentrations as indicated were measured by ELISA. 
Supernatant nitric oxide concentrations were also measured using Greiss reaction (d). 
Results in each panel represent mean values  SEM from triplicate samples and are 
representative of 3 separate experiments. *=p<0.05, **=p<0.01. 
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CD200R KO mice infected with S. pneumoniae three days after influenza virus 
infection displayed reduced weight loss 48 hours post S. pneumoniae infection 
compared to WT controls (Figure 5.9 b). In addition, wild type mice appeared 
physically more ill, displaying the characteristic hunched and immobile phenotype 
described earlier (data not shown). More significantly CD200R KO mice contained 
significantly less bacterial titres in both airway and lung compartments at 6 and 48 
hours post S. pneumoniae infection (Figure 5.9 c & d). CD200R KO mice also failed 
to develop systemic bacteraemia detected in wild type mice 48 hours post S. 
pneumoniae infection (Figure 5.9 e). Interestingly, as was observed in the single S. 
pneumoniae infection (section 5.2.2.), the levels of bacteria recovered from the 
nasopharyngeal cavity increased over the course of infection but did not significantly 
differ in titre between the two groups at all time points analysed (Figure 5.9 f).  
 
This large reduction in bacterial titre in CD200R KO mice was also observed when S. 
pneumoniae was administered 7 days after influenza infection. Once more, CD200R 
KO mice lost significantly less weight in response to S. pneumoniae infection, 
appeared less ill and displayed a large reduction in bacterial titres recovered from 
airway and lung compartments compared to wild type mice (Figure 5.10 b-f). 
CD200R KO mice again failed to develop systemic bacteraemia observed in wild 
type mice 48 hours after S. pneumoniae infection (Figure 5.10 e). Infection with S. 
pneumoniae 14 days after influenza produced the same results. However, at this 
time point wild type mice did not exhibit any significant weight loss upon S. 
pneumoniae infection (Figure 5.11 b). In addition to the differences in bacterial 
susceptibility, CD200R KO mice recovered from the primary influenza virus infection 
more rapidly (Figure 5.11 b). Nevertheless, CD200R KO mice again displayed 
reduced bacterial titres recovered from the airway and lung compartments and again 
failed to develop systemic bacteraemia (Figure 5.11 c-f). Regardless of when S. 
pneumoniae was added and the time point harvested there was no differences in 
nasopharyngeal bacterial titres.  
 
Closer inspection of the data revealed that wild type mice were least able to contain 
S. pneumoniae when bacteria were administered 7 days after the initial influenza 
infection (Figure 5.12 a-d). This was demonstrated by calculating the fold increase of 
S. pneumoniae titres recovered 48 hours after infection from mice infected with S. 
pneumoniae alone and mice previously infected with influenza virus and comparing 
this value across the differing time points of infection after influenza infection (Figure 
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5.12 a-d). In addition to the significant differences in bacterial titres, 100 % of 
CD200R KO mice infected with S. pneumoniae following influenza virus survived 
regardless of when they are infected with bacteria (Figure 5.12 e).   
 
5.2.5 The lack of CD200R provides enhanced antiviral immunity  
 
It is likely that alteration in immunity and pathology to an influenza infection in 
CD200R KO mice contributes to the reduced susceptibility to secondary bacterial 
pneumonia. Wild type mice recruited significantly more cells to the airways (p 0.04) in 
response to influenza infection on day three and seven post influenza infection 
compared to CD200R KO mice (Figure 5.13 a & b). This was also confirmed by H & 
E histology (Figure 5.14 b). In both wild type and CD200R KO mice the cellular 
infiltrate subsided to naïve levels by day 14. The enhanced airway cellularity in wild 
type mice was mirrored in the lung tissue on day 7 of an influenza infection (Figure 
5.13 b). We next examined viral clearance kinetics in wild type and CD200R KO 
mice. A lack of CD200R enhanced anti-viral ability (Figure 5.13 c). This may result 
from the increased percentage and total numbers of airway NK cells in CD200R KO 
mice (Figure 5.13 d & e). There was no increase in NK number observed in the lung 
tissue of CD200R KO mice (data not shown).  
 
There were no significant differences in the proportions of alveolar macrophages, 
recruited F480+ macrophage or neutrophils at any time point analysed between WT 
and CD200R KO mice (data not shown), however there was a general increase in 
the total number of myeloid subsets in both the airway and lung tissue of wild type 
mice at all time points analysed. This failed to reach significance at any time point 
analysed. Analysis of macrophage activation also highlighted no significant difference 
in the expression of PRRs, such as TLR2 and MARCO, or the percentage of TNF-α 
and IFN-γ producing macrophages in the airway or lung. However, there was a 
significant increase in the intensity of MHC class II expression on alveolar 
macrophages in CD200R KO mice 7 and 14 days post influenza infection (p 0.0286 
and p 0.0159 respectively) (data not shown).   
 
Analysis of lymphocyte populations showed a general increase in the proportion of 
CD4+ and CD8+ T cells in CD200R KO mice over the course of influenza infection. 
This trend was mirrored in the lung tissue. The only significant difference was an 
elevated proportion of CD8+ T cells in the airway of CD200R KO mice on day 7 post 
influenza infection (p 0.029). Despite this, the total number of CD4+ and CD8+ T cells  
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Figure 5.9 A lack of CD200R protects mice from a secondary S. pneumoniae 
infection. CD200R KO and WT controls were infected intranasally (i.n.) with 50 HAU 
HK/X31 influenza A virus. After three days, mice were infected i.n. with 1 x 104 cfu S. 
pneumoniae (a). Weight loss (b) was monitored daily and expressed as a mean % of 
original body mass. 6 and 48 hours post S. pneumoniae infection BAL and nasal wash 
was performed and lung tissue removed. Airway (c), lung (d), nasopharyngeal (e) and 
peripheral blood (f) bacterial titres were calculated using serial dilutions of single cell 
suspensions plated on blood supplemented Columbia agar. Data are presented as the 
mean ± SEM of 4 - 8 mice per group. p<0.05 was taken to be significant. * = p<0.05  ** = 
p<0.01
Bacteria
d3
Flu
d0
WT CD200R KO
Time (d) post influenza
O
ri
g
in
a
l 
b
o
d
y
 m
a
s
s
 (
%
)
C
F
U
 (
lo
g
1
0
)/
m
l
Time (h) post S. pneumoniae
0 6 48
0
1
2
3
4
5
6
7
2
3
4
5
6
0 6 48
C
F
U
 (
lo
g
1
0
)/
m
l
C
F
U
 (
lo
g
1
0
)/
m
l
0
1
2
3
4
5
6
0 6 48
C
F
U
 (
lo
g
1
0
)/
m
l
0
1
2
3
4
5
6
C
F
U
 (
lo
g
1
0
)/
m
l
48
C
F
U
 (
lo
g
1
0
)/
m
l
b c
d e f
a
*
0 1 2 3 4 5
70
80
90
100
110
S. pneumoniae
Time (h) post S. pneumoniae Time (h) post S. pneumoniae
Airway
Lung Blood Nasopharynx
*
**
**
*
CHAPTER 5: INNATE HOMEOSTASIS AND INHIBITORY MYELOID RECEPTORS 
152 
 
0
1
2
3
4
5
6
7
0 6 48
0
1
2
3
4
5
6
7
48
C
F
U
 (
lo
g
1
0
)/
m
l
C
F
U
 (
lo
g
1
0
)/
m
l
0
1
2
3
4
5
6
7
0 6 48
C
F
U
 (
lo
g
1
0
)/
m
l
0 1 2 3 4 5 6 7 8 9
70
80
90
100
110
0
1
2
3
4
5
6
7
0 6 48
Time (d) post influenza
O
ri
g
in
a
l 
b
o
d
y
 m
a
s
s
 (
%
)
C
F
U
 (
lo
g
1
0
)/
m
l
Time (h) post S. pneumoniae
WT CD200R KO
Bacteria
d7
Flu
d0
a
b c
d e f
Figure 5.10 A lack of CD200R protects mice from a secondary S. pneumoniae 
infection on day 7 of an influenza infection. CD200R KO and WT control mice (n=5) 
were infected intranasally (i.n.) with 50 HAU HK/X31 influenza A virus. After seven days, 
mice were infected i.n. with 1 x 104 cfu S. pneumoniae (a). Weight loss (b) was monitored 
daily and expressed as a mean % original body mass. 6 and 48 hours post S. 
pneumoniae infection BAL and nasal wash was performed and lung tissue removed. 
Airway (c), lung (d), nasopharyngeal (e) and peripheral blood (f) bacterial titres were 
calculated using serial dilutions of single cell suspensions of each tissue sample and 
plated on blood supplemented Columbia agar. Data are presented as the mean ± SEM. 
p<0.05 was taken to be significant. * = p<0.05  ** = p<0.01
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Figure 5.11 A lack of CD200R protects mice from a secondary S. pneumoniae on 
day 14 of an influenza infection. CD200R KO and WT mice (n=5) were infected 
intranasally (i.n.) with 50 HA HK/X31 influenza A virus. After fourteen days, mice were 
infected i.n. with 1 x 104 cfu S. pneumoniae (a). Weight loss (b) was monitored daily and 
expressed as a mean % original body mass. 6 and 48 hours post S. pneumoniae infection 
BAL and nasal wash was performed and lung tissue removed. Airway (c), lung (d), 
nasopharyngeal (e) and peripheral blood (f) bacterial titres were calculated using serial 
dilutions of single cell suspensions of each tissue sample and plated on blood 
supplemented Columbia agar. Data are presented as the mean ± SEM. p<0.05 was taken 
to be significant. * = p<0.05  ** = p<0.01
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Figure 5.12 Susceptibility to a secondary bacterial infection is greatest 7 days after 
influenza virus infection. Normalised bacterial titres recovered from the airway (a), lung 
tissue (b), nasopharyngeal cavity (c) and peripheral blood (d) 48 hours after S. 
pneumoniae infection in mice infected 3, 7 or 14 days previously with influenza virus. 
Recovered bacterial titres are expressed as the fold increase over the bacterial titres 
recovered 48 hours after infection of naïve mice with S. pneumoniae. Survival (e) at each 
time point post influenza infection was also measured. Data represent the mean ± SEM n 
= 5.
S. pneumoniae titres 48 hours post bacterial infection
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Figure 5.13 A lack of CD200R reduced cellular recruitment and influenza viral 
titres. CD200R KO and WT controls (n=4-8) were intranasally (i.n.) infected with 50 
HAU HK/X31 influenza A virus on day 0. BAL (a) and lung (b) cells were quantified, at 
specified time points, using Trypan blue exclusion. Influenza viral titres (c) were 
determined from frozen lung lobes. The % (d) and total number (e) of airway NK cells 
were determined using flow cytometry. Data are presented as the mean ± SEM.  
p<0.05 was taken to be significant. * = p<0.05  ** = p<0.01
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Figure 5.14 Lung pathology in WT and CD200R KO mice infected with S. 
pneumoniae on day 7 of an influenza infection. Wild type and CD200R KO mice (n=4) 
were infected intranasally with 50 HAU HK/X31 influenza virus on day 0. 7 days later the 
mice were intranasally infected with 1 x 104 cfu S. pneumoniae. Mice were subsequently 
harvested 48 hours post S. pneumoniae infection. Processing of mouse lungs for histology 
and light microscopy of H & E stained sections were carried out as described in section 
2.7.1. Magnification was x 10. Sections are representative of four mice studied at each 
time point. 
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and the proportion that were CD69+ and TNF-α and IFN-γ producing were, in 
general, elevated in wild type mice on day 7 post infection. However, none of these 
differences were statistically significant (data not shown).  
 
5.2.6 Cytokine environment of the airway and lung at time of S. pneumoniae 
infection 
 
Since many cytokines are also anti-bacterial we examined whether there were any 
differences between wild type and CD200R KO mice at the time of bacterial 
administration. Wild type mice demonstrated elevated levels of TNF-α and IL-6 in the 
airway at 3 and 7 days post influenza (Figure 5.15 a & e). Airway IFN-γ levels were 
only elevated in wild type mice 7 days after influenza infection (Figure 5.15 c). On 
analysis inflammatory cytokine levels measure from lung tissue a similar pattern was 
observed. IFN-γ and IL-6 levels were elevated on day 7 whilst TNF-α was higher at 
day 3 post influenza in wild type mice (Figure 5.15 b, d & f). Therefore, mice that 
survive the bacterial secondary infection had less inflammatory cytokines present at 
the time of bacterial infection.   
 
5.2.7 Airway cellular differences between wild type and CD200R mice 7 days 
after influenza infection 
 
Having demonstrated that wild type mice recruit a greater number of cells to the 
airway and lung and have elevated levels of inflammatory cytokine 7 days after 
influenza infection, we next investigated what influence this may have on 
susceptibility to bacterial infection. Administration of S. pneumoniae to influenza 
infected mice at day 7 resulted in 100 % mortality in wild type mice by day 4 post 
infection (Figure 5.16 a). S. pneumoniae infection also caused a further increase in 
airway cellularity that was more pronounced in wild type compared to CD200R KO 
mice (Figure 5.16 b). This difference was less apparent in the lung but still significant 
at early time points (data not shown). Of these additional cells neutrophils dominated 
in wild type mice (Figure 5.16 c & d). This was accompanied by an increase in the 
expression OX40L, an immune potentiator on alveolar and tissue macrophages at 48 
hours post S. pneumoniae infection (Figure 5.16 e & f). Furthermore, we observed 
higher levels of IL-10R 48 hours post S. pneumoniae infection on alveolar 
macrophages from CD200R KO mice (p 0.0159) (Figure 5.16 g). Having previously 
demonstrated that TLR and MARCO expression was increased on innate immune 
cells during an ongoing influenza infection, we also compared the expression levels 
of TLR2, TLR4 and MARCO on alveolar macrophage in wild type and CD200R KO 
mice, however no significant differences were detected (data not shown).  
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5.2.8 CD200+ leukocytes are present in the airway during influenza infection 
and secondary bacterial infection   
 
Recent literature proposes that phagocytic function of alveolar macrophages can be 
altered by the presence of inflammatory cytokines produced in response to influenza 
infection and through cognate interactions with infiltrating cells 472-475. We 
hypothesised that the negative influence of CD200R on macrophages following 
influenza infection may play a role in reducing their anti-bacterial function. To support 
this idea CD200+ T cells were present in both the airway and lungs of wild type and 
CD200R KO mice during a secondary bacterial infection (Figure 5.17 a-d). The 
intensity of CD200 expression was also elevated on wild type CD4+ and CD8+ T cells 
with higher levels observed in the lung (Figure 5.17 e & f). The presence of apoptotic 
CD200+ expressing monocytes in the airway was also observed in both wild type and 
CD200R KO 7 and 14 days after influenza infection (Figure 5.18 a-e).   
 
To investigate whether the presence of CD200 expressing leukocytes can reduce the 
anti-bacterial function of alveolar macrophages, we next examined, in vitro, the 
effects of CD200R ligation on macrophage phagocytic functionality. After 
demonstrating that alveolar macrophages engulfed GFP expressing S. pneumoniae  
ex vivo (Figure 5.19) we stimulated wild type and CD200R KO naive alveolar 
macrophage with OX110, a CD200R agonistic antibody, for 30 minutes prior to 
exposure to S. pneumoniae. Our findings demonstrated that in vitro ligation of 
CD200R does not alter the phagocytic function of alveolar macrophage (Figure 5.19 
b & c).  
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Figure 5.15 Wild type mice show elevated inflammatory cytokine production in 
response to influenza. CD200R KO and WT controls were intranasally (i.n.) infected with 50 
HAU HK/X31 influenza A virus on day 0. Airway levels of TNF-α (a), IFN-γ (c) and IL-6 (e) were 
quantified, using ELISA, at time point specified. Lung tissue was removed, at specified time 
points, homogenised and assayed for TNF-α (b), IFN-γ (d) and IL-6 (f) using ELISA. Data 
represent the mean ± SEM n = 4 (airway) or 5 (lung). p<0.05 was taken to be significant. * = 
p<0.05  ** = p<0.01
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Figure 5.16 CD200R KO mice recruit less neutrophils and activated alveolar 
macrophages. WT and CD200R KO  mice (n=4) were intranasally (i.n.) infected with 
either 50 HAU HK/X31 influenza A virus on day 0. Seven days later 1 x 104 cfu S. 
pneumoniae was administered i.n. BAL (a) and lung (b) total cells were enumerated at 
specified time points using Trypan blue exclusion. Neutrophil % (c) and total numbers 
(d) were quantified using FCM. OX40L expression was also analysed on CD11c+ cells 
in airway and lung. Data are presented as the mean ± SEM. p<0.05 was taken to be 
significant. * = p<0.05  ** = p<0.01
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Figure 5.17 The presence of CD200+ T cells in the airways and lung of co-
infected mice. WT and CD200R KO mice (n=5) were intranasally (i.n.) infected with 50 
HAU HK/X31 influenza A virus on day 0. Seven days later 1 x 104 cfu of S. 
pneumoniae was administered i.n. Mice were culled 48 hours post S. pneumoniae. 
The proportion (a & b) and total number (c & d) of CD200+ CD4+ and CD8+ T cells 
were determined using flow cytometry. Mean fluorescence intensity of CD200 on T cell 
subsets was also determined (e & f). Data are presented as the mean ± SEM. p<0.05 
was taken to be significant. * = p<0.05  ** = p<0.01
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Figure 5.18 CD200 is expressed on apoptotic exudate monocytes in the airway 
during influenza infection. WT and CD200R KO mice (n=4) were intranasally (i.n.) 
infected with 50 HAU HK/X31 influenza A virus on day 0. BAL was performed at 
specified time points after influenza infection. The total number (a) of exudate 
monocytes were determined by flow cytometry and shown to be CD11b+ F480+ as 
described in section 2.6.1. % CD200+ (b) and CD200+ TUNEL+ (c) was determined. A 
representative flow cytometric plot from day 7 (d) and day 14 (e) WT mice is shown. 
Data are presented as the mean ± SEM. p<0.05 was taken to be significant. * = p<0.05  
** = p<0.01
a b c
d e
Wild type CD200R KO
CHAPTER 5: INNATE HOMEOSTASIS AND INHIBITORY MYELOID RECEPTORS 
163 
 
 
Figure 5.19 In vitro CD200R ligation does not alter alveolar macrophage 
phagocytic function. Alveolar macrophages were isolated from naive WT mice (n=5) 
and incubated at a density 5 x 104 cells per well with opsonised WT or pGFP
expressing S. pneumoniae (MOI 5). The % GFP+ alveolar macrophages were 
subsequently determined using FCM (a). In a separate experiment, 5 x 104 of WT and 
CD200R KO alveolar macrophages were pre-stimulated for 30 mins with or without 
10μg/ml of OX110 before the addition of pGFP+ S. pneumoniae (b & c). Data are 
presented as the mean ± SEM of 5 mice per group. p<0.05 was taken to be significant. 
* = p<0.05  ** = p<0.01
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5.3 Discussion 
5.3.1. Susceptibility to S. pneumoniae is increased in C57BL/6 mice following 
influenza virus infection 
  
In Chapter 3 we showed that C57BL/6 mice demonstrated a dose related increase in 
susceptibility to a S. pneumoniae infection, here we demonstrate that a preceding 
influenza virus infection significantly reduces the dose of S. pneumoniae that results 
in lethal systemic bacteraemia. Using the secondary bacterial infection model 
developed in Chapter 4 we illustrate that 1 x 104 cfu of S. pneumoniae, a non lethal 
dose when given to naïve mice, results in lethal bacteraemia when administered 3, 7 
or 14 days after an influenza infection. We also show that peak susceptibility to a 
secondary bacterial super infection, determined by total bacterial load and time to 
mortality, coincides with peak influenza-associated illness, 7 days after an influenza 
infection. Furthermore, the development of a secondary bacterial super infection 
significantly enhances weight loss and results in a hypothermic syndrome 
characteristic of systemic septic shock. We therefore highlight that the clinical 
manifestation of a S. pneumoniae secondary bacterial infection is considerably more 
severe than what is observed during a GBS secondary bacterial infection. This 
increase in severity of bacterial infection is likely a consequence of the niche 
adaptation of S. pneumoniae to inhabiting and infecting respiratory mucosa and its 
associated virulence factors, such as its polysaccharide capsule, pneumolysin and 
hyaluronidase that allows tissue invasion and dissemination 4;255;259;476. Our findings 
are similar to existing epidemiological evidence, with regards to the temporal 
relationship between influenza and secondary bacterial pneumonias, and existing 
animal models of influenza induced S. pneumoniae super infections, therefore 
validating both our experimental setup and results 412;472;477-480. However, it is 
important to remember, as discussed in Chapter 3, the strain of mouse, the infective 
dose of both influenza and S. pneumoniae used and timing of the secondary 
bacterial infection post influenza infection all independently affect the outcome of a 
model and should be taken into consideration when interpreting secondary bacterial 
infection model results.  
 
Further comparison of the GBS and S. pneumoniae secondary infection models 
highlights interesting differences including the lack of synergistic cellularity and the 
enhancement of neutrophil numbers observed when S. pneumoniae is administered 
on day 3 of an influenza infection. However, due to the extensive discussion on 
contrasting neutrophil responses in BALB/c and C57BL/6 mice in Chapter 3 and the 
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clear difficulties in comparing the two different secondary bacterial infection models 
there is no further discussion concerning these differences. 
 
5.3.2. The role of CD200R and CD200 during homeostasis and Influenza virus 
infection  
 
There is growing evidence that myeloid cell immune homeostasis, in the absence of 
antigen, is an active process mediated by tissue specific micro-environmental factors 
that define a threshold for responsiveness 169. The maintenance of this threshold is 
likely to represent an evolutionary strategy that limits inflammation, particularly in 
mucosal sites that are exposed to an abundance of innocuous antigen and 
opportunistic micro-organisms. We show that CD200R is highly expressed by 
alveolar macrophages at homeostasis and that expression on pulmonary dendritic 
cells is bi-modal, therefore suggesting the existence of two distinct dendritic cell 
populations during homeostasis. Intriguingly, only myeloid cells within (alveolar 
macrophages), or in contact with (dendritic cells dendrites), the airway lumen express 
high levels of CD200R at homeostasis, compared to macrophages resident in the 
lung parenchyma or at distant sites that express significantly lower levels of CD200R 
during homeostasis. However, in order for them to be restrained, CD200 is required. 
In homeostasis we detect CD200 expression on airway epithelium, lung endothelial, 
T lymphocytes and B cells, similar to that described in other sites 114;118-120. However, 
haematopoietic cells are of low abundance in the non-inflamed airway and luminal 
myeloid cells are unlikely to be influenced by CD200 expressed on endothelial cells. 
We therefore propose that CD200 expressed on the luminal aspect of airway 
epithelial cells is the most likely mechanism for controlling alveolar macrophages that 
express abundant CD200R levels. This suggests the existence of a dynamic 
homeostatic regulatory system that is determined at the level of the tissue 
compartment.  
 
It has been previously shown that naive CD200 KO mice display elevated numbers of 
activated macrophages in their spleen, mesenteric lymph nodes and CNS, compared 
to wild type controls, and that alveolar macrophages from aged CD200 KO mice 
respond more vigorously to inflammatory stimuli ex vivo, thus suggesting that a lack 
of CD200R ligation intrinsically alters alveolar macrophages in a manner that makes 
them more primed to respond to activating stimuli 458. This novel mechanism of 
maintaining a hypo-responsive state of alveolar macrophages is akin to other 
important lung specific homeostatic pathways for example: 1) epithelial v6 integrin 
bound TGF- 456;457 and 2) binding of surfactant proteins to the inhibitory receptor 
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signal regulatory protein-α (SIRP-α)481. Furthermore, we show that the homeostatic 
level of CD200R on BALB/c derived alveolar macrophages is significantly lower than 
that detected on alveolar macrophage from C57BL/6 mice. Could this difference in 
CD200R expression levels reduce the level of homeostatic regulation placed upon 
BALB/c alveolar macrophage, thereby reducing their threshold of activation and thus 
explaining the robust innate cellular responses we observe in BALB/c mice in all 
infection models used in this thesis? Could this observation also explain the 
differences in neutrophil responses observed between C57BL/6 and BALB/c mice? It 
is fascinating to postulate that a loss of CD200R, as is the case in CD200R KO mice, 
pushes the CD200R KO (C57BL/6 background) toward a BALB/c phenotype that 
elicits rapid innate immune responses to respiratory bacterial and viral infection such 
as S. pneumoniae and influenza virus.  
 
If CD200 determines myeloid regulation during homeostasis how would immune 
responses be initiated in tissues that exhibit high CD200 and CD200R expression, 
such as the lung or CNS? One could assume that for an immune response is to 
occur, CD200 or its receptor would have to be shed or their inhibitory function 
reduced. SIRP- (another inhibitory myeloid regulator) on macrophages is lost in 
response to LPS stimulation to permit an inflammatory response and a re-
introduction restores macrophage homeostasis 482. Similarly, microbial products 
cause the loss of v6 on airway epithelial cells, removing the TGF- mediated 
suppression of alveolar macrophages 456. We fail to see any such loss of CD200R 
expression on lung and airway myeloid populations but rather an increase in its 
intensity throughout an influenza infection. Furthermore, we show an increase in the 
number of CD200+ leukocytes in the lung when infected with influenza. However, 
closer analysis reveals CD200 expression is reduced on airway infiltrating CD4+ and 
CD8+ T cells. Therefore, in homeostasis airway epithelial CD200 signals to the 
myeloid cell through CD200R; not to prevent an inflammatory response but rather to 
raise the threshold required for activation, thus preventing an immune response to 
innocuous antigen. During heightened inflammation however, leukocytes enter the 
airways, lose CD200 expression and compete with epithelial cells for myeloid cell 
interaction, thus allowing inflammation to proceed with vigour. It is also possible that, 
in the course of infection, other molecules are up-regulated on the surface of ligand 
and receptor bearing cells that may impede a meaningful interaction. Conversely, not 
only is CD200 lost on many cells entering the airways but the scarcity of any 
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structural organization may limit the close association of infiltrating cells and the 
potential to impart an inhibitory signal through CD200R to myeloid cells at this site.   
 
5.3.3. A loss of CD200R protects against lethal bacteraemia during secondary 
bacterial pneumonias 
 
As discussed above, the dynamic interaction of CD200R, expressed on alveolar 
macrophages, and CD200, expressed on the luminal aspect of respiratory 
epithelium, determines a level of immune hypo-responsiveness during homeostasis 
that prevents unwarranted inflammation in response to innocuous antigen. Pathways 
governing immune homeostasis are also likely to restrain the amplitude of 
inflammation and ultimately return the system to a state of homeostasis. Toll-like 
receptor signalling marks the presence of an invading pathogenic microorganism, but 
ensuing inflammatory cascades must be moderated to prevent unnecessary 
inflammatory disease 483;484. We show that a loss of CD200-CD200R homeostatic 
regulation, utilising CD200R KO mice, results in an enhanced ability to initially 
contain a non lethal S. pneumoniae infection in both the airway and lung tissue. This 
intervention also results in enhanced basal activation of alveolar macrophages, 
shown by increased MHC II expression, an increase in airway cellularity and an 
increase in inflammatory cytokine production in response to S. pneumoniae infection 
in both in vivo and in vitro circumstances. These results provide evidence that 
CD200-CD200R interaction imparts a hypo-responsive immune state, present in 
homeostasis that increases the level of activation needed to initiate anti-bacterial 
immunity. CD200R ligation has previously been shown to suppress TNF-α and IL-6 
production by mouse peritoneal macrophages, IFN-γ induced IL-8, MIG and IP-10 by 
human U937 monocytes,  IgE mediated degranulation and IL-13 and TNF-α 
production by mouse and human mast cells 125;144. These findings are analogous to 
our in vitro studies that highlight ligation of CD200R reduces pro-inflammatory 
cytokine production from stimulated bone marrow derived macrophages. The precise 
downstream signalling events following CD200R ligation are not currently known, 
however, Zhang et al utilized an in vitro mast cell based system to show that 
phosphorylation of a tyrosine residue within an NPXY signature in the cytoplasmic tail 
of CD200R resulted in the inhibition of downstream RAS/MAPK pathways 124.  
 
As previously alluded to, pathways that maintain immune homeostasis and limit the 
amplitude of ongoing inflammation are also likely to restore it to its original resting 
state. It has been previously postulated that ROS produced by myeloid cells act as 
pro-inflammatory mediators during early inflammation, but ultimately also facilitate 
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resolution of inflammation by inducing apoptosis of the very cells that produce them 
130;485. Similarly, the transcription factor NF-B is critical for the production of many 
inflammatory mediators, but also ultimately fulfils an active role in the resolution of 
inflammation and lung epithelial tethered TGF- acts to prevent initial inflammation 
but also restores homeostasis 456;486. We have previously shown that CD200 KO mice 
display prolonged illness and pulmonary cellularity in an influenza infection model, 
highlighting a potential role for CD200-CD200R in tempering innate immunity and 
shaping the resolution of acute inflammation 458. In addition, the increase in CD200R 
expression on myeloid populations during influenza induced lung inflammation might 
increase the sensitivity of macrophages to CD200 mediated suppression, as has 
been shown on basophils in alternative viral infection models 137. This led us to the 
hypothesis; in an attempt to temper innate immunity and to initiate resolution of 
influenza induced inflammation, the lung inadvertently imposes a state of 
macrophage hypo-responsiveness that renders the host susceptible to secondary 
bacterial infection. To support this hypothesis, we show that mice lacking CD200R  
are able to limit S. pneumoniae infection and prevent the development of a lethal 
bacteraemia at all time points post influenza infection. These data suggest a novel 
mechanism explaining the increase in susceptibility to opportunistic bacterial 
pathogens observed shortly after influenza viral infections. However, there remain 
several caveats that might also explain the enhanced resistance to secondary 
bacterial pneumonia observed in CD200R KO mice. Our data illustrates that CD200R 
KO mice limit influenza viral replication and contain lower total cell and inflammatory 
cytokine levels in the airway at 3 and 7 days post influenza infection relative to WT 
controls. Could this reduction in viral titres and attenuated inflammatory response 
result in less pathology, such as epithelial damage, in CD200R KO mice, thus 
accounting for the resistance to secondary S. pneumoniae infection? Could the lack 
of CD200R expression on other myeloid cells, such as neutrophils and monocytes, 
alter their phenotype or function that could also impact on resistance to S. 
pneumoniae infection? Our investigations revealed no differences in TLR or MARCO 
expression levels between CD200R KO and wild type mice. Another potential caveat 
surrounds the enhanced NK cell responses observed in response to influenza virus 
infection in CD200R KO mice. As discussed in Chapter 3, the role NK cells play in 
bacterial infections remains controversial but must also be considered in this model 
system.  
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An additional observation that warrants a brief discussion was the similar titres of S. 
pneumoniae recovered from the nasopharyngeal compartment of wild type and 
CD200R KO mice in both the S. pneumoniae single infection model and the influenza 
secondary infection model. This observation adds validity to our suggestion of tissue-
specific regulatory mechanisms that determine innate responsiveness and function. 
This distinction in immune responsiveness between the lower and upper respiratory 
tract is discussed further in Chapter 6.  
 
5.3.4. CD200 expressing cells and alveolar macrophage anti-bacterial 
functionality 
 
We postulate that luminal expression of CD200 on epithelial cells plays an important 
role in myeloid homeostasis and its potential role in mediating resolution of 
inflammation once the TLR burden has been reduced sufficiently. However, the 
concept that CD200 expressing leukocytes can also regulate myeloid immune 
responsiveness is also an intriguing possibility. The very cells activated by innate 
immunity may actually in turn mediate myeloid immune regulation and suppression. 
The potential of T cells to temper initial innate inflammatory responses has been 
reported previously although the precise mechanism involved remains elusive 487. 
More recently Guarda et al describe a novel mechanism of macrophage 
inflammasome inhibition by effector and memory T cells that suppress potentially 
damaging inflammation yet leave primary innate responses intact 488.  
 
As discussed previously, efferocytotic uptake of apoptotic cells by macrophages 
leads to a reduced microbicidal state that prevents long term tissue damage by 
chronic inflammation, but may also inadvertently reduce responsiveness to a 
subsequent infection through the production of prostaglandin E2 (PGE2) and 
inhibition of NADPH oxidase 489;490. However, in addition we now postulate that 
clearance of apoptotic inflammatory cells, during the resolution of influenza infection, 
mediates alveolar macrophage immune suppression. Phagocytosis can be 
inflammatory if the ingested particle is pathogenic; however the ingestion of apoptotic 
host cells is not, a mechanism critical in distinguishing between harmless and 
harmful antigens. CD200 is a p53 gene target and is up-regulated on apoptotic cells, 
thereby reducing the inflammatory response to self antigen 491. This begs the 
question; does CD200, up regulated on apoptotic leukocytes, interact with elevated 
CD200R, highly expressed on alveolar macrophage after influenza infection, affect 
their bacterial phagocytic capacity or intracellular killing mechanisms? Unfortunately 
our in vitro attempts to produce data to support this concept were unsuccessful; 
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however this may be due to the existence of additional in vivo soluble or cognate 
inhibitory signals that in combination with CD200R ligation detrimentally affect 
alveolar macrophage anti-bacterial function. Furthermore, there may exist unknown 
ligands for CD200R? As surfactant protein A and D have been shown to induce 
inhibitory effects via the ligation of SIRP-α 492.  
 
There are a growing number of mechanisms, such as terminating lymphocyte 
survival, induction of programmed cell death by apoptosis and the reprogramming of 
pro-inflammatory monocyte macrophages toward alternative phenotypes that 
continue to add complexity to how innate and adaptive immune systems reciprocally 
regulate one another 493;494. These and many more questions remain unanswered 
and further explanation is needed in order to further understand the role inhibitory 
paired receptors play in resolution of acute inflammation and their role in secondary 
bacterial pneumonias. 
 
5.4 Conclusion 
The precise mechanisms that explain how respiratory viral infections, in particular 
influenza virus, result in increased susceptibility to secondary bacterial pneumonias 
remain elusive. In this study we shed light on a novel mechanism whereby influenza 
virus causes an overshoot in the expression of an innate immune negative regulator, 
CD200R, which essentially raises the level above which subsequent bacteria are 
recognised and inadvertently imposes a state of macrophage hypo-responsiveness 
that renders the host susceptible to secondary bacterial infection.  If we remove such 
pathways using genetically modified mice then pathology to influenza and secondary 
bacterial infection is reduced. Furthermore, this study highlights an important 
quandary regarding the use of CD200R as an immunotherapeutic target. CD200R 
has been proposed as a promising target for alleviating the excessive inflammation 
associated with autoimmune, allergic and excessive respiratory inflammatory 
diseases. A complete understanding of the potential therapeutic risk, with regards to 
bacterial susceptibility, is needed when developing such immunotherapeutic 
intervention strategies 140;141;143;144. Figure 5.20 schematically represents our novel 
mechanism of how influenza virus increases susceptibility to secondary bacterial 
pneumonias.  
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Figure 5.20 Influenza induced macrophage hypo-responsiveness  
During homeostasis alveolar macrophage are maintained in a state of immune 
homeostasis through interaction of CD200, expressed on respiratory epithelium, and 
CD200R, expressed on alveolar macrophages (a). In an attempt to temper and 
resolve innate inflammation CD200R levels are increased and interact with CD200 
expressed by airway lymphocytes, monocytes and apoptotic cells. The presence of 
yet unidentified CD200R ligands might also be elevated during inflammation 
resolution (b).  
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Chapter 6 
 
 
6.0 Proteomic landscape and the bacterial microbiota 
 
The preliminary data sets in this results chapter were produced from proof of 
principal experiments. All work contained herein, unless stated in the 
acknowledgement section, was carried out by myself, under the supervision of Dr 
Robin Wait and Dr Markus Hilty. This results chapter is divided into two sections;  
 
1. Proteomic analysis of murine airway anti-microbial proteins. 
2. Characterisation of the respiratory tract commensal flora during homeostasis 
(naïve mice) and an ongoing influenza virus infection.   
 
6.1 Introduction 
 
6.1.1 Antimicrobial peptides and their role in respiratory tract immunity 
 
The respiratory mucosa is constantly exposed to a myriad of potential pathogens, 
pollutants and inflammatory stimuli. However, these exogenous particles rarely cause 
problems in a healthy lung owing to the existence of an array of innate defence 
proteins, commonly referred to as antimicrobial peptides (AMPs), present in the 
mucous that cover the respiratory epithelium. A detailed classification and description 
of AMPs mechanisms of action can be found in section 1. 2. AMPs are constitutively 
produced by respiratory epithelium and resident alveolar macrophages and provide 
early, broad spectrum, protection against invading pathogens 5. In vertebrates, basal 
expression of AMPs by gut epithelial cells also plays a critical role in dictating the 
density and composition of the resident gut commensal flora 495. Although numerous 
AMPs are constitutively expressed, they are also regulated by inflammatory 
cytokines produced in response to MAMP recognition by PRRs. The best known 
example of this type of regulation is the induction of β-defensins and lipocalin-2, an 
iron sequestering AMP, in response to IL-1β stimulation of respiratory epithelium 
cells 496;497. Furthermore, IL-17A and IL-22, produced by Th17 T cells, can induce the 
expression of human β-defensin 2 (HBD2), HBD3 and the chemokine CCL20 in 
bronchial epithelium. IL-22 and IL-17 can also synergistically induce lipocalin-2 
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expression in mouse tracheal epithelium cells, which is indispensable for 
antimicrobial activity against Klebsiella pneumoniae 498-501. AMP expression is also 
altered during infection. Chong et al demonstrate that the expression of β-defensin 3 
and 4 is enhanced in the lungs, trachea and sinonasal mucosa of mice infected with 
influenza virus 502. The respiratory fungal pathogen, Aspergillus fumigates, also 
augments HBD2 and HBD9 gene expression in A549 pneumocyte cells 503. 
Nonetheless, it is difficult to ascertain from in vivo experiments whether a pathogen, 
such as influenza virus, itself directly augments AMPs expression or indirectly via the 
action of ensuing inflammatory cytokines. This quandary is highlighted in a recent 
study that shows LPS indirectly augments β-defensin transcription levels in A549 
pulmonary epithelial cells via the production of IL-β and TNF-α by mononuclear 
phagocytes 504. Furthermore, AMPs themselves can regulate the expression of other 
AMPs. Zhang et al highlights the role of human cathelicidin LL37 and its synergistic 
interaction with IL-1β to increase the production of IL-8, IL-10 and the chemokine CC-
chemokine ligand 2 (CCL2) as well as increasing local concentrations of α-defensin 
505.  
 
AMPs also play a pivotal role in providing feedback regulation that can limit and 
resolve inflammation. Surfactant protein A (SP-A) inhibits downstream signalling via 
Akt from TLR2 and TLR4, which decreases pro-inflammatory cytokine production 
from stimulated human airway macrophages 506. In a similar fashion, α-defensins can 
block the secretion of IL-1β by LPS activated monocytes. Furthermore, SP-A, along 
with a related family member SP-D, reduces the activity and phagocytic capacity of 
alveolar macrophages by binding to and activating the signal inhibitory regulatory 
protein alpha (SIRP-α), an inhibitory receptor highly expressed on these cells 492.  
 
There is growing evidence that suggests that AMPs play a complex role in host 
defence of the airway providing a self contained response to extracellular microbial 
stimuli that encompasses pathogen recognition, inflammation, pathogen clearance 
and resolution of inflammation. However, there remains a lack of knowledge 
surrounding how infection history affects AMP expression and whether the loss of 
respiratory epithelium and other cells responsible for AMP production, observed 
during respiratory viral infections, results in a distorted AMP repertoire that could 
have important consequences for the host‟s anti microbial competence. AMPs and 
their mechanism of action have attracted growing interest in light of increasing 
numbers of multiple drug resistant bacteria, such as methicillin resistant 
Staphylococcus aureus (MRSA), and the decline in the development of new 
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antibacterial therapies 507-509. Research into the modulation of AMP gene and protein 
expression in animal models, as well as increased investigation into peptide-based 
therapeutics could provide novel therapeutics for the treatment and prevention of 
respiratory infections. 
 
6.1.2 The respiratory tract commensal flora 
 
Much of what is known regarding the diversity and function of the commensal 
microbiota of the respiratory tract is based on data derived from traditional culture-
based techniques 510. However, these methods are limited and only detect a small 
fraction of the bacterial diversity therefore providing only a selective and invariably 
biased analysis on bacterial diversity. Consequently, little is known about the specific 
composition and dynamics of the respiratory commensal flora in disease and health. 
Although the mucosal surfaces of the upper respiratory tract harbour a complex 
mixture of microbial species, the relative paucity of cultivated bacteria and the 
necessity for efficient gaseous exchange has led to the common assumption that the 
lower respiratory tract is devoid of a complex microbial biota. Molecular methods of 
bacterial detection have the potential to offer more detailed insights into the complex 
microbial communities present in the entire respiratory tract. 16S rRNA sequencing 
has been used to characterize the microflora of the human oral cavity, oesophagus, 
colon and stool, revealing many novel uncultivable bacterial species 511-515. However, 
despite the routine use of molecular diagnostic testing to detect causative pathogens 
of community acquired pneumonia and the molecular identification of bacteria 
present in the airways of patients with cystic fibrosis, COPD and ventilated 
associated pneumonia, these methods have not been utilised to characterise the 
resident microflora of the upper and lower respiratory tract of mice, or humans, 
during homeostasis and infection with influenza virus 516-519.  
 
As is observed in the gut, the density and complexity of the respiratory tract 
commensal flora provides an important layer of defense against invasion by 
pathogenic microbes. However, the challenge for the innate immune system of the 
host is to discriminate between inactivating pathogens whilst tolerating colonization 
by commensal organisms. Calibrating this immune response to „commensal‟ 
microbes, however, is complex, as microbial virulence is often context dependent, 
being influenced by the homeostatic immune status of the host and the presence of 
co-inhabiting micro-organisms 520;521. Streptococcus pneumoniae, Streptococcus 
pyogenes, Staphylococcus aureus and Haemophilus influenzae commonly reside 
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asymptomatically in the nasopharyngeal cavity of healthy individuals 522;523, however 
despite growing understanding and identification of pathogen virulence factors that 
are responsible for colonization and invasive disease, the mechanisms behind how 
the host‟s immune response tolerates the presence of „commensal‟ microbes and 
how the status quo is altered that allows „commensal‟ pathogens to outgrow and 
cause disease remains to be elucidated. 
 
6.1.3 Proteomic analysis of airway anti-microbial proteins aims and hypothesis 
 
As discussed above, AMPs are abundant at the respiratory mucosal surface and play 
an essential role in antibacterial immunity and immune modulation. Epithelial cells 
and airway macrophages contribute to this diverse array of AMPs and some even 
suppress airway macrophage function. It therefore follows that any alteration of 
epithelia or macrophages will impact on the anti-microbial protein repertoire and 
subsequent control of secondary bacterial species. We therefore initiated a global 
screen of BAL specimens from naive and influenza infected mice to ask:  
  
1. Can qualitative alterations in antimicrobial peptide expression by identified 
using mass spectrometry to determine the proteomic landscape?  
2. Does influenza infection alter the repertoire of AMPs expressed in the airway 
mucosal surface? 
 
6.1.4 Characterisation of the commensal landscape in naive and influenza 
infected mice aims and hypothesis 
 
Many bacterial species cultured from patients with severe influenza induced 
pneumonia are present in the nasopharynx of healthy individuals, therefore 
suggesting influenza infection provides an opportunity for certain bacterial species to 
gain access to and colonise the lower respiratory tract 523. Though the precise 
composition of respiratory microbiota may alter between species, the innate 
pathways that limit their load and location, during health and disease, are likely to be 
conserved. Therefore, we wished to investigate two hypotheses; 
 
1. The level of innate immune cell responsiveness determines the composition 
of respiratory commensal flora during homeostasis.  
2. Infection with influenza virus alters the diversity of resident bacterial species 
in both the upper and lower respiratory tract.  
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To test these hypotheses we will determine the bacterial species present in the 
nasopharynx, distal airways and lungs of naive and influenza infected mice using 
denaturing gradient gel electrophoresis (DGGE) and 16S rRNA gene identification. 
We will also examine the role CD200R plays in influencing the commensal bacterial 
landscape during homeostasis and during an ongoing influenza virus infection.  
 
6.2 Results 
 
6.2.1 A secondary bacterial infection significantly reduces total airway protein 
compared to mice infected with influenza virus alone 
 
Before analysing the precise protein constituents of bronchoalveolar lavage fluid 
(BALF), we first investigated the total protein concentration found in the airways of 
mice infected with each pathogen independently and in combination (see section 
2.11.1 for method details). At day six of a single influenza infection there was more 
than six times the total protein present in the BALF compared to that of naive 
uninfected controls (Figure 6.1 a). However, the intranasal administration of Group B 
streptococcus (GBS) on day three of an influenza infection significantly reduced the 
amount of total protein present in the BALF 3 days after GBS infection compared to 
mice infected with influenza alone. GBS infection alone resulted in a small, yet 
significant, increase in the total protein constituent of BALF compared to naive 
controls. However, this was significantly less than that measured in mice infected 
with both influenza and GBS (Figure 6.1 a).   
 
After quantifying the differences in BALF total protein content in mice infected with 
both influenza and GBS compared to those infected with GBS alone, we next 
investigated the qualitative differences in individual protein constituents of each 
infection group. Total airway protein from each infection group was separated by 
molecular weight using gel electrophoresis (Figure 6.1 b) and after in-gel protein 
band trypsin digestion the resulting peptides were subjected to liquid chromatography 
and electrospray mass spectrometry (LC-ESI-MS/MS), as described in section 
2.11.3.  An example of how this technique can be used to determine the presence of 
a protein in a tissue sample is demonstrated in Figure 6.2 a & b. Utilising this mass 
spectrometry technique and subsequent downstream bio-informatic processing, 
Table 6.1 compares, between all infection groups, the total readout of proteins that  
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Figure 6.1 Influenza and GBS co-infection reduces total protein concentration in 
BALF. BALB/c mice (n=4) were infected intranasally (i.n.) with 50 HA HK/X31 influenza A 
virus (Flu) or PBS control. Three days after influenza infection mice were challenged i.n. 
with 5 x 106 cfu of Group B streptococcus (GBS) or PBS control. All mice were harvested 
3 days post GBS or PBS infection. BAL was performed on each mouse and subsequently 
pooled within each group. BAL supernatant was purified, by passage through a 0.2 µm 
sieve and centrifugation, to remove remaining cells and cell debris. Total protein 
concentration (a) was determined using Pierce BCA Protein assay kit. Equal volumes of 
BALF were prepared, as described in section 2.11, and loaded onto a 4-12% graded Bis-
Tris SDS Page gel (b). Resolved protein bands were stained with Coomassie Blue for 
visual inspection and proteomic analysis. Data are presented as the mean ± SEM of 4 
mice per group. Significance was determined by using Mann Whitney T test and Kruskal
Wallis ANOVA with Dunns multiple comparison post test . * = p<0.05  ** = p<0.01
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832.43
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1371.63
Figure 6.2 Mass spectra of an Apolipoprotein A1 peptide fragment and the coverage 
attained of the complete amino acid sequence. BALB/c mice (n=4) were infected 
intranasally (i.n.) with 50 HA HK/X31 influenza A virus or PBS control. Three days after 
influenza infection mice were challenged with 5 x 106 cfu GBS i.n or PBS control. All mice 
were harvested 3 days post GBS or PBS infection. Bronchoalveolar lavage (BAL) was 
performed on each mouse and subsequently pooled within each group. BAL supernatant 
was purified, by passage through a 0.2µm sieve and centrifugation, to remove cells and 
cell debris. Protein bands were subjected to in gel trypsin digestion. Peptides were 
subsequently analysed using liquid chromatography coupled to tandem electrospray mass 
spectrometry (LC-ESI-MS/MS). Spectra were recorded using a Q-Tof spectrometer 
interfaced to a Micromass CapLC capillary chromatograph. Proteins were subsequently 
identified by correlation of uninterpreted spectra to entries in SwissProt/TrEMBL, using 
ProteinLynx Global Server (further methodology can be found in section 2.11). Panels a & 
b illustrate a representative mass spectrum from Apolipoprotein A1 recovered from a 
pooled BAL sample and its corresponding alignment to the complete amino acid 
sequence respectively. 
a
Peptide sequence identified: VAPLGAELQESAR
10 20 30 40 50 60
MKAVVLAVAL VFLTGSQAWH VWQQDEPQSQ WDKVKDFANV  YVDAVKDSGR DYVSQFESSS 
70 80 90 100 110 120
LGQQLNLNLL ENWDTLGSTV  SQLQERLGPL TRDFWDNLEK ETDWVRQEMN KDLEEVKQKV
130 140 150 160 170 180
QPYLDEFQKK WKEDVELYRQ KVAPLGAELQ ESARQKLQEL QGRLSPVAEE FRDRMRTHVD
190 200 210 220 230 240
SLRTQLAPHS EQMRESLAQR LAELKSNPTL NEYHTRAKTH LKTLGEKARP ALEDLRHSLM 
250 260
PMLETLKTKA QSVIDKASET LTAQ 
SwissProt complete amino acid sequence for Apolipoprotein A1 (Mus musculus) 
b
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were considered significantly valid. A significant protein sequence was identified 
when two or more peptide sequences, from the same excised protein band, 
independently matched a predicted protein sequence, the peptide sequence score 
was greater than 55 (p<0.05) and that manual interpretation of the peptide spectra 
confirmed agreement between spectra and protein sequence. Visual inspection of 
the significant protein constituents of BALF highlighted a large abundance of high 
molecular weight (250-298 kDa) proteins produced in response to single influenza 
infected and co-infected mice (Table 6.1). Murinoglobulins (IgG and IgA), 
ceruloplasmin, transferrin, serine protease inhibitors, serum albumin and other 
plasma proteins were also abundantly represented in BALF from mice infected with 
influenza virus. Interestingly, vitamin D binding protein was only detected in mice co-
infected with influenza and GBS whilst being undetectable in mice infected with either 
influenza virus or GBS alone.   
 
Anti-microbial proteins that are involved in innate defence and immunomudulation range 
in size from 20 kDa to approximately 3 kDa, with the exception of 80 kDa lactoferrin 5. 
Comparison of significant proteins detected within this size range highlighted a number 
of differentially expressed proteins in mice previously infected with influenza and then 
infected with GBS compared to mice infected with GBS alone. Table 6.2 expands this 
interesting region to reveal several anti-bacterial proteins expressed in response to 
single GBS infection that are not present in mice infected with influenza and GBS. These 
proteins include: Chitinase 3 like protein, lysozyme C type M and surfactant protein B. 
Conversely, a large number of proteins of low molecular weight were only present in 
mice previously infected with influenza. These include several complement precursor 
components, anti oxidant proteins such as peroxiredoxin 2 and apolipoprotein A-1, a 
constituent of blood serum. The presence of lung carbonyl reductase (NADPH) was 
detected in both infection groups but not in the naïve uninfected group (Table 6.2). This 
preliminary screen has validated the use of this technique on BALF and demonstrates 
further detailed analysis and quantification is warranted.   
 
6.2.2 Influenza virus infection increases the nasopharyngeal commensal 
burden and allows bacteria access to the distal airways 
 
In recent years there has been an explosion of interest into the intestinal microbiota 
and its phylogenetic composition 524. Many interesting results have shed light on the 
mechanisms by which the immune system tolerates the presence of certain 
microorganisms and how the microorganisms themselves play a vital role in the  
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GBS alone Flu+ GBS
Both infections
Table 6.2 Unique anti-bacterial protein expression
Airway expression of anti-microbial proteins is altered by influenza virus infection. 
BALB/c mice (n=4) were infected intranasally (i.n.) with 50HA HK/X31 influenza A virus 
(Flu) or PBS control. Three days after influenza infection mice were challenged i.n. with 5 
x 106 cfu GBS or PBS control. All mice were harvested 3 days post GBS or PBS infection. 
Bronchoalveolar lavage (BAL) was performed on each mouse and subsequently pooled 
within each group. BAL supernatant was purified, by passage through a 0.2µm sieve and 
centrifugation, to remove cells and cell debris. Protein bands of interest were subjected to 
in gel trypsin digestion. Peptides were subsequently analysed using liquid 
chromatography coupled to tandem electrospray mass spectrometry (LC-ESI-MS/MS). 
Spectra were recorded using a Q-Tof spectrometer interfaced to a Micromass CapLC
capillary chromatograph. Proteins were subsequently identified by correlation of 
uninterpreted peptide spectra to entries in SwissProt/TrEMBL, using ProteinLynx Global 
Server (further methodology can be found in section 2.11). Table 6.2 identifies proteins 
uniquely expressed in each infection group. 
MW Entry Name Name Classification MW Entry Name Name Classification
64-50 ch3l1_Mouse Chitinase 3 like 
protein 1 (Precursor)
Remodelling & 
defense
64-50 VTDB_Mouse Vitamin D Binding Protein Serum Protein
64-50 A2HS_Mouse Alpha 2 HS Glycoprotein 
precursor  a.k.a Fetuin A 
Countertrypin
64-50 A2HS_Mouse Alpha 2 HS Glycoprotein 
precursor  a.k.a Fetuin A 
Countertrypin
50 Q80XP1_Mouse Compliment Component 3 Compliment
50 HPT_Mouse Haptoglobin (Precursor) Plasma Protein
50-36 HPT_Mouse Haptoglobin (Precursor) Plasma Protein
50-36 CO3_Mouse Compliment C3 
(Precursor)
Compliment
36 CBR2_Mouse Lung carbonyl 
reductase [NADPH]
36 CBR2_Mouse Lung carbonyl reductase 
[NADPH]
36 CO3_Mouse Compliment C3 
(Precursor)
Compliment
36-30 APOA1_Mouse Apolipoprotein A-1 
(Precursor)
Serum Protein
36-30 PRDX2_Mouse Peroxiredoxin 2 Anti Oxidant
16 Lyscm_Mouse Lysozyme C type M 
(Precursor)
Anti Bacterial 16 hbb2_Mouse Haemoglobin subunit beta 
2
Serum Protein
6-4 gi22296601 Surfactant Protein B
Single GBS infection only Single Flu infection only
Peptide/protein present in: 
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health and function of the intestinal tract 524. However, the precise mechanisms that 
determine which micro-organisms are allowed to colonise a mucosal surface and 
how the immune status and health of the host determines the specific diversity and 
density of the microbiota has received less attention. The upper respiratory tract 
(defined as proximal to the larynx), similar to the intestine, has a complex milieu of 
commensal microflora 525;526. In contrast, the lower respiratory tract (defined as distal 
from the larynx) is assumed to have no resident commensal flora, due to its vital 
physiological function of efficiently exchanging gases (Figure 6.3 a & b). We 
therefore investigated the total bacterial load present in the nasopharyngeal cavity 
and distal airways in naive mice and at specific time points after influenza virus 
infection. We observed that bacterial colonies can be cultured from the 
nasopharyngeal cavity of naïve mice but not from the distal airways (Figure 6.3 c & d 
day 0). Nevertheless, mice infected with influenza virus alone (note; no exogenous 
bacteria were administered) demonstrated a significant increase in total bacterial 
load present in the nasopharyngeal compartment between 2 and 6 days after 
influenza infection (Figure 6.3 c). The total bacterial load returned to naïve levels by 
day 14 post influenza infection. In contrast, despite there being no culturable bacteria 
in the airways of a naïve mice, bacteria were cultured from the distal airway 2 days 
post influenza and remained, in 50 % of the mice, until day 14 post influenza (Figure 
6.3 d).  
 
6.2.3 Qualitative comparison of tissue specific bacterial species in naïve wild 
type and CD200R KO mice 
 
Aerobic culture techniques, although quantitative, can not determine the presence of 
unculturable bacterial species, the dominant bacterial species present or the range of 
bacterial diversity within the tissue of interest. We therefore wanted to use a culture 
independent method that could provide a more comprehensive view of bacterial 
diversity and could be utilised to evaluate complex bacterial community dynamics, 
particularly during an ongoing influenza infection. Utilising primers to highly 
conserved regions of the 16S rRNA we amplified the intervening variable region and 
discriminated between closely related bacterial species. After demonstrating that the 
total bacterial load in both the nasopharyngeal and distal airway compartments is 
augmented during an influenza infection, we next identified the bacterial species 
present in these tissue compartments during homeostasis (naïve mice) and an 
ongoing influenza infection. We utilised two techniques, described in detail in section 
2.12, to illustrate the qualitative differences in bacterial species recovered from three  
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Figure 6.3 Influenza virus infection increases nasopharyngeal bacterial burden 
and results in the appearance of unidentified bacteria in the distal airways. Naïve 
C57BL/6 wild type mice (n=5) were infected intranasally (i.n) with 50 HA HK/X31 
influenza virus on day 0. On specified days post influenza infection bronchoalveolar
lavage (BAL) and nasal wash was preformed. Panels a & b highlight the sites of the 
upper and lower respiratory tract, respectively, that have or do not have permanent 
resident commensal flora. Total bacterial titres from the nasopharyngeal cavity (c) and 
airways (d) were calculated by serially diluting the respective samples and plated on 
non selective Columbia blood agar overnight at 37oC. Data are presented as the mean 
± SEM of 5 mice per group. p<0.05 was taken to be significant. * = p<0.05  ** = p<0.01
Panels a & b adapted from http://en.wikibooks.org/wiki/Human_Physiology/The_respiratory_system Dated 04/06/2009 
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distinct compartments of the respiratory tract. We also compared the differences in 
commensal diversity between wild type C57BL/6 (WT) and CD200R (KO) mice. The 
specificity of this technique was confirmed with the detection of S. pneumoniae in the 
lung tissue of mice 48 hours after S. pneumoniae infection (Figure 6.4 a). Using 
denaturing gradient gel electrophoreses (DGGE), our initial findings demonstrated 
the presence of multiple bacterial species (using a bacterial genus marker as a 
rudimentary guide) in both the distal airway and the lung tissue of naive WT and 
CD200R KO mice. By visually comparing the relative positions of the resulting cDNA 
bands on the denaturing gradient gel, which represent distinct groups of bacterial 
species, there was a clear distinction between both the WT and CD200R KO mice 
and between different respiratory tract locations (Figure 6.5 a-c). Despite variations 
between individual mice within each group, the reliability of the technique was 
validated by the presence of uniform bacterial bands observed in all individual mice 
within a specific group (see white boxes highlighting consistent bacterial DNA bands 
present across individual groups. Figure 6.5). Note that exogenous administration of 
S. pneumoniae in Figure 6.4 dramatically reduced the repertoire of commensal 
bacteria found in uninfected mice (Figure 6.5). This suggests a dominant bolus of 
bacteria can outgrow those already present.  
 
To investigate further the precise bacterial species present within each compartment, 
we cloned and subsequently sequenced the extracted and purified cDNA from a 
selection of individual mice (see section 2.12 for method details). We wanted to 
identify the bacterial species present in the naive distal airway of WT and CD200R 
KO mice before investigating whether bacterial diversity is altered during an influenza 
virus infection. Figure 6.6 demonstrates the presence of both Acinetobacter sp. and 
Prevotella sp. in the naive distal airways of both WT and CD200R KO mice. There 
are several other interesting bacterial species present in both the WT and CD200R 
KO distal airway, however Brevundimonas sp., Rhizobium sp., Stenotrophomonas 
sp., Moraxella sp. and Pseudomonas sp. were only identified in the airway of naive 
WT mice. On comparison of the bacterial landscape in the nasopharyngeal 
compartment, several species were present in both WT and CD200R KO mice, 
including Prevotella sp., Lachnospiraceae sp., Porphyromonadaceae sp. and 
Streptococcus sp. species (Figure 6.6 b). The presence of Staphylococcus sp. and 
Alphaproteobacteria sp. was unique to the nasopharyngeal compartment of CD200R 
KO mice. The results also highlighted a disparity of species present between the 
nasopharynx and the distal airways. Lachnospiraceae sp., Lactobacillus sp and 
Porphyromonadaceae sp. were found exclusively in the nasopharyngeal cavity of WT  
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Figure 6.4 Specific bacterial species can be identified ex vivo using culture 
independent 16S rRNA sequencing. Naïve C57BL/6 wild type (WT) and CD200R 
KO mice (n=4) were infected intranasally (i.n) with 50 HA HK/X31 influenza A virus. 
After three days, mice were challenged with 1 x 104 colony forming units S. 
pneumoniae. Mice were culled 48 hrs post S. pneumoniae infection and lung tissue (a) 
was removed. Total RNA was purified from each tissue sample and 16S rRNA was 
amplified using a nested PCR approach. 10 µl of 16S rRNA product was then loaded 
onto a 30-60% denaturant DGGE gel and run at 100 v for 16 hours. A more in depth 
description of the protocol used can be found in section 2.12. A bacterial genus marker 
was used to allow comparison of band migration between gels and to quickly identify 
the presence of specific bacterial species (see table).  i = Streptococcus pneumoniae
WT KO
a Lung
i
1 Bacteroidales sp 6 Prevotella sp. & S. pneumoniae
2 Staphylococcus sp 7 Prevotella sp
3 Megaspaera sp 8 Neisseria sp
4 Porphyromonas sp 9 Veillonella dispar
5 Porphyromonas sp 10 Veillonella sp.
Bacterial genus marker (GM)   
1/2
3
4
5
6
7
8
9
10
GM
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1/2
3
4
5
6
7
8
9
10
WT KO WT KO WT KO
a b c
GM GM GM GM GM
Naive nasopharynx Naive distal airway Naive lung 
1 Bacteroidales sp 6 Prevotella sp. & S. pneumoniae
2 Staphylococcus sp 7 Prevotella sp
3 Megaspaera sp 8 Neisseria sp
4 Porphyromonas sp 9 Veillonella dispar
5 Porphyromonas sp 10 Veillonella sp.
Figure 6.5 Qualitative comparison of tissue specific bacterial species present in 
naïve wild type C57BL/6 and CD200R KO mice. Naïve wild type (WT) and CD200R KO 
(KO) mice (n=4) were culled and nasal wash (a), BAL (b) and lung tissue (c) were 
removed. Total RNA was purified from each tissue sample and 16S rRNA was amplified 
using a nested PCR approach. 10 µl of 16S rRNA product were then loaded onto a 30-
60% denaturant DGGE gel and run at 100 v for 16 hours. A more in depth description of 
the protocol used can be found in section 2.12. A bacterial genus marker was utilised to 
allow comparison of band migration between gels and to quickly identify the presence of 
specific bacterial species (see table). White boxes highlight uniform bacterial bands 
observed within individual groups of mice. 
Bacterial genus marker (GM)   
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Figure 6.6 Qualitative comparison of tissue specific bacterial species in naïve wild 
type C57BL/6 and CD200R KO mice. BAL (a) and nasal wash (b) was performed on 
naïve wild type (WT) and CD200R (KO) mice (n=4). Total RNA was purified from each 
tissue sample and 16S rRNA was amplified using a nested PCR approach. Individual 16S 
rRNA products were subsequently cloned using a pGEM-T easy vector into Escherichia 
coli. Resulting colonies were sequenced and subsequently designated as belonging to a 
particular bacterial species. A more in depth description of the protocol used can be found 
in section 2.12. The axis in panel a and the frequency in panel b represents the n number 
of individual 16S rRNA sequences of a given bacterial species isolated from a selected
mouse within each group.  
a Naïve distal airway
WT KO
Species n number n number
Alphaproteobacteria sp. 0 1
Bacteroidales. Sp 3 0
Bradyrhizobium sp 1 0
Lachnospiraceae sp. 12 3
Lactobacillus sp. 2 1
Mesorhizobium sp 1 0
Microbacteriaceae  sp 1 0
Porphyromonadaceae sp 9 7
Prevotella sp. 1 2
Rhodobacteraceae sp. 0 1
Staphylococcus sp. 0 6
Streptococcus sp. 1 10
Uncultured cyanobacterium sp. 1 0
Unknown bacteria 1 0
b
Present in both WT & KO Present in WT only Present in KO only
Naïve nasopharynx
WT KO 
0
2
4
6
8
Acinetobacter sp. 
Allobaculum sp. 
Bacteroides acidifaciens
Brevundimonas sp. 
Citrobacter sp.
Enterobacteriaceae sp.
Flavobacterium sp.
Lachnospiraceae sp.
Lactobacillus sp.
Moraxella sp. 
Papillibacter sp. 
Paracoccus sp. 
Porphyromonadaceae sp.
Prevotella sp.
Propionibacterium sp. 
Pseudomonas sp.
Rhizobium sp.
Stenotrophomonas maltophilia
Unknown bacteria
Variovorax sp. 
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mice, whilst they were present in both the nasopharyngeal cavity and airway of 
CD200R KO mice.  
 
6.2.4 Influenza virus infection qualitatively alters the commensal landscape  
 
After identifying the bacterial species present in the nasopharyngeal cavity and distal 
airways of naive WT and CD200R KO mice, we next wanted to ascertain whether an 
influenza virus infection alters the diversity of bacterial species present in each of 
these compartments. As was seen in the distal airway of naive mice, Acinetobacter 
Sp. was also detected in the airway at day 7 of an influenza infection in both WT and 
CD200R KO mice (orange box ii Figure 6.7 b and 6.8 a). Both Moraxella sp. and 
Prevotella sp., which were detected in the naive airway, remained in the airway at 
day 7 of an influenza virus infection in WT mice. These species were not detected in 
the airway of CD200R KO mice during an influenza infection, Moraxella was also 
absent from the airways of naive CD200R KO mice (Figure 6.6 a). Nevertheless, 
Staphylococcus sp. were detected in the airway of both WT and CD200R KO mice 
during an influenza infection despite being absent from the naive airways of both 
mice strains (orange box i Figure 6.7 b and 6.8 a). Staphylococcus sp. were also 
detected in the nasopharynx of naive CD200R KO mice (Figure 6.6 b). We also 
observed the emergence of Streptococcus sp. and Haemophilus parahaemolyticus in 
the airway of WT mice infected with influenza virus (Figure 6.8 a). These bacterial 
species were absent from the airways of naive WT mice (Figure 6.6 a). Interestingly 
these species were not detected in the airways of CD200R KO mice either during 
naive homeostasis or at day 7 of and influenza infection (Figure 6.6 a & 6.8 a). 
Despite this, the appearance of Proteus mirablis in the airway of CD200R KO mice 
was detected during an ongoing influenza virus infection (Figure 6.8 a & b). Due to 
time constraints the precise elucidation of bacterial species in the nasopharyngeal 
cavity of mice infected with influenza was not analysed, however DGGE analysis 
highlighted an alteration in the diversity of bacterial commensal composition as seen 
in the distal airway in both WT (Figure 6.9 a) and CD200R KO (Figure 6.10 a) mice. 
Furthermore, it is interesting to note that the number of unique bacterial species 
present in the distal airways during homeostasis (n=20) was greater than the number 
present during an ongoing influenza infection (n=17). This was also apparent in the 
nasopharyngeal cavity upon visual inspection of the DGGE gels (Figures 6.9 & 6.10).  
 
Utilising the sequence data generated a phylogenetic tree was constructed, as 
described in section 2.12, to highlight the prevalence of specific bacterial species  
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1/2
3
4
5
6
7
8
9
10
WT
GM GM GM GM
KO WT KO
GM
a b
Bacterial genus marker   
Flu nasopharynx Flu distal airway
ii
i
1 Bacteroidales sp 6 Prevotella sp. & S. pneumoniae
2 Staphylococcus sp 7 Prevotella sp
3 Megaspaera sp 8 Neisseria sp
4 Porphyromonas sp 9 Veillonella dispar
5 Porphyromonas sp 10 Veillonella sp.
Figure 6.7 Qualitative comparison of nasopharyngeal and airway bacterial flora 
during an influenza infection in wild type C57BL/6 and CD200R KO mice. Wild type 
(WT) and CD200R (KO) mice (n=4) were infected intranasally (i.n) with 50 HA HK/X31 
influenza A virus on day 0. 7 days later nasal wash (a) and BAL (b) was performed and 
subsequently used to identify bacterial specie presence. Total RNA was purified from 
each tissue sample and 16S rRNA was amplified using a nested PCR approach. 10 µl of 
16s rRNA product was then loaded onto a 30-60% denaturant DGGE gel and run at 100 v 
for 16 hours. A more in depth description of the protocol used can be found in section 
2.12. A bacterial genus marker was used to allow comparison of band migration between 
gels and to quickly identify the presence of specified bacterial species (see table). i = 
Staphylococcus sp. and ii = Acinetobacter sp. 
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Figure 6.8 Qualitative comparison of airway bacterial flora during an influenza 
infection in wild type C57BL/6 and CD200R KO mice. BAL (a & b) was performed on 
wild type (WT) and CD200R (KO) mice (n=4) infected with 50HA HK/X31 influenza A virus 
7 days previously. Total RNA was purified from each tissue sample and 16S rRNA was 
amplified using a nested PCR approach. Individual 16S rRNA products were subsequently 
cloned using a pGEM-T easy vector into Escherichia coli. Resulting colonies were 
sequenced and subsequently designated as belonging to a particular bacterial species. A 
more in depth description of the protocol used can be found in section 2.12. The axis in 
panel a and the frequency in panel b represents the n number of individual 16S rRNA
sequences of a given bacterial species isolated from a selected mouse within each group. 
a
WT KO
Species n number n number
Acinetobacter sp. 24 22
Corynebacterium tuberculostearicum 0 1
Devosia sp. 2 0
Enterobacteriaceae sp. 0 1
Haemophilus parahaemolyticus 3 0
Jonquetella anthropi 7 0
Methylobacterium sp. 1 0
Moraxella sp. 6 0
Mycobacterium sp. 1 0
Nocardioidaceae sp. 0 1
Peptostreptococcus sp. 7 0
Prevotella sp. 7 0
Proteus mirabilis 0 29
Rhizobium sp. 4 0
Staphylococcus sp. 15 6
Streptococcus sp. 3 0
Uncultured Alistipes sp. 1 0
0
10
20
30
Acinetobacter sp. 
Corynebacterium tuberculostearicum
Devosia sp. 
Enterobacteriaceae sp.
Haemophilus parahaemolyticus
Jonquetella anthropi
Methylobacterium sp. 
Moraxella sp. 
Mycobacterium sp. Nocardioidaceae sp.
Peptostreptococcus sp. 
Prevotella sp. 
Proteus mirabilis 
Rhizobium sp. 
Staphylococcus sp. 
Streptococcus sp. 
Uncultured Alistipes sp. 
Day 7 Flu distal airway
b
Present in both WT & KO Present WT only Present in KO only
WT KO 
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present at a specified anatomical location during homeostasis and during an 
influenza infection (Figure 6.11). The tree demonstrates more clearly the reduction in 
bacterial diversity observed in the distal airway and nasopharyngeal cavity during an 
ongoing influenza infection in both WT and CD200R KO mice. It also clearly 
highlights the bacterial species that become dominant (dark blue and black squares) 
during an ongoing influenza infection, namely Staphylococcal sp., Acinetobacter 
lwoffi, Proteus mirabilis and Streptococcus sp. Interestingly, a bronchiole brush 
sample from a patient suffering from chronic obstructive pulmonary disease (COPD) 
also highlighted the presence and dominance of Streptococcus sp. and 
Acinetobacter sp (lane 7 Figure 6.11).  
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1 Bacteroidales sp 6 Prevotella sp. & S. pneumoniae
2 Staphylococcus sp 7 Prevotella sp
3 Megaspaera sp 8 Neisseria sp
4 Porphyromonas sp 9 Veillonella dispar
5 Porphyromonas sp 10 Veillonella sp.
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Bacterial genus marker   
GM
Figure 6.9 Influenza virus infection qualitatively alters the bacterial landscape in 
both nasopharyngeal and airway compartments in WT C57BL/6 mice. Wild type (WT) 
mice (n=4) were infected intranasally (i.n) with either 50HA HK/X31 influenza A virus or 
PBS on day 0. 7 days later nasal wash (a) and BAL (b) was performed and subsequently 
used to identify bacterial specie presence. Total RNA was purified from each tissue 
sample and 16S rRNA was amplified using a nested PCR approach. 10 µl of 16S rRNA
product were then loaded onto a 20-80% denaturant DGGE gel and run at 100 v for 16 
hours. A more in depth description of the protocol used can be found in section 2.12. A 
bacterial genus marker was used to allow comparison of band migration between gels and 
to quickly identify the presence of specified bacterial species (see table). 
Nasopharynx Distal airway
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1 Bacteroidales sp 6 Prevotella sp. & S. pneumoniae
2 Staphylococcus sp 7 Prevotella sp
3 Megaspaera sp 8 Neisseria sp
4 Porphyromonas sp 9 Veillonella dispar
5 Porphyromonas sp 10 Veillonella sp.
Figure 6.10 Influenza virus infection qualitatively alters the bacterial landscape in 
both nasopharyngeal and airway compartments in CD200R KO mice. CD200R KO 
mice (n=4) were infected intranasally (i.n) with either 50HA HK/X31 influenza A virus or 
PBS on day 0. 7 days later nasal wash (a) and BAL (b) was performed and subsequently 
used to identify bacterial species presence. Total RNA was purified from each tissue 
sample and 16S rRNA was amplified using a nested PCR approach. 10 µl of 16S rRNA
product were then loaded onto a 30-60% denaturant DGGE gel and run at 100 v for 16 
hours. A more in depth description of the protocol used can be found in section 2.12. A 
bacterial genus marker was used to allow comparison of band migration between gels and 
to quickly identify the presence of specified bacterial species (see table). 
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Figure 6.11 Phylogenetic analysis of bacterial 16S rRNA detected during 
homeostasis and peak influenza infection. Bronchoalveolar lavage and nasal wash 
was taken from naive and influenza infected (day 7) wild type (WT) C57BL/6 and CD200R 
KO (KO) mice (n=4). Total RNA was purified from each tissue sample and 16S rRNA was 
amplified using a nested PCR approach. Individual 16S rRNA products were subsequently 
cloned using a pGEM-T easy vector into E. coli. Resulting colonies were sequenced and 
subsequently designated as belonging to a particular bacterial species. A more in depth 
description of the protocol used can be found in section 2.12. Colour represents the 
prevalence of a specific species within each sample. 
1 = Naive WT airway
2 = Flu WT airway Exp.1
3 = Flu WT airway Exp.2
7 = Human COPD sample
8 = Naive WT nasal wash
9 = Naive KO nasal wash
4 = Naive KO airway
5 = Flu KO airway Exp.1
6 = Flu KO airway Exp.2 
Lane legend
0.1 – 5 % 5 – 15 % 15 – 25 % > 25 %     of total sequences
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6.3 Discussion 
 
6.3.1 A reduction in total protein concentration in the airway of co-infected 
mice 
 
In this study we utilised an innovative proteomic screening platform to investigate the 
protein composition of BALF from BALB/c mice infected with either influenza or GBS 
alone or in combination. We demonstrated that the amount of total protein detected 3 
days after a GBS infection was marginally higher than that detected in a naive 
airway, whilst the total protein concentration 6 days after an influenza virus infection 
was six times greater than that detected during homeostasis. Furthermore, 
administration of GBS three days after an influenza infection significantly reduced the 
concentration of total protein compared to the level detected in response to a single 
influenza infection. We also showed preliminary evidence that suggests a prior 
influenza infection alters the expression of several anti-bacterial proteins that are 
produced in response to a GBS infection.  
 
The large disparity observed in airway protein concentration most likely reflects the 
inflammatory nature of the respective infectious agents or the presence of pathogen 
associated virulence factors that limit immune responses and inflammation. Total 
airway protein concentration is commonly used as a surrogate for respiratory 
epithelial damage and airway inflammation 527. Influenza virus is cytopathic in nature 
and principally infects respiratory epithelial cells resulting in the secretion of a 
plethora of inflammatory mediators and other proteins that, in turn, recruit additional 
leukocytes to the site of infection 195. Upon arrival, these recruited leukocytes add to 
the milieu of secreted proteins by releasing further inflammatory mediators and 
effector proteins 195;202-204. A recent study highlights tumour necrosis factor-related 
apoptosis inducing ligand (TRAIL), produced by infiltrating monocytes, as a key 
mechanism involved in alveolar leakage and mortality in a murine influenza infection 
model 417. These mechanisms, in combination with virus induced epithelial cell 
necrosis, likely explain the enhanced total protein concentration observed in the 
airway during an influenza virus infection. In contrast, we have previously 
demonstrated that a non lethal dose of GBS elicits a transient neutrophil and 
macrophage cellular response that results in the elimination of bacteria from the 
airway and lungs by day seven post infection (see results Chapter 3.0). Despite the 
presence of cytolytic GBS virulence factors, the presence of additional virulence 
factors, such as the C5a peptidase, that cleaves the chemotactic complement 
component C5a, inhibits innate immune responses and impairs leukocyte recruitment 
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to the site of infection 217;219;221-223. GBS also expresses β-haemolysin/cytolysin 
(βH/C), a toxin that is co-expressed with an orange-red carotenoid pigment on the 
bacterial cell surface 220. This pigment contains potent antioxidant properties, which 
confers protection against antimicrobial effects of hydrogen peroxide, singlet oxygen 
and superoxide 221. Could the expression of this antioxidant pigment scavenge 
reactive oxygen and nitrogen species produced by infiltrating leukocytes that could in 
turn reduce the collateral damage caused by ROS commonly attributed to influenza 
infection? Recent evidence highlights the damaging effects of ROS produced in 
response to influenza infection. The administration of a superoxide dismutase 
mimetic significantly reduces influenza associated pathology and peak viral load 528. 
Taken together, the presence of immune suppressive virulence factors, produced by 
GBS, might explain the reduction in total protein concentration measured in the 
airway of mice co-infected with influenza and GBS.  
 
An alternative explanation for the reduction in total airway protein observed in co-
infected mice could involve GBS administration enhancing the quality of the immune 
response elicited or even increasing the rate at which influenza induced inflammation 
is resolved. In Chapter 4, we demonstrate that administration of GBS on day three of 
an influenza infection results in a significant reduction in viral titre compared to mice 
infected with influenza alone. Amelioration of influenza induced pathology and 
vascular permeability is also observed during co-infection with Trichinella spiralis, a 
parasitic worm 529. It is plausible that GBS may therefore actually prove to be 
beneficial in controlling viral replication. However, there exists substantial evidence 
that bacterial co-infection results in enhanced inflammation and pathology in 
response to influenza virus infection. Bacterial proteases have been shown to 
enhance influenza viral load by increasing the rate of HA0 to HA1 cleavage that 
results in enhanced viral infectivity 530-532. Furthermore, neuraminidase, present on 
the surface of influenza virus, increases adherence of S. pneumoniae to tracheal 
epithelial in an organ perfusion model 296. There are likely to be many interconnected 
factors that contribute to reducing the amount of protein present in the airway in co-
infected mice. This is a puzzling result that may provide interesting evidence for 
unknown in vivo pathogen-pathogen interactions that contribute to disease pathology 
and progression.  
 
6.3.2 Influenza virus infection alters anti microbial protein (AMP) expression 
Despite the intriguing observation that the administration of GBS reduced total airway 
protein levels in response to an influenza infection, our original question was to 
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investigate whether damage to respiratory epithelium, caused by influenza virus 
infection, resulted in a reduction in AMPs expression. Our preliminary findings 
illustrate that surfactant protein B, lysozyme C type M and chitinase 3 like protein 1 
were expressed in the airway three days after a GBS infection. However, in mice that 
were previously infected with influenza virus they were not. Again, these findings 
could have many possible explanations, however, before speculating it is imperative 
to consider the limitations and potential caveats of analysing proteomic data 
producing using mass spectrometry. All existing proteomic interrogation techniques 
contain several inherent weaknesses that mainly arise due to the complexity of the 
proteome. The major considerations surround the huge dynamic range of the 
proteins under interrogation and the contamination of tissue samples by highly 
abundant serum proteins. The latter problem is of particular significance when 
looking for very low abundant proteins such as AMPs. There are also many 
limitations in the peptide sequencing methodological itself that must be considered, 
such as which algorithm or combination of algorithms to use when searching public 
protein databanks, the level of statistical stringency applied and the quality of expert 
interpretation of the resulting data set. Nevertheless, these problems exist when 
analysing any data produced using these techniques and despite ones caution in 
interpreting these preliminary data the results remain intriguing. An additional caveat 
present in this study was the different amounts of protein loaded into the gel 
electrophoresis, therefore potentially introducing quantitative errors into the 
interpretation of our data.  
 
Our findings are similar to that observed by another study that utilised HPLC and 
mass spectrometry to investigate AMPs expression in response to UV killed 
nontypeable H. influenzae (NTHi) 533. They show that lysozyme, surfactant protein D 
and chitinase 3-like protein 1 expression in response to UV killed NTHi protects mice 
against a lethal S. pneumoniae infection. Existing evidence implicates both surfactant 
protein B and lysozyme C type M in having direct anti-bacterial and 
immunomodulatory effector function against both GBS and S. pneumoniae in in vivo 
infectious models 5;534-537. Despite the lack of a comprehensive proteomic analysis of 
AMP expression during an influenza virus infection, there is evidence highlighting 
that beta defensins and surfactant protein D expression are altered 538. We do not 
provide any potential mechanism for the observed reduction in surfactant protein B, 
lysozyme C type M and chitinase 3 like protein 1 in our study, however, potential 
explanations could involve the apoptosis and necrosis of the cells involved in 
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producing AMPs or local inhibition by IFN produced in response to influenza virus 
infection interfering with AMP transcription and translation.    
 
Although we postulate the absence of specific AMPs in influenza infected mice could 
explain the increase in susceptibility to bacterial infection, we cannot rule out the 
contribution of immunomodulatory proteins produced in response to influenza virus 
infection that are absent from the airway in a single GBS infection. Several proteins 
were observed in the co-infected mice that were absent from mice infected with GBS 
alone. These include vitamin D binding protein, several complement precursor 
components, peroxiredoxin 2 and apolipoprotein A1 (Apo-A1). Apo-A1 is the major 
constituent of high density lipoprotein (HDL) and binds to LPS in vivo and reduces 
acute lung injury and sepsis in mice treated with LPS and LTA 539;540. Indeed Apo-A1 
increases inflammatory cytokine production and cellular apoptosis during influenza 
infection in one study but others suggest Apo-A1 suppresses inflammation and 
inhibits the production of inflammatory cytokines from influenza infected type II 
pneumocytes 24;541. Thus increased apoptosis of professional phagocytes and 
reduced inflammatory cytokine production by Apo-A1 may be required to resolve 
influenza induced inflammation but enhance susceptibility to subsequent bacterial 
infection. A suppressive role for Apo-A1 is supported by mimetic peptides that protect 
against atherosclerosis, asthma, diabetes and renal inflammation in vivo 542;543.  
 
This proteomic screen produced preliminary data that sought to identify potential 
AMPs and/or immune modulatory proteins that are differentially expressed in the 
airways of mice infected with bacteria alone or bacteria following an influenza 
infection. The investigation produced many intriguing results that warrant further 
investigation and validation. Exploration of the expressed proteome of an influenza 
infected lung is an extremely novel and topical subject. To our knowledge this is the 
first attempt at analysing and comparing the proteomic signature of an influenza 
infected airway to that of a bacteria infected airway.  
 
6.3.3 The commensal microbiota of the respiratory tract during homeostasis 
 
Using traditional microbiological techniques we show that bacteria can be cultured 
from the nasopharynx of naive mice but not from the distal airway and lung tissue. 
However, upon infection with influenza virus, culturable bacteria appear in the distal 
airways and the number of bacteria present in the nasopharynx increases 
significantly. Furthermore, the use of a more sensitive detection technique highlights 
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the existence of a diverse assortment of bacteria present in the lung, distal airway 
and nasopharynx of naive mice and that the composition of this flora differs between 
different anatomical sites of the respiratory tract and under different homeostatic 
conditions. It is commonplace that the upper respiratory tract, including the 
nasopharynx, contains a complex commensal population and increasing evidence 
indicates the existence of intricate host-microbe and inter microbial interactions 521;544. 
In contrast, little is known about the presence of „commensal‟ bacteria in the lower 
respiratory tract as until recently it was assumed to be sterile and contain no resident 
microflora. Nevertheless, inhaled air is not sterile and microbe bearing secretions 
from the upper respiratory tract can aspirate into the lower airways. Thus the lower 
respiratory tract faces the same challenges confronted by other mucosal surfaces, 
balancing inflammatory responses to levels that prevent microbial invasion without 
compromising vital organ function.   
 
As with the proteomic profiling of innate anti-bacterial proteins discussed above, this 
study contains preliminary data that does not allow sufficient statistical interrogation, 
therefore appropriate consideration is needed when interpreting and discussing the 
results. The approach used in this study also contains several limitations such as the 
risk of generating artefacts from contaminating environmental bacterial when using 
samples with very low bacterial DNA content, as is the case when using murine 
tissue samples. We also only selected one representative mouse from each specified 
infection group to determine the specific bacterial species present. However, taking 
these limitations into consideration, there are several intriguing findings of which the 
most salient will be discussed here.  
 
There are obvious anatomical and physiological features of the respiratory tract that 
may give particular bacterial species a growth advantage, such as airflow pressure, 
temperature and oxygen gradient, the presence of respiratory cilia and the existence 
of competing microflora. However, we have shown that status of innate immunity also 
plays an important role. We found similarities between WT and CD200R KO mice, 
such as the presence of both Acinetobacter sp and Prevotella sp in the naive airway, 
and differences, such as the  presence of Staphylococcus sp. in the nasopharynx of 
CD200R KO mice whilst being absent in WT mice. These findings are consistent with 
human studies, in that Acinetobacter sp. are commonly found in the nasopharyngeal 
cavity of healthy individuals but are implicated in a variety of diseases including 
pneumonia and serious blood infections 545. Interestingly, we also observed an 
apparent increase in the prevalence of Acinetobacter sp, amongst others, in the 
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airway of both WT and CD200R KO mice during an ongoing influenza infection. The 
disparity in commensal diversity between WT and CD200R KO mice in homeostasis 
suggests that CD200R bearing cells such as macrophages may be required to limit 
nasal commensals in homeostasis. In this way, innate immunity trims the density of 
commensals most likely via receptors that detect and phagocytose specific bacteria 
and that these may be enhanced in CD200R KO mice.  A recent paper highlights 
TREM2 as an important receptor for bacterial phagocytosis 546. Is this, or are 
receptors involved in phagocytosis, differently expressed in WT and CD200R KO 
mice? Neutrophil NADPH oxidase plays a crucial role in the defence against 
Acinetobacter baumannii infection 547. It is likely that these are altered in CD200R KO 
cells. TLR expression may also be adjusted and more ready to respond. This 
suggests that the readiness of innate immune inflammation may dictate the 
composition of bacterial flora and even mediate competitive interactions between 
competing commensal species. This is highlighted by Lysenko et al that show that 
neutrophil recruitment and activation may underlie the H. influenza induced clearance 
of S. pneumoniae 548.  
 
6.3.4 Influenza virus infection alters the composition of commensal bacteria in 
the distal airways and nasopharynx 
 
Perhaps the most significant finding in this preliminary investigation is that, despite 
an increase in total bacteria in the distal airway and nasopharynx during an influenza 
virus infection, the diversity of the species of bacteria detected is not only reduced 
but largely consists of bacteria that are implicated in respiratory disease. The 
appearance of Staphylococcus, Streptococcus and Haemophilus species in the distal 
airway of wild type mice infected with influenza virus is striking. We also observe the 
appearance of Proteus mirabilis in the distal airway of KO mice in response to 
influenza virus infection. These findings are consistent with a large body of evidence 
investigating the presence and composition of bacterial flora in the lungs of cystic 
fibrosis (CF) and COPD patients 549-551. These patients have altered airway 
physiology and likely altered inflammatory homeostasis, which may be responsible 
for the increased colonisation of respiratory opportunistic pathogens such as P. 
aeruginosa, S. pneumoniae and S. aureus. A recent study investigating the bacterial 
diversity in endotracheal aspirates from intubated patients colonised with P. 
aeruginosa shows that bacterial diversity decreases following the administration of 
antibiotics, but surprisingly, results in P. aeruginosa dominating the community of 
bacteria that remain 552. This occurred despite P. aeruginosa demonstrating 
sensitivity to the antibiotics used in vitro. The loss of bacterial diversity may therefore 
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contribute to pathogen selection and persistence. It was previously assumed that an 
increase in the diversity of bacterial species would enhance virulence of individual  
species 553. However, mounting evidence now suggests that in polymicrobial 
infections, less-virulent strains are often favoured; suggesting that increased diversity 
may in fact reduce virulence 554. These observations beg the question of how and 
why do certain bacterial species gain access to the distal airways during respiratory 
viral infections or during times of „altered‟ homeostatic states and what causes the 
loss of bacterial diversity? Other than those reasons discussed in Chapters 4 and 5 
for why bacteria may gain access to the airway during influenza infection, one 
potential explanation through which a reduction in bacterial diversity might lead to 
increased dominance of specific pathogenic species is quorum  sensing. The altered 
airway microenvironment caused by influenza infection may result in altering gene 
expression of bacteria such as Staphylococcus sp., H. influenzae and Streptococcus 
sp., normally found in the nasopharyngeal cavity. This may result in the production of 
virulence factors that can interfere or even kill surrounding bacterial species therefore 
allowing these bacteria to outgrow and resist immune effector functions.  
 
Another explanation to why specific bacterial species appear to dominate during 
times of altered homeostasis could be related to their ability to survive during times of 
enhanced inflammation. As discussed previously, influenza infection provokes an 
inflammatory response consisting of many antimicrobial mediators such as 
interferons, TNF-α and ROS. It is known that the expression of catalase by S. aureus 
contributes significantly to the survival of this pathogen in environments high in 
oxidative stress and allows it to survive in the presence of other pathogenic bacteria 
such as S. pneumoniae 555;556. Other explanations for the observed alteration of 
bacterial communities associated with CF and Crohns sufferers involves alterations 
in mucin glycosylations that allow certain bacterial species to dominate over another 
557;558. This may also occur during an ongoing influenza infection?   
 
6.4 Conclusion 
 
These preliminary studies highlight the immense complexity of how one respiratory 
infection can affect the host‟s immunity to a subsequent infection. It also highlights 
the importance of recognizing and understanding the complex bacterial community 
that exists within the respiratory tract and how infection and/or therapeutic 
intervention can have untold consequences to its dynamic composition. Further 
studies investigating the contribution of bacterial dynamics to the pathogenicity in 
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health and disease will lead to more targeted use of existing antimicrobial therapies 
and the development of much needed novel therapeutics.    
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Chapter 7 
 
 
7.0 General Discussion  
 
Influenza A virus causes significant and well publicised morbidity and mortality as a 
single infection. However, in combination with a secondary bacterial super infection, 
a common complication following influenza infection, the resulting prognosis is worse 
and can result in hospitalisation or death. Despite extensive clinical and 
epidemiological evidence, the precise immunological mechanism(s) responsible for 
increasing susceptibility to secondary bacterial infections remain to be fully 
elucidated. In this thesis we developed a robust in vivo experimental model to 
investigate host innate immunity against respiratory bacterial pathogens and how a 
preceding influenza viral infection might modify this. We revealed two novel 
mechanisms explaining how a preceding influenza viral infection influences innate 
immunity resulting in a period of increased susceptibility to bacterial pathogens. Our 
data show that a previous viral infection desensitises the airway in its ability to detect 
and respond to bacterial ligands. Furthermore, in an attempt to resolve viral 
associated inflammation the airway inadvertently over regulates, by enhancing an 
innate immune negative regulator, CD200R, resulting in a transient state of immune 
hypo-responsiveness. Removal of this single receptor limits bacterial burden in the 
airway and lung and completely prevents bacterial dissemination and bacteraemia. 
Finally, we provide preliminary data that suggests antimicrobial peptide expression is 
altered during an influenza infection and that innate immune status can influence the 
bacterial commensal community of the upper respiratory tract.  
 
There are many concepts arising from this thesis that merit further consideration, but 
for brevity I will concentrate on the following topics for further discussion: 
 
1. Macrophage homeostasis and infection history determine airway responsiveness. 
2. A chronology of mechanisms enhance susceptibility to secondary bacterial 
pneumonias. 
3. The contribution from commensal bacteria in inflammatory lung disease. 
4. Antibiotic usage in inflammatory lung disease – a clinical case. 
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7.1 Macrophage homeostasis and infection history determines airway 
responsiveness  
 
Our data show that host genetic factors influence resistance and responsiveness to 
both respiratory bacterial and viral infections. We show that BALB/c (H2d) mice 
consistently elicit an enhanced innate cellular response to all model pathogens used 
in this thesis (GBS, S. pneumoniae and influenza virus) and demonstrate increased 
resistance to respiratory bacterial infections compared to C57BL/6 (H2b) mice. 
However, despite these differences in the vigour of immunity during a single bacterial 
infection, the outcome with regards to bacterial load, phenotype of cells recruited and 
final endpoint, i.e. lethal bacteraemia, is consistent across the two mouse strains in a 
secondary bacterial infection model. This suggests that an environmental insult, such 
as a viral infection, can override pre-existing genetic resistance, thereby influencing 
the immune responsiveness of the host. For the purposes of this discussion innate 
immune responsiveness is defined as the ability of tissue specific macrophages to 
detect and respond to a bacterial pathogen. How a preceding environmental insult or 
viral infection achieves this remains unknown, however we discuss a number of 
concepts herein that attempt to provide insight into these underlying mechanisms. 
 
7.1.1 Tissue specific regulation establishes macrophage responsiveness 
 
The threshold above which a threat is perceived by innate immune cells is 
established through a dynamic interaction that exists between host genetic 
determinants and the local microenvironment. At sites of high antigenic burden, such 
as mucosal surfaces, resident innate immune cells require an additional degree of 
„tolerance‟ compared to cells that inhabit less environmentally exposed sites of the 
body. We have previously demonstrated and discussed in Chapters 4 & 5 several 
mechanisms that actively regulate the „threshold of activation‟ of innate immune cells 
resident in the airway during homeostasis 446;458. We now suggest that the threshold 
of innate responsiveness can be determined by past inflammatory experiences thus 
explaining why some individuals, such as asthmatics, respond inappropriately to 
environmental allergens; in this case the „threshold of activation‟ is set too low 
resulting in unwarranted inflammation. On the other hand a high „threshold of 
activation‟ can be equally damaging as we show in this thesis for lung bacterial 
secondary infections during the resolution of a respiratory viral infection. One can 
imagine a scenario in which macrophages, resident in the upper and lower 
respiratory tract, play an important role in limiting commensal microbial burden, even 
in the absence of exogenous infection. If the threshold for activation is set or driven 
too high then commensal or environmental micro-organisms could potentially be 
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„ignored‟ and subsequently given the opportunity to invade host tissue compartments. 
The concept of commensal opportunism is discussed in greater detail later in this 
discussion.  
 
This high threshold found at mucosal surfaces, or following influenza virus infection, 
may occur spontaneously, through as yet unidentified polymorphisms in either 
CD200R or its ligand CD200, or as a consequence of an attempt to return the lung to 
its pre-infection state. The belief that inflammation recedes once the antigen is 
eliminated is, to some extent, redundant. Instead resolution is an active process and 
involves analogous pathways that limited innate immune cell reactivity during 
homeostasis. Following severe, life threatening inflammation, such as that 
experienced in a small number of individuals during an influenza infection, these 
regulatory pathways are over-exuberant as previously exemplified by the excess 
production of IL-10 and enhanced CD200R expression on airway antigen presenting 
cells 458;480. We are not suggesting that this post-influenza deleterious state occurs in 
all those infected with influenza, but that the activation threshold in resolution is 
similarly affected, in some, by the parameters described earlier during homeostasis. 
We believe it is in these subsets of patients that bacterial complications, 
hospitalisation and mortality may occur. Indeed an overshoot in innate immune 
regulation with untoward consequences is not unique to inflammatory lung disease 
as the CD200/CD200R axis is already thought to contribute to the suppressive 
tumour microenvironment either directly 559-562 or via the induction of Treg cells 
563;564.  
 
Resolution not only requires a cessation of inflammation but also the clearance of the 
inflammatory infiltrate; a large proportion of which undergoes programmed cell death 
via apoptosis. As discussed in Chapter 5, efferocytotic uptake of apoptotic cells by 
macrophages leads to a reduced microbicidal state that prevents long term tissue 
damage by chronic inflammation, but may also inadvertently reduce responsiveness 
to a subsequent bacterial infection. The influenza induced desensitisation of airway 
macrophages to respiratory bacteria we discussed in Chapter 4 may thus be an 
indirect effect of the clearance of inflammatory cells rather than direct viral effects per 
se. Efferocytosis induced production of prostaglandin E2 (PGE2) alone suppresses 
the anti-microbial activity of alveolar macrophages by inhibiting NADPH oxidase 
489;490. The role of CD200 in this process is not currently known, but is possible since 
it leads to an inhibition of inflammation in the CNS by reducing microglial cytokine 
expression and we report a large number of CD200 expressing cells present in the 
airway during the time of peak susceptibility to a secondary bacterial super-infection 
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565. Apoptotic cell expression of CD200 may thus signal to CD200R expressing 
macrophages and prevent presentation of self antigen. Therefore, in an attempt to 
return to homeostasis CD200 expressing apoptotic cells ingested by CD200R lung 
myeloid cells may reduce their anti-bacterial capability allowing subsequent bacteria, 
if present, to outgrow. A similar macrophage dysfunction is also observed in severe 
sepsis, however the link with apoptotic cells remains unverified providing another 
potential role for CD200-CD200R interaction and reduced macrophage functionality 
566-568. An absence or blockade of CD200R signalling may therefore release airway 
myeloid cells, or other myeloid phagocytes, from apoptotic cell-mediated suppression 
and enhance their bactericidal activity.        
 
7.1.2 Infection history modulates the innate immune system  
 
As discussed above, infection history can transiently alter lung innate responsiveness 
through enhancing regulatory pathways involved in tempering indiscriminate innate 
immune responses and restoring „homeostasis‟. However, a return to pre-infection 
homeostasis may never actually occur. Our data show that an influenza viral infection 
reduces the ability of alveolar macrophages to detect and respond to the presence of 
bacterial Toll ligands. This evidence demonstrates that a self limiting acute 
inflammatory insult can alter tissue specific immune responsiveness over a 
prolonged period of time. Infection history may therefore influence the way in which a 
specific tissue responds to subsequent immune stimulation. We often attribute such 
immune adaptation to acquired T and B lymphocytes and assume that innate 
immune compartments return to their pre-infection state even after multiple episodes 
of infection and inflammation. However, there is a growing body of evidence to 
suggest that we all develop a unique but subtle inflammatory profile. This uniqueness 
is determined by the sequence of infections or antigenic insults encountered that 
„permanently‟ mould our lungs through experience 377;569;570.  
 
Influenza viral infection, for example, protects against respiratory syncytial virus 
(RSV) induced immunopathology and lymphocytic choriomeningitis virus (LCMV)-
infected mice exhibit heightened clearance of the unrelated vaccinia virus 570-572. The 
outcome of infection history depends on the precise sequence of pathogens 
encountered by the host. Influenza, for example, inhibits vaccinia virus replication but 
enhances LCMV and murine cytomegalovirus (MCMV). The critical determinant 
appears to be the amplitude of cellular infiltrate in response to the second infection 
572. In most, but not all, cases, the improved outcome to the second infection can not 
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be explained through cross reactive T or B cell epitopes. Rather, we believe that the 
microenvironment of the lung stromal or innate immune cells is „permanently‟ altered. 
Evidence for long term modification of the innate immune compartment is provided by 
studies where microbial products such as unmethylated CpG dinucleotides or a 
modified bacterial labile toxin (LTK63) afford protection against an array of 
subsequent respiratory pathogens 298;573;574. This phenomenon has been coined 
„innate imprinting‟ and can be defined as “the long term modification of a 
microenvironment, which will consequently lead to a reduced, and in some cases 
more protective, immune response to a subsequent pathogen”. Myeloid inhibitory 
molecules such as CD200 and its receptor may also contribute to this „matured‟ or 
„educated‟ environment.  
 
Experiments in invertebrate models of infection add credence to this concept of long 
term innate immune adaptation 427. Injection of the bacterial cell wall component LPS 
provides long-lasting antimicrobial resistance in mealworm beetles when 
subsequently challenged with a heterologous natural fungal pathogen 428. Copepods, 
which are miniature crustaceans, infected with a natural parasitic tapeworm are 
capable of specific memory responses and react more efficiently upon subsequent 
rechallenge with antigenically similar pathogens 575. It appears that innate immunity 
not only contains mechanisms that calibrate its own responsiveness but also, more 
intriguingly, remember. Whether this is inherent or a consequence of additional 
regulatory pathways remains to be determined. This learning process, in the absence 
of adaptive immunity, also occurs with homologous or closely related pathogens. 
This innate imprinting, by sequential waves of inflammation or infection, may be 
beneficial, as shown for successive viral infections, or detrimental, as illustrated by 
the increased susceptibly to life threatening bacterial pneumonia in patients infected 
with seasonal and pandemic influenza. It is important to remember that in all of these 
situations, we are not describing cross-reactive acquired immunity but nonspecific 
influences from either what has gone before or what is currently present. We are 
therefore all unique because prior local or distal antigenic experiences have shaped 
our responsiveness to future antigenic insults, all in the absence of cross-reactive 
acquired immunity.  
 
The mechanisms underlying this educated innate immunity are currently unclear but 
are believed to require phagocytes and the Toll like receptor pathway 576. If this can 
happen in invertebrates, there is a high probability it will also happen in vertebrates. 
Speculation into the potential mechanisms that may explain this desensitisation 
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include augmented expression or regulation of intracellular TLR signalling adapters 
such as TOLLIP, A20 and IRAK M 9;10;577. The induction of IL-10 producing Treg cells 
may also explain how one inflammatory event can impact on subsequent 
heterologous infections in a bystander fashion. IL-10 levels are enhanced in the lung 
after secondary pneumococcal or meningococcal challenge in mice that have 
previously been infected with influenza virus, this in turn reduces antibacterial effector 
functions of neutrophils and other myeloid cells 410;480;578. Alternative ideas also 
include epigenetic modification of lung stromal cells or even the local stem cells 
responsible for renewing airway epithelium 579. The concept of stromal cell adaptation 
is expanded in the following section. 
 
7.1.3 Is there a role for resident stromal cells in tissue imprinting and bacterial 
susceptibility? 
 
The long term adaptation and altered responsiveness of the airway epithelium has 
been extensively studied in other inflammatory lung disease models 580-586. Airway 
metaplasia can continue in ex-cigarette smokers for more than two years after they 
have stopped smoking 587. Such long term changes are likely to affect innate immune 
responsiveness to subsequent infections. Further evidence that epithelial cells are 
modified for prolonged periods is provided by the development of resistance to 
peroxide exposure through long-term changes in epithelial cytoskeletal structure, 
molecular forms of p53 and heat shock proteins and genome-wide reprogramming of 
gene expression 588. If this occurs in vivo, then epithelial cell heterogeneity would be 
extensive and depend on the type of prior inflammatory insult and precise 
composition of the ensuing cellular response. The longevity of these alterations is 
assumed to be transient but has never been investigated. It is feasible that this 
influence may occur during resolution of the first inflammatory insult when epithelial 
integrity is regenerated by bone marrow progenitors or local stem cells in a process 
controlled by interaction with underlying sentinel mesenchymal cells, such as 
fibroblasts 589. These mesenchymal cells may be altered by the primary inflammatory 
insult and maintain the „memory‟ of these inflammatory events to educate newly 
regenerated epithelium. The transformation of airway epithelial cells into secretory 
epithelium containing mucus-secreting cells (mucous cell metaplasia) is a feature of 
many bronchial diseases in humans and is also observed in numerous rodent 
experimental systems.  
 
Finally, we cannot rule out indirect effects on epithelial permeability. Loss of epithelial 
integrity is a key step in the pathogenesis of acute respiratory distress syndrome 
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whether caused by viral infection, pneumonia, aspiration, sepsis or trauma 590-592. 
Reduced integrity results in the transition of airway bacteria into the parenchymal 
tissues and blood and allows direct contact with antigen presenting cells that are less 
restrained by the local microenvironment compared to the airways 458. In CD200R KO 
mice influenza viral load is blunted from the outset, which will prevent the extent of 
epithelial damage and expression of putative receptors for bacterial adhesion. IFN-γ 
expression is also reduced and so in turn will impact less on bacterial scavenger 
receptor expression such as MARCO 593. Furthermore, during infection, epithelial 
cells secrete a plethora of chemokines, such as CCL2, that recruit inflammatory 
leukocytes that impact on epithelial integrity 417. A decreased viral load in CD200R 
KO mice may therefore liberate less chemokines causing the recruitment of fewer 
apoptosis-inducing immune cells or their release from the bone marrow 594;595. Figure 
7.1 combines all of these concepts to illustrate how an infection or inflammatory insult 
can modify airway responsiveness over time.  
 
 
 
 
 
 
Innate immune responsiveness at different stages of inflammation 
Figure 7.1 The concept of altered innate immune responsiveness. Alveolar 
macrophages are tightly regulated during homeostasis through intimate interactions with 
respiratory epithelium (a). Upon influenza virus infection, epithelium integrity is lost allowing 
TLR and OX40L signalling to potentiate inflammation (b). Apoptotic cells expressing CD200 
bind to elevated CD200R levels on alveolar macrophage resulting in a reduced inflammatory 
capacity (b). Altered epithelium, elevated CD200R levels, heightened IL-10 levels and 
aberrant TLR signalling induce a hypo -responsive state (c). 
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7.2 A chronology of mechanisms enhance susceptibility to secondary bacterial 
pneumonias 
 
There clearly exists a temporal relationship between influenza viral infection and the 
occurrence of secondary bacterial pneumonias 412. As previously discussed, there 
exist an array of mechanisms that explain the increase in bacterial susceptibility 
following an influenza viral infection, these include: viral mediated epithelium 
damage, mucociliary dyskinesia, phagocyte apoptosis, neutrophil dysregulation and 
aberrant chemotaxis and IFN-γ mediated phagocyte dysfunction 279;593;596. This list is 
by no means exhaustive. In addition to these we now add two novel mechanisms, 
proposed above, providing further insight into this complex conundrum. It is highly 
likely that a specific combination of several mechanisms results in the development 
of lethal bacteraemia. This combination of mechanisms might be strongly influenced 
by; the precise influenza viral strain and its associated virulence and replicative 
ability, exemplified by PB1-F2 expressing strains; initial host genetic susceptibility to 
respiratory viral and or bacterial infections; polymorphisms in CD200 and CD200R 
and their down stream signalling adapters; pre-existing nasopharyngeal colonisation 
with bacterial species capable of culminating in invasive pneumonia and also the 
health and fitness of the host which can be determined by other underlying medical 
conditions or the environment in which the host lives 597-599. To try and determine the 
relative contribution of each individual mechanism would be extremely difficult and 
possibly meaningless in the context of actual clinical disease. It is known, and we 
have shown, that bacterial secondary infection is most commonly observed after viral 
elimination 417;600. Therefore it is likely that influenza virus infection sets up a chain of 
events that causes direct pathology itself but also indirect long term consequences, 
through regulating innate immune responsiveness, that collectively determine 
bacterial susceptibility. Figure 7.2 attempts to highlight this multifactoral process of 
influenza induced bacterial susceptibility.  
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Figure 7.2 Susceptibility mechanisms and their temporal relationships. The various 
mechanisms that enhance susceptibility to secondary bacterial pneumonias occur in a 
temporal fashion each collectively contributing to reducing the host‟s capacity to protect 
against bacterial pathogens. The longevity of a number of these mechanisms remains 
unknown.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The chronology of mechanisms that enhance bacterial susceptibility 
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7.3 The contribution from commensal bacteria in inflammatory lung disease 
Despite extensive research into the fundamental mechanisms that enhance the 
susceptibility to respiratory bacterial infections following influenza viral infection, there 
has been less interest in understanding why specific bacterial species gain access to 
the lung and from where do they originate. Extensive epidemiological and clinical 
data identify S. pneumoniae, S. aureus and H. influenzae as the three major bacterial 
pathogens responsible for invasive secondary bacterial pneumonias in individuals 
previously infected with influenza virus 412. A common theme shared between these 
bacterial pathogens is there ability to asymptomatically colonise the nasopharyngeal 
cavity of healthy individuals. It is highly unlikely that these bacteria simultaneously 
co-circulate with seasonal or pandemic influenza viral strains, thus providing a 
hypothesis that commensal bacteria, residing in the nasopharyngeal compartment, 
gain access to the lower respiratory tract during times of innate homeostasis 
disruption, as is evident during a severe influenza viral infection.  
 
Our data show that during an ongoing influenza viral infection there is an increase in 
the number of commensal bacterial present within the nasopharyngeal compartment 
and also the appearance of unknown commensal bacteria in the distal airways. An 
outgrowth of particular commensals almost certainly contributes to the severity of 
many inflammatory pathologies modelled in animals and human disease. To date 
there is more evidence for this in the intestinal tract where symbiotic bacteria provide 
tonic signals that contribute to „normal‟ physiological functions such as epithelial 
homeostasis and the exclusion of pathogenic micro-organisms through binding site 
competition 601-603. Mucosal epithelial cells in particular play a pivotal role in 
discriminating between pathogens and commensals 604. However they may also 
contain the ability to sense an increase or alteration in commensal density, which we 
have shown occurs in the nasopharynx during an ongoing influenza infection. The 
change in the local microenvironment by influenza is likely to benefit certain 
commensal species over others. Influenza causes cytopathology of epithelial cells 
and could effectively reduce key bacterial sensors such as TLR2, TLR4, NOD1 and 
MyD88 as has been shown in alternative infection models in the intestinal tract 605-607. 
Influenza neuraminidase also cleaves sialic acid residues, which was originally 
thought to contribute to secondary bacterial susceptibility by revealing putative 
bacterial binding sites. Recent evidence now suggests that cleaved sialic acid 
actually signals to bacteria to increase their number and act in a feedback loop to 
promote pneumococcal neuraminidase and virulence factor expression 608. This 
increase in bacterial titre combined with a reduction in mucociliary clearance, 
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enhanced aspiration of nasal mucus, a reduction in macrophage recognition and 
responsiveness is likely to result in their passage to the lower respiratory tract, 
effectively providing an opportunity for these otherwise asymptomatic commensals to 
cause invasive lung disease.  
 
Viral mediated effects on respiratory epithelium will also impact on other innate and 
adaptive immune cells (DCs and intraepithelial lymphocytes) to which they are 
intimately associated 609;610. Which bacterial species outgrow will also depend on the 
inciting agent and original immune status of the host 611. A lack of IgA (or its 
hypermutation) causes the selective expansion of particular commensal species and 
the depletion of specific T cell subsets, using T bet deficient mice, leads to a bacterial 
driven immune pathology reminiscent of ulcerative colitis 612-614. A loss of certain 
commensals at the expense of others may also be equally important since many 
encode virulence proteins that interfere with TLR and NF-κB signalling or its cellular 
location that may play unknown roles in maintaining homeostasis or immune 
tolerance 604;615.  
 
As discussed in Chapter 6, the local commensal community can also be selectively 
altered by a change in anti-microbial peptide (AMPs) expression during influenza-
induced cytopathology 616. An alteration in AMPs expression as a result of a primary 
bacterial infection enhances resistance to a subsequent malarial parasite infection in 
drosophila 617. AMPs (abundant in the respiratory tract) also alter with age, with older 
flies producing higher diptericin levels after live bacteria infection than young adult 
flies 618. Although effects that alter with age are attributed to senescence, another 
interpretation is that components of innate immunity are more tightly regulated as 
time progresses due to the experience of a greater number of infections. Thus, the 
older flies have a more experienced innate immune system, and therefore more 
focused production of diptericin, responding vigorously only in the presence of an 
infectious pathogen. Similar alterations in innate AMPs may also occur in 
vertebrates, mammals and even humans. In addition to lysing or opsonising bacteria, 
some AMPs synergise with cytokines to enhance other pro-inflammatory cytokines 
and chemokines that recruit bactericidal neutrophils and macrophages 619. In turn 
cytokines further enhance AMPs including beta defensins and lipocalin 2 620;621. We 
have shown that a preceding influenza infection might alter the expression pattern of 
a number of AMPs that in turn could impact on the complex mechanisms involved in 
determining commensal dynamics and tolerance in the upper respiratory tract. 
Therefore, the elevated cytokine responses we observe in CD200R KO mice 
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together with the reduced viral load may therefore improve anti-microbial immunity 
and explain the deceased susceptibility to subsequent bacterial super-infection 
following influenza.  
 
Finally, does any alteration in innate immune responsiveness, be that in response to 
a respiratory viral infection or through chronic inflammation, allow commensal 
bacteria to outgrow and therefore contribute to inflammatory lung disease? We show 
that during an acute inflammatory episode bacterial species implicated in human 
respiratory disease settings dominate the bacteria that appear in the distal airways 
545;549;551. It is known that asthmatics and COPD patients experience periods of 
disease exacerbation that are associated with bacterial co-pathologies 622-625. 
However, it is not known whether the disease exacerbations enhance susceptibility to 
bacterial infection or that an underlying pre-existing bacterial infection (asymptomatic 
commensal carriage) proceeds, during periods of innate immune dysregulation, and 
exacerbate existing inflammatory lung disease. Figure 7.3 highlights this concept with 
reference to a threshold over which commensal bacteria burden contributes to 
inflammatory lung disease. There is much data highlighting that a threshold exists in 
the intestinal tract in order to minimise potential immunopathology. If these intricate 
host-pathogen mechanisms were to be disrupted in the airway, for example during an 
acute or chronic lung inflammatory episode, one could envisage a situation in which 
commensal community dynamics would be altered leading to the outgrowth or 
dominance of pathogenic species that could lead to or contribute to the inflammatory 
situation.  
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7.4 Antibiotic usage in inflammatory lung disease settings – a clinical case 
Based on the data in this thesis one might envisage that antibiotics should routinely 
be administered during periods of inflammatory lung disease. Unfortunately, it is 
unlikely to be this straightforward as antibiotic usage increases the dominance of 
pathogenic species, as is seen with Clostridium difficile, and there remains the 
serious concerns regarding the increasing antibiotic resistance amongst common 
respiratory bacterial pathogens such as S. aureus and S. pneumoniae 626-631. There is 
also the issue of which antibiotic regimen to give and at what time they should be 
administered during an inflammatory lung event. This is currently of high interest as 
the numbers of H1N1 swine influenza infections and attributed deaths continue to 
rise 632. McCullers et al have show that ampicillin (a β-lactam antibiotic that lyses 
bacteria) completely clears S. pneumoniae from influenza co-infected mice however 
it also enhances inflammatory cytokine levels and associated mortality. The release 
of large quantities of bacterial TLR ligands by the antibiotics is thought to initiate and 
enhance the ongoing innate inflammation. In comparison clinidamycin (a macrolide 
that inhibits protein synthesis but does not lyse bacteria) treatment reduces TNF-α 
Does commensal burden contribute to inflammatory lung disease? 
Figure 7.3 The clinical bacterial threshold. During homeostasis bacterial commensal burden 
is kept in equilibrium by host innate immune responses (blue). In times of aberrant innate 
homeostasis, for example during an influenza infection (green) or an asthmatic/COPD 
exacerbation (orange), the burden of commensal flora increases and can result in clinical 
manifestation and contribution to clinical disease. In time of severe innate homeostasis 
disruption, such as during infection with highly virulent influenza (red), commensal burden 
increases substantially and can result in invasive bacterial disease.  
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levels, weight loss and increased survival despite less effective bacterial clearance 
633. The use of azithromycin, another macrolide protein synthesis inhibitor that also 
contains anti-inflammatory properties performs even better, but does not fully clear 
the bacteria from the host 633. This suggests that a certain level of bacteria can be 
tolerated without contributing to clinical disease but if a specific threshold of bacterial 
burden is reached (as described in Figure 7.3) or they are lysed through the use of β-
lactam antibiotics then worse inflammation ensues resulting in enhanced mortality. 
The best strategy therefore may be to use bacteriostatic antibiotics followed by a 
bactericidal one when bacterial levels are low. 
 
An understanding of how endogenous commensal bacteria contribute to 
inflammatory disease phenotypes and how combinations of existing anti-microbial 
therapies might be used to increase host tolerance to bacterial co-pathologies could 
be an interesting alternative approach to alleviate clinical disease. To date the 
incidence of secondary bacterial pneumonias following H1N1 swine and H5N1 avian 
influenza infections remains unknown, however, existing epidemiological studies 
from previous influenza pandemics suggest we may need to rethink the usage of 
antiviral and antibiotic combinations in the event of the appearance of secondary 
bacterial pneumonias 634;635. 
 
7.5 Final conclusions 
In this thesis, we show how infection history can determine the responsiveness of the 
airway to subsequent antigen challenge. This is achieved, in part, through long term 
alterations in regulatory mechanisms that ensure tissue resident macrophages exists 
in a state of hypo-responsiveness. Whether this is beneficial or detrimental to the 
host is determined by the severity of the first infection and the precise chronology of 
pathogens encountered by the host. Furthermore it also highlights the importance of 
recognizing and understanding the complex bacterial community that exists within the 
respiratory tract and how infection and/or therapeutic intervention can have unknown 
consequences to its dynamic composition. Further studies investigating the 
contribution of commensal bacterial dynamics to the pathogenicity in health and 
disease will lead to more targeted use of existing antimicrobial therapies and the 
development of much needed novel therapeutics. Adjustment of the level of innate 
responsiveness may therefore provide a novel opportunity to prevent life-threatening 
consequences of lung influenza virus infection. 
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